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Summary 
 
Staphylococcus aureus is a commensal bacterium that can also act as an 
opportunistic pathogen, causing a wide range of diseases in humans and in 
economically important livestock such as cows and rabbits. S. aureus quickly 
develops resistance against antibiotics and also evades the immune system of 
the host. As current treatments are difficult and expensive, new antibiotics, 
vaccines and the use of elements of the immune system are currently being 
studied as novel control approaches. 
 
A novel bactericidal mechanism able to kill S. aureus present in naive rabbit 
serum (NRS) was previously discovered in our laboratory. The bactericidal 
activity of the NRS had been characterized and the importance of the wall 
teichoic acids (WTA) on the bacteria for susceptibility was identified previously, 
but the mechanism involved in the bacterial killing remained unknown.  
 
In this study the role of the WTA as the bacterial receptor that interacts with the 
‘killing factor’ present in the NRS was established. The importance of WTA 
modifications were also determined in pathogen resistance to the NRS killing 
mechanism. Use of bacterial cell wall material as an affinity matrix led to the 
identification of secreted phospholipase A2 (sPLA2) as a potential part of the 
bactericidal mechanism. The use of a range of inhibitors and specific antibodies 
confirmed sPLA2 as part of the killing mechanism.  
 
Purified sPLA2 from a number of species was tested and cobra sPLA2 
(cvPLA2) was able to kill S. aureus in buffer but led to bacterial growth when 
added to NRS. This suggests that cvPLA2 interacts with rabbit serum 
components and this results in inactivation of both cvPLA2 and the bactericidal 
activity of the NRS. Annexin A1, a known regulator of PLA2, was identified 
through mass spectrometry as a serum protein also bound to the cell wall 
affinity matrix. This protein enhanced the bactericidal activity of cvPLA2 against 
S. aureus by direct protein-protein interaction. A model of NRS staphylococcal 
activity is presented.  
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CHAPTER 1: 
Introduction 
1.1 Staphylococci 
 
Staphylococci were first identified and named by Sir Alexander Ogston in 1881 
(Archer, 1998). They are Gram-positive, spherical, non-motile and facultative 
anaerobic bacteria. They are non-spore forming and have a diameter of 
approximately 0.5-1.5 µm (Harris et al, 2002; Hennekinne at al, 2012). The cells 
can divide in three perpendicular planes, forming grape-like clusters (Tzagoloff 
and Novick, 1977). 
 
Staphylococci have relative complex nutritional requirements that vary from 
strain to strain, but in general they require 5-12 essential amino acids, an 
organic source of nitrogen and B vitamins, including thiamine and nicotinamide 
(Kloos and Schleifer, 1986; Wilkinson, 1997; Harris et al, 2002). Staphylococci 
can resist desiccation and heat (Kloos and Lambe, 1991), and are tolerant to 
high concentrations of salt (Wilkinson, 1997). They are catalase-positive and 
oxidase-negative, which can distinguish staphylococci from other Gram-positive 
cocci like streptococci (Wilkinson, 1997; Madigan et al, 2006). 
 
Staphylococci are important pathogens with more than 50 species having been 
described. They are differentiated by their ability to produce coagulase, a 
protein that can react with prothrombin and clots the blood (Hennekinne et al, 
2012). Staphylococcus aureus, a coagulase positive strain (Bergdoll, 1990), is 
significantly important due to its interaction with humans. 
 
 
1.2 Staphylococcus aureus 
 
Staphylococcus aureus is the most frequent human pathogen of the 
Staphylococcus genus and is important due to the rise of antibiotic resistant 
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strains (Lowy, 1998; Harris et al, 2002). This pathogen has also been 
associated with infections in economically important livestock such as cows, 
sheep and rabbits (Viana et al, 2015). 
 
This bacterium can be distinguished from other staphylococcal species by the 
golden yellow pigmentation of its colonies on agar, coagulase activity, mannitol-
fermentation and deoxyribonuclease activity (Wilkinson, 1997; Lowy, 1998).  
 
The genome of several strains has been sequenced. The average size of the S. 
aureus chromosome is 2.8 Mbp (Kuroda et al, 2001) and there is a high degree 
of sequence similarity between strains (Lowy, 2010). Comparison of genomic 
sequences shows that large fragments of DNA have been acquired by 
horizontal transfer from other species. These mobile elements contain many 
antimicrobial resistance and virulence factor encoding genes (Lowy, 2010; 
Stefani et al, 2012). 
 
1.2.1 Antibiotic resistance in S. aureus 
 
Cells resistant to antibiotics and other drugs have emerged due to the selective 
pressure that their widespread use has caused (McKeegan et al, 2002). S. 
aureus is naturally susceptible to every antibiotic that has been developed 
(Chambers and DeLeo, 2009) but it has the ability to quickly acquire resistance 
(Demerec, 1945; Lowy, 2003; Gordon and Lowy, 2008; Chambers and DeLeo, 
2009) (Figure 1.1). This ability to gain resistance to antibiotics makes S. aureus 
an important issue for worldwide health not only because the treatment of the 
bacteria has become increasingly difficult and expensive, but because the 
mortality rate due to S. aureus infection has increased to about 30% (Dancer, 
2008). Resistance to antibiotics is often acquired by horizontal transfer of genes 
from outside sources, but chromosomal mutations and antibiotic selection are 
also important (Demerec, 1945; Livermore, 2000; McKeegan et al, 2002).  
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Figure 1.1 Chronology of the introduction of antibiotics and subsequent 
emergence of resistance in S. aureus 
Figure adapted from (Kabli, 2013)  
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Resistance to penicillin and other β-lactam antibiotics is caused by the 
inactivation of the antibiotic by β-lactamase, which hydrolyses the β-lactam ring 
(Lowy, 1998). This resistance was identified soon after the introduction of 
penicillin and by 1948 approximately 50% of isolates were resistant (Barber and 
Rozwadokawa-Dowzenko, 1948; Lowy, 1998). Approximately 5% of S. aureus 
isolates now show sensitivity to penicillin (Lowy, 1998). 
 
New antibiotics such as streptomycin, erythromycin, chloramphenicol and 
tetracycline were developed during the 1950s and staphylococcal isolates 
resistant to these antibiotics were discovered shortly after their introduction into 
clinical practice (Demerec, 1948; Lacey, 1975; Livermore 2000). The mode of 
action of these antibiotics is to block protein synthesis and resistance 
mechanisms are diverse: ribosome modification to alter antibiotic binding 
affinity, including acetylation of the antibiotics to reduce its toxicity and action of 
efflux pumps (Lacey and Chopra, 1972; Courvalin and Fiandt, 1980; Burdett, 
1991; Guay et al, 1993; Murray and Shaw, 1997; Roberts et al, 1999, Witte et 
al, 2008). 
 
Methicillin, cloxacillin and oxacillin are β-lactamase-resistant semi-synthetic 
penicillins that were developed to treat penicillin-resistant S. aureus (Rice, 
2006). However, methicillin-resistant S. aureus (MRSA) strains were isolated 
just two years after the introduction of methicillin into the United Kingdom (1961) 
and a few years later in the United States (1969) (Jevons, 1961; Rice, 2006). 
The resistance to methicillin derives from the acquisition of the mecA gene, not 
native in this species (Kono and Arakawa, 1995; Stefani et al, 2012). This gene 
encodes for modified penicillin-binding protein (PBP2a) that is able to replace 
the function of the essential PBPs in the presence of the antibiotics and has low 
affinity for them (Lim and Strynadka, 2002; Stefani et al, 2012). MRSA 
infections were first detected in hospitals, but in recent years infections have 
emerged in the community and livestock (Stefani, 2012). 
 
Gentamicin was introduced to treat MRSA in the United Kingdom in 1964, but 
by the mid-1970s reports of gentamicin-resistant S. aureus were published 
(Naidoo and Noble, 1978). Fluoroquinolone antibiotics were introduced in the 
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late 1980s, but S. aureus and MRSA easily developed resistance against them 
(Schaefler, 1989; Ng et al, 1994; Ferrero et al, 1995; Muñoz-Bellido et al, 1999). 
Vancomycin is a glycopeptide that has an important role in treating MRSA 
cases. Glycopeptides bind with high affinity to the D-ala-D-ala terminus of 
peptidoglycan precursors, blocking their incorporation into peptidoglycan (Loll 
and Axelsen, 2000; Courvalin, 2006). S. aureus with intermediate vancomycin 
resistance (VISA, MIC 8mg/L) were first reported in Japan in 1996 (Hiramatsu 
et al, 1997) and in the United States in 1999 (Hageman et al, 2001). This 
resistance is due to a thickening in the cell wall with reduced cross-linking, 
allowing the bacteria to sequester the vancomycin and reduce its diffusion 
across the cell wall (Cui et al, 2000; Cui et al 2006). In 2002, vancomycin-
resistant S. aureus (VRSA, with MIC > 32 mg/L) was first isolated (Avison et al, 
2002; Cui et al, 2006), but the incidence of VRSA is still very rare.  
 
Antibiotics like linezolid, daptomycin, synercid and tigecycline have been 
introduced recently for the treatment of MRSA and VRSA, but resistant strains 
have already been identified for all these antibiotics (Dowzicky et al, 2000; 
Tsiodras et al, 2001; Werner et al, 2001; Hayden et al, 2005; Hope et al, 2010; 
Kreis et al, 2013).  
 
1.2.2 S. aureus infections 
 
S. aureus is considered an opportunistic pathogen that can be found in the 
nasal cavities, skin, vagina, axilla, perineum and oropharynx (Lowy, 1998; 
Peacock et al, 2001; Lowy, 2010). Several biotypes have been isolated from 
different hosts, demonstrating the close adaptation of the bacterium to its host 
(Hennekinne et al, 2012; Viana et al, 2015.) 
 
This bacterium is part of the normal human flora as a commensal with 
approximately 20% of the healthy population are permanent carriers and 30-
50% transient (Lowy, 1998). People who are colonized by S. aureus have an 
increased risk of subsequent infection than those who are not carriers, and the 
host is usually infected with their own carriage isolate (Lowy, 1998; Peacock et 
al, 2001). S. aureus can also be acquired from other people or from 
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environmental exposures (Lowy, 2010). The risk of S. aureus infection is higher 
for intravenous drug users, diabetic and immunocompromised patients (Archer, 
1998; Lowy, 1998). 
 
This pathogen commonly enters the body through a wound and an abscess is 
formed at the initial site of infection to allow the bacteria to avoid the host 
defences (Clements and Foster, 1999). After colonization the bacteria replicates 
at the initial site of infection and produces enzymes that facilitate bacterial 
survival and local spread across tissues (Lowy, 2010). S. aureus is responsible 
for a wide range of diseases such as local skin infections including acne, 
mastitis, folliculitis, impetigo and cellulitis, but it can also cause systemic 
illnesses such as wound infections and metastatic complications, endocarditis, 
musculoskeletal and respiratory infections, and toxin-mediated diseases like 
toxic shock syndrome and food poisoning. Once toxin has been incorporated 
into food, food poisoning can develop without any viable bacteria (Archer, 1998; 
Lowy, 1998; Foster, 2005; Lowy 2010; Hennekinne et al 2012).  
 
1.2.3 S. aureus virulence factors 
 
It has been shown that the wide range of diseases that are caused by S. aureus 
are the result of several secreted and cell-surface associated virulence factors 
expressed by the bacteria. Expression of these virulence determinants is 
growth-phase dependent in vitro (Projan and Novick, 1997). In the exponential 
phase the bacteria synthetizes surface-associated virulence factors, switching 
to extracellular virulence factors such as toxins in the post-exponential phase. 
This corresponds with the formation of the abscess in vivo. Once high cellular 
density is reached within the abscess, the cells produce enzymes and toxins 
that allow their dispersal to other sites (Elek, 1956; Projan and Novick, 1997; 
Foster, 2005; Lowy, 2010; Johannessen at al, 2012). 
 
S. aureus expresses these determinants in order to help spread and perpetuate 
the infection by avoiding the immune system. They facilitate colonization and 
bacterial migration to other tissues, tissue destruction, cytolytic effects on host 
cells and protect the bacteria from the host immune system (Tompkins et al, 
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1990; Bhakdi and Tranum-Jensen, 1991; Thakker et al, 1998; Navarre and 
Schneewind, 1999; Foster, 2005). 
 
Virulence factors include surface proteins like protein A, iron-regulated surface 
determinant A (IsdA) and clumping factors A and B that are covalently bound to 
the bacterial peptidoglycan (Foster, 2005; Brown et al, 2014). These proteins 
promote the adhesion to damaged tissue and to the surface of host cells, and 
can also act as immune evasion molecules (Harris et al, 2002; Foster, 2005; 
Lowy, 2010). S. aureus also produces several toxins that can lyse eukaryotic 
cells and induce pro-inflammatory responses in the host, such as cytotoxins, 
leukotoxins and haemolysins (Lowy, 1998; Foster 2005). α-toxin is the best 
characterized and potent of the cytotoxins and is capable of pore formation in 
different types of host cells at low concentrations (Bhakdi and Tranum-Jensen, 
1991).  
 
Extracellular enzymes including proteases, catalase, lipases and coagulase are 
also produced and released by S. aureus and are involved in the spread of the 
infection and damage to host tissue (Foster, 2005).  
 
Superantigens bind to major histocompatibility class II proteins. They are 
recognized by the β-chain variable regions of the T cell receptors, stimulating 
up to 20% of all T-cells (McCormick et al, 2001; Llewelyn and Cohen, 2002; 
Schlievert et al, 2008; Lowy, 2010; Kim et al, 2012). This large T-cell 
proliferation results in a massive release of cytokines, producing host-mediated 
tissue damage that can lead to hypotension, shock, multi-organ failure and 
even death (Kotb, 1995). Superantigens have also been implicated in 
autoimmune disorders including multiple sclerosis and rheumatoid arthritis 
(McCormick et al, 2001). 
 
Finally, S. aureus produces capsular polysaccharides that protect the bacteria 
from phagocytosis (Foster, 2005). There are several capsular polysaccharides 
described, but most human infections are caused by serotypes 5 and 8 (Dassy 
et al, 1993; Foster, 2005; Lowy, 2010). The S. aureus capsule also plays a role 
in the induction of abscess formation (Lowy, 2010). 
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1.3 The bacterial cell wall 
 
The bacterial cell wall serves as the interface between a bacterium and its 
environment, and performs several functions that are essential for its growth, 
division and survival (Scheffers and Pinho, 2005; Hayhurst et al, 2008). The 
main functions are the preservation of cell integrity and cell shape (Errington et 
al, 2001; Pichoff and Lutkenhaus, 2007), maintenance of the internal turgor 
pressure (Osborn and Rothfield, 2007), biofilm formation (Lévesque et al, 2005) 
and providing a physical barrier for protection from external influences (Silhavy 
et al, 2010). The cell wall also plays an important role in sensing external 
signals, acquiring nutrients and in the resistance to the host defences through 
the proteins that can be found embedded in it (Schneewind and Missiakas, 
2012).  
 
Bacteria can be separated into two groups based on differences in the cell 
envelope structure, Gram-positive bacteria and Gram-negative bacteria (Figure 
1.2) (Madigan et al, 2006). Bacteria from the Thermoplasma genus are able to 
live without a cell wall as protoplasts in osmotically protected environments, 
such as animals (Madigan et al, 2006; Vinogradon et al, 2012), and only 
recently it has been demonstrated that the Chlamydiales possess functional 
peptidoglycan (Liechti et al, 2014; Jacquier et al, 2015). 
 
1.3.1 Gram-negative bacteria 
The cell envelope of Gram-negative bacteria is comprised of the cytoplasmic or 
inner membrane, the outer membrane and the peptidoglycan cell wall (Figure 
1.2A) (Silhavy et al, 2010). The inner membrane works as a barrier between the 
cytoplasm and the external environment. In addition to a thin layer of 
peptidoglycan, these bacteria contain an outer membrane comprised of 
proteins, lipoproteins and lipopolysaccharide (Madigan et al, 2006; Silhavy et al, 
2010). The inner and outer membranes delimit a protein-rich compartment 
called the periplasm, which contains the peptidoglycan and also serves as a 
scaffold for proteins and polysaccharides that mediate the interactions between 
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Figure 1.2 General structure of Gram-negative and Gram-positive cell envelope 
The major structural components of the A) Gram-negative and B) Gram-positive cell 
envelope are shown. LPS: lipopolysaccharide; LTA: Lipoteichoic acid; WTA: wall 
teichoic acid. Adapted from (Silhavy et al, 2010). 
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the organism and its environment (Mullineax et al, 2006; Silhavy et al, 2010; 
Swoboda et al, 2010). 
 
1.3.2 Gram-positive bacteria 
 
S. aureus has a characteristic Gram-positive cell wall structure, which lacks an 
outer membrane and a distinct periplasm (Swoboda et al, 2010). Gram-positive 
bacteria have very thick peptidoglycan layers (20-35 nm) (Vollmer and 
Seligman, 2010) which can account for up to 60-90% of the cell wall mass 
(Madigan et al, 2006; Silhavy et al, 2010). Peptidoglycan stabilizes the cell 
membrane and also works as a scaffold for other molecules like bacterial 
surface proteins (Silhavy et al, 2010; Schneewind and Missiakas, 2012). The 
peptidoglycan is modified with carbohydrate-based anionic polymers called wall 
teichoic and lipoteichoic acids (Figure 1.2B) (Neuhaus and Baddiley, 2003) that 
appear to perform some of the functions of the outer membrane, influencing 
membrane permeability, extracelullar interactions and also act as a scaffold for 
extracytoplasmic proteins (Swoboda et al, 2010).  
 
1.3.3 Peptidoglycan 
 
Peptidoglycan (or murein) is an essential component of the cell wall that can be 
found on the outside of the cytoplasmic membrane of almost every bacterium 
(Mengin-Lecreulx and Lemaitre, 2005; Vollmer et al, 2008). Its main function is 
the preservation of cell integrity and any inhibition of its biosynthesis or 
degradation will result in cell lysis (Mengin-Lecreulx and Lemaitre, 2005). 
Peptidoglycan is also involved in maintaining cell shape (Vollmer et al, 2008), 
interaction with the host (Mengin-Lecreulx and Lemaitre, 2005; Turner at al, 
2014) and in the anchoring of proteins (Dramsi et al, 2008) and teichoic acids 
(Neuhaus and Baddiley, 2003). 
 
Peptidoglycan is a polymer made of glycan strands that are cross-linked via 
short peptide stems (Vollmer et al, 2008). The glycan strands are made up of 
repeating units of β- (1,4) linked N-acetylglucosamine (GlcNac) and N-
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acetylmuramic acid (MurNac) (Vollmer et al, 2008) with different degrees of 
polymerization and terminating with MurNac residues at the reducing ends, 
forming relatively short glycan strands for S. aureus (Boneca et al, 2000).  
 
The composition of the glycan strands is highly conserved between species but 
its length varies considerably between organisms, from short glycan strands 
(e.g. S. aureus mean length is 6 disaccharides) to very long (e.g. B. subtilis 
mean length between 50-250 disaccharides, with 25% of strands with a mass of 
500 disaccharides) (Hayhurst et al, 2008; Vollmer et al, 2008; Vollmer and 
Seligman, 2010). 
 
The MurNac or GlcNac can be modified by O-acetylation, N-deacetylation and 
N-glycolylation (Vollmer, 2008). While the presence of N-deacetylation reduces 
the activity of autolysins and the susceptibility to lysozyme (Vollmer and 
Tomasz, 2002; Vollmer, 2008), the O-acetylation is not only associated with 
resistance to lysozyme and other hydrolysins, but also pathogenesis and 
modulation of the host immune response (Boneca et al, 2007; Vollmer, 2008). 
N-glycolylation is mainly found in bacteria with mycolic acids in their envelope 
(Sutcliffe, 1998; Vollmer, 2008) and while its role is not known it appears to be 
involved in lysozyme resistance and stability of the cell envelope (Brennan and 
Nikaido, 1995; Vollmer, 2008).  
 
During synthesis covalently attached to the MurNac of S. aureus there is a 
pentapeptide chain consisting of L-alanine, D-glutamine, L-lysine and D-alanyl-
D-alanine moiety, called the stem peptide (Vollmer et al, 2008). In S. aureus the 
stem peptide chain is connected to other side chain via a pentaglycine cross-
bridge, forming a mesh-like layer (Figure 1.3) (Madigan et al, 2006; Silhavy et 
al, 2010). The stem peptides are involved in the association of surface proteins 
and resistance to β-lactam antibiotics (Chambers, 2003; Silhavy, 2010). 
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Figure 1.3 Structure of peptidoglycan 
The figure shows the structure of one peptidoglycan disaccharide pentapeptide with a 
typical pentapeptide, even though its composition may vary. Adapted from (Fournier 
and Philpott, 2005; Madigan et al, 2006). 
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1.3.4 Surface proteins 
 
S. aureus expresses several virulence factors to aid the colonization of the host, 
including surface proteins that interact with the environment and facilitate 
adherence to tissue (Tompkins et al, 1990; van Belkum et al, 2009). The 
adherence is mediated by the microbial surface components recognizing 
adhesive matrix molecules (MSCRAMM) family, which can be covalently 
attached to the peptidoglycan (Foster and Höök, 1998). They can interact with 
host proteins such as fibronectin, fibrinogen and elastin (Clarke and Foster, 
2006; Silhavy et al, 2010). Adhesins are also surface proteins but they are 
attached to the peptidoglycan or teichoic acids via non-covalent ionic 
interactions (Dramsi et al, 2008;Silhavy et al, 2010).  
 
1.3.5 Teichoic acids 
 
Teichoic acids are anionic polymers that can be found on the cell surface of a 
wide range of Gram-positive organisms, including S. aureus. Teichoic acids are 
capable of performing some of the functions of the outer membrane, such as 
scavenging divalent cations, influencing membrane permeability, providing 
additional stability to the plasma membrane, mediating extracellular interactions 
and invasion of the host, and, along with peptidoglycan, act as a frame for 
extra-cytoplasmic enzymes (Silhavy et al, 2010; Hanson and Neely, 2011). 
There are two major types: wall teichoic acids (WTA) and lipoteichoic acids 
(LTA) (Swoboda et al, 2010; Hanson and Neely, 2011). 
 
Even Gram-positive bacteria that lack WTA and LTA have functionally similar 
anionic polymers on their cell wall, illustrating the importance of these polymers 
(Neuhaus and Baddiley, 2003). For example, Micrococcus luteus has 
lipomannan instead of LTA (Powell et al, 1975; Neuhaus and Baddiley, 2003), 
and B. subtilis grown in phosphate-limited medium has teichuronic acid instead 
of WTA (Ellwood and Tempest, 1972; Neuhaus and Baddiley, 2003). 
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Whilst mutants without lipoteichoic or wall teichoic acids exist, they have 
morphological or growth defects (Weidenmaier et al, 2005b; Fedtke et al, 2007; 
Koprivnjak et al, 2008). Mutants lacking both LTA and WTA are non-viable, 
suggesting that one type of teichoic acid can compensate the other to some 
extent (Schirner et al, 2009; Xia et al, 2010a). 
 
1.3.5.1 Lipoteichoic acids 
 
Lipoteichoic acids (LTA) are anionic cell surface polymers that are anchored to 
the cell membrane through their glycolipid fraction and the hydrophilic chain 
extends into the cell wall (Figure 1.4) (Neuhaus and Baddiley, 2003: Silhavy et 
al, 2010). In most of the Gram-positives, including Staphylococcus aureus, this 
chain is made of poly-[glycerophosphate] (Gro-P), but in others like 
Lactococcus garvieae and Clostridium innocuum the repeating units are 
(GalGal-Gro-P) or (Gal-Gro-P), respectively (Fisher, 1994; Neuhaus and 
Baddiley, 2003). The length of the hydrophilic chain also varies, as well as the 
degree of D-alanylation and the kind and extent of glycosyl substitution (Iwasaki 
et al, 1986; Fischer, 1993; Roethlisberger et al, 2000; Neuhaus and Baddiley, 
2003). 
 
During biosynthesis LTA is assembled at the outer surface of the cytoplasmic 
membrane by the LTA polymerase (LtaS) directly on the glycolipids that will 
serve as anchor structures using phosphoglyceryl units from the 
phosphatidylglycerol present in the bacterial membrane as building blocks to 
elongate the LTA. Once the biosynthesis of the polymer is completed the LTA 
can be modified by D-alanylation or glycosylation (Figure 1.5) (Glaser and 
Lindsay, 1974; Neuhaus and Baddiley, 2003; Grundling and Schneewind, 
2007a; Weidenmaier and Peschel, 2008; Xia et al, 2010a). 
 
LTA has a crucial role in cell division, which might explain why it is 
indispensable for the viability of the cell (Weidenmaier and Peschel, 2008). 
Whilst mutants for some of the genes involved in the synthesis of LTA exist, 
they display aberrant cell shape and increased size (Kiriukin et al, 2001; 
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Grundling and Schneewind, 2007b; Richter et al, 2013). Loss of LTA has been 
associated with decrease in autolysin activity in S. aureus (Hanson and Neely, 
2011). LTA is also involved in the interaction of S. aureus with the host 
(Weidenmaier and Peschel, 2008).  
 
1.3.5.2 Wall teichoic acids 
 
Wall teichoic acids (WTA) are anionic glycopolymers that are covalently 
attached to the peptidoglycan through a link to the 6-hydroxyl of the N-
acetylmuramic acid residues via a disaccharide composed of N-
acetylglucosamine-1-P and N-acetylmannosamine, followed by two units of 
glycerol phosphate (Neuhaus and Baddiley, 2003; Swoboda et al, 2010; Sewell 
and Brown, 2014). 
 
The composition of the repetitive subunits varies between species and even 
between clonal groups, and typically comprises glycerol or ribitol phosphate 
(Qian et al, 2006; Xia et al, 2010a). S. aureus WTA are composed of D-ribitol 
connected by a 1,5 phosphodiester bond (Baddiley et al, 1962; Swoboda et al 
2010). The subunits are modified by cationic D-alanine esters or 
monosaccharides (Figure 1.4) (Neuhaus and Baddiley, 2003; Swoboda et al, 
2010). The length of the main chain of the wall teichoic acid polymers can vary, 
with 10-40 residues long for S. aureus, 40 residues for B. subtilis W23 and 45-
60 residues for B. subtilis 168 (Foster and Popham, 2002).  
 
The biosynthesis of WTA uses undecaprenol phosphate (C55-P) as lipid carrier 
during the assembly process and it starts with C55-P at the inner leaflet of the 
cytoplasmic membrane (Neuhaus and Baddiley, 2003; Xia et al, 2010a). The 
process has several stages that can be summarized as follows: i) linking of the 
disaccharide linkage unit (Gro-P)3-ManNac-GlcNac to the C55-P, ii) 
polymerization of the subunits on the lipid intermediate, iii) glycosylation of the 
moiety, and iv) attachment of the WTA linkage unit to the peptidoglycan (Figure 
1.6) (Neuhaus and Baddiley, 2003; Brown et al, 2008; Xia et al, 2010a; Brown 
et al, 2013).  
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Figure 1.4 Schematic structure of lipoteichoic and wall teichoic acid of S. aureus 
Lipoteichoic acids are anchored to the cytoplasmic membrane of the bacteria through 
their glycolipid fraction (fatty acids). The length of the poly-(glycerolphosphate) chain 
varies in different species. Wall teichoic acids are covalently attached to the 
peptidoglycan, with repeating units of poly-(ribitol) connected through phosphodiester 
bonds. The teichoic acids can be modified by D-alanine esters or monosaccharides. P: 
phosphate; A: D-alanine; GlcNac: N-acetylglucosamine; ManNac: N- 
acetylmannoseamine. Adapted from (Xia et al,2010b).  
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Figure 1.5 Synthesis of lipoteichoic acid in S. aureus 
A. LtaS assembles the lipoteichoic acid at the outer surface of the cytoplasmic 
membrane. The first glycerolphosphate subunit is cleaved from phosphatidyl glycerol 
(PG) and is attached to diglycosyl-diacylglycerol (Glc2DAG), the glycolipid anchor. The 
reaction leads to the release of DAG. 
B. PgcA, GtaB and YpfP synthesize the Glc2DAG glycolipid anchor and the 
transmembrane protein LtaA moves it to the outside of the cytoplasmic membrane. 
LtaS adds glycerolphosphate residues to the distal end of the growing 
glycerolphosphate chain. 
Adapted from (Percy and Gründling, 2014; Schneewind and Missiakas, 2014). 
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Figure 1.6 Proposed polyribitol-phosphate WTA biosynthetic pathway for S. 
aureus. 
The genes encoding the enzymes for the assembly of WTA have been isolated and 
characterized in B. subtilis 168 (tag genes, for teichoic acid glycerol). Functions were 
assigned to the tar genes (for teichoic acid ribitol) of S. aureus based on sequence 
homology to the tag genes. This wall teichoic acid is linked to a nascent peptidoglycan 
chain. 
 
Adapted from (Neuhaus and Baddiley, 2003; Brown et al, 2008; Pereira et al, 2008; 
Brown et al, 2013) 
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S. aureus is capable of modulating the structure of WTA according to bacterial 
cell density and environmental changes through the repression of some of the 
WTA biosynthesis genes by the agr quorum sensing system (Meredith et al, 
2008). The genes encoding enzymes for the assembly of WTA have been 
isolated and characterized in B. subtilis and S. aureus, and it was shown that 
they are organized in several operons. The regulatory elements of the operons 
are modulated by signals coupled to cell division and growth phase (Neuhaus 
and Baddiley, 2003; Brown et al, 2008).  
 
The WTA can be modified via D-alanylation or glycosylation. The D-alanylation 
occurs after the completion of the biosynthesis of the glycopolymer via the 
activity of the dltABCD operon (Perego et al, 1995; Clemans et al, 1999; May et 
al, 2005). Glycosylation is modulated by TarM and TarS with α-GlcNac or β-
GlcNac transferase activity, respectively (Xia et al, 2010a; Sobhanifar et al, 
2015). The modifications affect cation homeostasis, antibiotic susceptibility and 
survival in the host, among other properties (May et al, 2005; Swoboda et al, 
2010). 
 
The presence of WTA in most of the Gram-positive bacteria suggests it has an 
important role (Weidenmaier and Peschel, 2008). Mutants lacking WTA have 
altered localization, assembly and activation of cell the wall elongation and 
division machinery (Bhavsar et al, 2001; D’Elia et al, 2006; Campbell et al, 
2011; Brown et al, 2013). Wall teichoic acids are also important in cation 
homeostasis, provide a reservoir for ions that might be required for enzyme 
activity, create localized changes in the pH and modulate the function of 
enzymes, and help in the prevention of fluctuations in osmotic pressure 
between the inside and outside of the cell (Swoboda et al, 2010; Biswas et al, 
2012; Brown et al, 2013). 
 
WTA protects the cell from damage caused by cationic antibiotics (Peschel and 
Sahl, 2006), lysozymes, surfactants and antimicrobial peptides (Weidenmaier 
and Peschel, 2008; Silhavy et al, 2010; Swoboda et al, 2010). They have a role 
in the adherence to biomaterials and biofilm formation in in vitro and in vivo 
models (Gross et al, 2001; Fabretti et al, 2006; Xia et al, 2010b), and are 
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required for adhesion to the host tissue (Weidenmaier et al, 2004; Weidenmaier 
et al, 2005b; Swoboda et al, 2010). WTA are a potent immunogenic agent, and 
are recognized by the adaptive immune system and can be targeted effectively 
by antibodies (Neuhaus and Baddiley, 2003). WTA can also be a target for 
bacteriophages to adhere to the bacterial cell surface (Chatterjee, 1969; 
Weidenmaier and Peschel, 2008).  
 
1.3.5.3 D-alanylation of the teichoic acids 
The teichoic acids can be modified by D-alanylation once their synthesis is 
complete (Perego et al, 1995; Clemans et al, 1999; May et al, 2005) by the 
proteins encoded by the dltABCD operon (Figure 1.7) (Perego et al, 1995; 
Peschel et al, 1999).  
 
In a two-step reaction that occurs in the cytoplasm of S. aureus, the product of 
the dltA gene, a D-alanyl carrier protein ligase (Dcl), activates the D-alanine by 
hydrolysis of ATP and transfers this high energy D-alanyl AMP intermediate to 
the phosphopantetheine cofactor of the D-alanine carrier protein (Dcp), which is 
encoded by dltC (Perego et al, 1995; Peschel et al, 1999; Koprivnjak et al, 
1996). The roles of DltB and DltD are not completely clear, and several models 
exist (Percy and Gündling, 2014). The Fischer model suggests that DltB helps 
with the movement of D-alanine across the membrane while DltD is involved in 
the final transfer of the D-alanine to the LTA on the outside of the cell (Figure 
1.8A) (Perego et al, 1995; Reichman et al, 2013). On the other hand, the 
Neuhaus and Baddiley model suggests that the DltD protein helps in the 
delivery of the activated Dcl-D-alanyl AMP intermediate complex to the Dcp 
protein (Debabov et al, 2000; Koprivnjak et al, 2006), while DltB is a 
transmembrane protein that is involved in the passage of the D-alanyl-Dcp 
complex through the cytoplasmic membrane and the incorporation of the D-
alanine into the teichoic acids (Figure 1.8B) (Koprivnjak et al, 2006; Reichman 
et al, 2013). 
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Figure 1.7 Organization of the dlt operon in S. aureus 
This operon consist of dltA, dltB, dltC and dltD, which encodes for proteins of 485, 404, 
78 and 391 amino acids, respectively (Peschel et al, 1999). The structure of the dlt 
operon is conserved in other organisms such as E.faecalis, L. rhamnosus, B. subtilis 
and S. agalactiae (Neuhaus and Baddiley, 2003; Fabretti et al, 2006). Adapted from 
(Peschel et al, 1999). 
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Figure 1.8 Models for the D-alanylation of teichoic acids in S. aureus 
A. Fischer model: DltA activates D-alanine and transfers it to the carrier protein DltC. 
The DltB protein helps with the transfer of the D-alanine from DltC to undecaprenyl 
phosphate, while DltD is involved in the transfer of the residue to the LTA on the 
outside of the cell (Perego et al, 1995; Reichman et al, 2013). 
 
B. Neuhaus and Baddiley model: the DltA and DltC proteins maintain the same 
function, but DltD increases the efficiency of the delivery of the activated D-alanine 
from DltA to DltC. The DltB protein helps the charged DltC to cross the membrane and 
in the incorporation of the D-alanine into the teichoic acids (Debabov et al, 2000; 
Neuhaus and Baddiley, 2003; Koprivnjak et al, 2006; Reichman et al, 2013). 
 
Models adapted from (Reichmann et al, 2013). 
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It has been reported that D-alanine esterified to lipoteichoic acids is the 
precursor for the D-alanylation of the WTA (Haas et al, 1984; Koprivnjak et al, 
2006), and that they are transferred to the wall teichoic acids by transacylation 
(Perego et al, 1995; Fabretti et al, 2006). 
 
Changes in the degree of D-alanylation can affect the conformation and charge 
of the surface of S. aureus. The D-alanyl ester content of WTA is variable and 
can be modulated by environmental influences such as pH, temperature and 
salt concentrations (Neuhaus and Baddiley, 2003; Koprivnjak et al, 2006).  
 
Considering that the amino group of the D-alanine is protonated at neutral pH 
(predicted pKa of 8.42), the D-alanine moiety has a positive charge (Bernal et 
al, 2009). Due to the positive charge of the amino acid, the esterification of the 
cell wall leads to a decrease in the negative charge of the cell surface, 
conferring resistance to cationic antimicrobial peptides (Peschel et al, 1999; 
Fedtke et al, 2004) and other components of the immune system of the host 
such as defensins and phospholipase A2 (Peschel et al, 1999; Koprivnjak et al, 
2002). 
 
The inactivation of the dlt operon affects the susceptibility of S. aureus to 
glycopeptide antibiotics such as vancomycin (Peschel et al, 2000). Mutant 
strains for these genes have altered the activity of autolysins (Peschel et al, 
2000), biofilm formation (Gross et al, 2001; Fabretti et al, 2006) and virulence in 
the mouse model (Weidenmaier et al, 2004). The lack of D-alanylation also 
leads to increased susceptibility to phagocytic cells (Poyart et al, 2003) and to 
neutrophil killing (Collins et al, 2002), suggesting a role for the D-alanylation of 
teichoic acids in the modulation of the immune response (Fournier and Philpott, 
2005; Chan et al, 2007). 
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1.4 Host response and defence mechanisms 
 
Evolutionary evidence suggests that mechanisms of host defence existed by 
the time the ancestors of plants and animals diverged. This system is the Toll 
pathway of NFκB activation of gene function, and can be found in fruit flies such 
as Drosophila and in vertebrates, and evidence exists that occurs in plants 
(Wilson et al, 1997; O’Neil and Greene, 1998; Valanne et al, 2011). 
 
Recent evidence suggests that the emergence of vertebrates with jaws 
(gnathostomes) was accompanied by a change in the structure and function of 
the immune system that led to the appearance of the adaptive immune system 
(Flajnik and Du Pasquier, 2004; Cooper and Alder, 2006; Boehm et al, 2012). 
The vertebrate immune system can be classified into two sub-systems: the 
innate and adaptive immune systems. Innate immunity is evolutionary ancient 
and immediate, and is considered a non- specific response, while the adaptive 
system mediates highly specific but delayed response (Vivier and Malissen, 
2005). 
 
1.4.1 Innate immune system 
 
The innate immune system is capable of recognizing molecules that are 
evolutionary conserved and shared by many infectious agents, such as 
lipopolysaccharides, peptidoglycan, non-methylated CpG, mannan in yeast and 
double-stranded RNA (Beutler, 2004; Vivier and Malissen, 2005). These 
molecules are called "pathogen-associated molecular patterns" (PAMPs) and 
can be recognized due to a set of defined receptors called pathogen- or pattern-
recognition receptors (PRRs) (Ausubel, 2005; Akira et al, 2006). 
 
This first line of defence against infections is composed of the skin, the secreted 
mucus layer that overlays the epithelium in the respiratory, gastrointestinal and 
genitourinary tracts, soluble proteins such as antimicrobial peptides, bacterial 
permeability increasing proteins and complement system components, pattern-
recognition receptors that recognize and bind to molecular patterns expressed 
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on the surface of pathogens, and by cells like NK cells, macrophages and 
neutrophils (Figure 1.9) (Parkin and Cohen, 2001; Beutler, 2004; Carroll, 2004; 
Chaplin, 2010; Kumar and Sharma, 2010).  
 
1.4.1.1 Cellular components 
 
Neutrophils, mast cells, natural killer cells, macrophages and dendritic cells 
comprise the cellular components of the innate immune system (Kumar and 
Sharma, 2010). Vertebrates are largely dependent upon these cells for the 
engulfment and destruction of pathogens (Beutler, 2004). These cells can 
defend the organism on their own but they have evolved to work better with the 
elements of the adaptive immune system.  
 
Mast cells function as immune ‘sentinel’ cells that can respond directly to 
pathogens through phagocytosis and the production of reactive oxygen species 
and antimicrobial peptides (Dawicki and Marshall, 2007; Abraham and St John, 
2010). Mast cells also send signals that can modulate the innate and adaptive 
immune responses (Parkin and Cohen, 2001; Urb and Sheppard, 2012).  
 
Dendritic cells also work as ‘sentinels’ and are known as the link between innate 
and adaptive immunity. They can capture and process antigens, which cause 
their differentiation, which is called ‘maturation’. This maturation influences the 
type of the following immune response (Th1 vs Th2) (Clark et al, 2000; 
Steinman and Hemmi, 2006). 
 
Natural killer cells eliminate virally infected cells using cytotoxic proteins 
(Topham and Hewitt, 2009). Macrophages eliminate pathogens via 
phagocytosis, and they can also regulate lymphocyte activation and proliferation 
(Elhelu, 1983; Parkin and Cohen, 2001).  
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Figure 1.9 Components of the innate immune response in humans 
When a pathogen gets in contact with the host several elements work together in order 
to stop the infection. Some of these elements are shown here. Adapted from (Beutler, 
2004) and University of California San Francisco, Immunology Module 
(http://missinglink.ucsf.edu/lm/immunology_module/prologue/objectives/ obj02.html). 
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Neutrophils are dynamic cells that survey connective tissue, mucosal 
membranes, skeletal muscle and lymphatic organs for any sign of tissue 
damage, inflammation or invading microorganisms (Rigby and De Leo, 2012). 
Neutrophils can migrate to the site of infection for containment and clearance of 
the pathogens through the engulfment of the infectious particles, followed by 
destruction using large quantities of reactive oxygen species that are cytotoxic 
to pathogens (Beutler, 2004; Chaplin, 2010; Kumar and Sharma, 2010). These 
cells also produce enzymes that are involved in tissue repair after injury (Kumar 
and Sharma, 2010), as well as cytokines and chemokines, expanding the role 
of neutrophils to regulators of the immune response (Chaplin, 2010; Kumar and 
Sharma, 2010; Mantovani et al, 2011; Rigby and De Leo, 2012). 
 
1.4.1.2 Soluble components 
 
Cells are not the only components of the innate immune system. The soluble 
components of the innate immunity can be separated into two groups: sensors 
and effectors. Different molecules are responsible for sensing pathogens. For 
example, mannose-binding protein can recognize the terminal mannosyl 
residues on the surface of pathogens and activates the complement system via 
the lectin pathway (Matsushita and Fujita, 1992; Matsushita and Fujita, 1995; 
Thiel et al, 1997). C-reactive protein and other pentraxins can also bind directly 
to pathogens via lectin-like interactions (Beutler, 2004; Shishito et al, 2012). 
 
Collectins are calcium-dependent lectins that can be found in mammals and 
target and bind to carbohydrates in the surface of bacteria, fungi, viruses and 
even potential allergens. This binding leads to the agglutination of the target 
particle, mediating phagocytosis through specific receptors on the phagocytes 
(Hakansson and Reid, 2000; Beutler, 2004). Lipopolysaccharide-binding protein 
and CD14, in its soluble form, recognize lipopolysaccharide from several 
species of Gram-negative bacteria. This interaction leads to the activation of 
monocytes and macrophages with the subsequent secretion of inflammatory 
cytokines and other mediators (Schumann et al, 1994; Gutsmann et al, 2001; 
Beutler, 2004). 
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The previously discussed proteins are able to sense the pathogens in the host, 
but they are not able to eliminate them. Other extracellular molecules take care 
of that. Human skin is able to secrete fatty acids into the sebum and these 
molecules are extremely effective killing agents against S. aureus. They can 
prevent colonization by the bacteria, reduce the severity of the infection and kill 
S. aureus within abscesses (Miller et al, 1988; Wille and Kydonieus, 2003; 
Georgel et al, 2005; Cartron et al, 2014; Neumann et al, 2015). 
 
Human cells can produce proteins that are able to destroy the bacterial 
envelope like lysozyme and phospholipase (Femling et al, 2005), and iron-
binding proteins like transferrin and lactoferrin that are able to restrict the iron 
available for bacterial growth (Bullen, 1981; Bullen et al, 2005; Ling and 
Schryvers, 2006). Lactoferrin can also affect the motility and biofilm formation of 
certain bacteria (Singh et al, 2002). The bactericidal/permeability increasing 
protein (BPI) is produced by polymorphonuclear leukocytes and acts against 
Gram-negative bacteria, binding to the cells and causing growth arrest and 
outer membrane alterations, increasing its permeability (Mannion et al, 1990; 
Holweg et al, 2011). This protein can work together with phospholipase and kill 
Gram-negative bacteria such as E. coli and S. typhimurium (Elsbach et al, 
1979; Nevalanien et al, 2008).  
 
Mammals are able to synthesize two kinds of antimicrobial peptides: defensins 
and cathelicidins, which are expressed in neutrophils and in epithelia, 
respectively (Beutler, 2004). These antimicrobial peptides are normally short 
with an overall positive charge and a substantial proportion of hydrophobic 
residues (≥ 30%) (Zasloff, 2002; Hancock and Sahl, 2006). Because they are 
cationic peptides they can electrostatically interact with the bacterial membrane, 
which usually comprises negative polymers such as lipopolysaccharides and 
wall teichoic acids (Brodgen, 2006; Hancock and sahl, 2006; Thomas et al, 
2010). These peptides cause cell death through the disruption of the integrity of 
bacterial cell membrane, or the inhibition of extracellular polymer synthesis (like 
peptidoglycan synthesis) or intracellular functions (Ong et al, 2002; Yeaman 
and Yount, 2003; Hancock and Sahl, 2006). 
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1.4.1.3 Complement system 
 
The complement system is a family of about 30 serum and cell membrane 
proteins that can recognize and kill pathogens such as bacteria, virus infected 
cells and parasites (Gasque, 2004), and also takes part in the enhancement of 
B and T cells responses (Barrington et al, 2001; Carroll et al, 2004; Gál et al, 
2007; Ansari and Sayegh, 2008) and in tissue regeneration (Kimura et al, 2003; 
Shishido et al, 2012).  
 
Phylogenetically, complement is an ancient arm of the innate immunity 
(Gasque, 2004). While the adaptive immune system is present only in jawed 
vertebrates, complement components can also be found in jawless fish and 
non-vertebrate deuterostomes. The liver is the major source of most of the 
complement components in mammals, with the exception of C1q, Factor D and 
C7 (Morgan and Gasque, 1997; Gasque, 2004): C1q can be synthesized by 
epithelial cells, monocytes and fibroblasts (Tenner and Volkin, 1986), Factor D 
is mainly produced by adipocytes (White et al, 1992) and the major sources of 
C7 are monocytes and macrophages (Würzner et al, 1994).  
 
The components circulate in the serum as pro-proteins and can be activated 
through cleavage, which removes the inhibitory fragment of the molecule and 
exposes the active site. This activation occurs in a cascade-like manner, with 
components activating each other (Gál et al, 2007). Once activated, these 
components have a short half- life before being inactivated again. 
 
When activated, the complement system generates a potent response and 
causes intense local inflammation that can severely damage host tissues. To 
control the correct activation of the complement system the host cells are 
protected by regulatory molecules that inhibit the assembly of the central C3-
cleaving enzymes or the formation of the membrane attack complex (Morgan, 
1995; Miwa and Song, 2001; Gasque, 2004; Kim and Song, 2006). These 
regulatory molecules can be soluble plasma proteins or can be expressed on 
the cell membrane (Chaplin, 2010).  
 31 
Three separate pathways can activate the complement system: classical, 
alternative (or properdin) and lectin pathways (Figure 1.10). The classical 
pathway is activated by antibodies; the lectin pathway is activated by the 
recognition of the mannose binding protein target in the bacteria; and the 
alternative pathway is spontaneously activated by C3 and the interaction 
between Factor B and the microbial surface (Beutler, 2004; Carroll, 2004; 
Gasque, 2004). The three activation pathways include the activation of C3b, 
which is able to bind to pathogens and opsonize them for phagocytosis, and the 
generation of C5a (inflammatory and chemotactic molecule) and C5b (Beutler, 
2004). The activation and sequential deposition of C5b through C9 is essential 
for the formation of the membrane attack complex (MAC), a ring shaped 
assembly of protein subunits that can kill Gram-negative bacteria through 
osmotic lysis but is ineffective against Gram-positive bacteria due to their thick 
peptidoglycan layer (Muller-Eberhard, 1986; Bestebroer et al, 2010; Yongqing 
et al, 2012).  
 
1.4.1.3.1 Classical Pathway 
 
The classical pathway can be activated by the formation of a soluble antigen-
antibody complex or by the binding of an antibody to an antigen on a suitable 
target, like a bacterial cell (Figure 1.10) (Gasque, 2004).  
 
The first component of this pathway is C1q, a very versatile pattern recognition 
molecule (Ricklin et al, 2010). The C1q component can interact with these 
immune complexes and cause the sequential activation of the C1r and C1s 
proteases, forming the C1 complex (C1qC1r2C1s2) (Ricklin et al, 2010). C1q 
can also interact and be activated by bacterial, fungal and virus membrane 
components (Brown et al, 2002; Gasque, 2004). Activated C1s can cleave C2 
and C4, activating them and forming a C3 convertase, C4bC2a. This C3 
convertase can cleave C3 into C3a and C3b. 
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Figure 1.10 Activation pathways of the complement system 
The complement system can be activated by three pathways: classical (CP), lectin (LP) 
or alternative (AP). The CP is activated by immune complexes, LP by the recognition of 
carbohydrates present on the cell surface and AP is spontaneously activated by 
activating surfaces, water and factor B. These three pathways include the activation of 
C3b through the C3 convertases, the generation of C5b by the C5 convertases and the 
liberation of C3a and C5a, inflammatory and chemotactic molecules. The three 
pathways lead to the formation of the membrane attack complex (MAC). Adapted from 
(Gasque, 2004; Ricklin et al, 2010). 
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The C3a fragment is a small cationic pro-inflammatory peptide (Klos et al, 2009) 
that also has potent antimicrobial activity by itself (Nordahl et al, 2004). Along 
with C5a, anaphylatoxin produced by the cleavage of the component C5 by the 
C5 convertases, the C3a fragment is involved in the regulation of vasodilation 
and permeability of small blood vessels (Ember et al, 1998), tissue regeneration 
(Mastellos et al, 2001; Klos et al, 2009), tissue fibrosis (Hillebrandt et al, 2005) 
and brain development (Klos et al, 2009). As an anaphylatoxin C3a acts as a 
chemoattractant for neutrophils, eosinophils, monocytes, mast cells and 
macrophages towards the sites where the complement system has been 
activated (Hartmann et al, 1997; Haas and van Strijp, 2007; Klos et al, 2009; 
Ricklin et al, 2010). This molecule is also able to modulate the synthesis of IL-6 
and TNF-α from B cells and monocytes (Fischer and Hugli, 1997; Fischer et al, 
1999). 
 
The cleavage of the complement component C3 also produces the C3b 
molecule. This cleavage exposes an intramolecular thioester bond present in 
C3b that allows it to bind covalently to amines and carbohydrates found in the 
bacterial surface (Law and Dodds, 1997; Rooijakkers and van Strijp, 2007; 
Ricklin et al, 2010; Berends et al, 2013). 
 
This deposition of the C3b molecule on the bacterial surfaces acts as a signal 
for phagocytic uptake by neutrophils and macrophages (Rooijakkers and van 
Strijp, 2007; Shishido et al, 2012). The opsonisation of the bacteria also leads 
to the amplification of cleavage of C3 via the activation of the alternative 
pathway (Rooijakkers et al, 2005c; Laarman et al, 2011) and the formation of its 
C5 convertase (Petersen et al, 2000; Ricklin et al, 2010). The binding of C3b to 
C4bC2a shifts the substrate specificity from C3 to C5 and leads to the formation 
of the lectin and classical pathway C5 convertase (C4bC2aC3b) (Petersen et al, 
2000; Ricklin et al, 2010). 
 
The C5 convertase cleaves C5 producing C5a, another protent anaphylatoxin 
(Haas and van Strijp, 2007; Klos et al, 2009), and C5b. The C5b molecule leads 
to the generation of the C5b-C9 complex (also known as membrane attack 
complex or MAC), which is capable of inserting itself into the bacterial 
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membrane and generate pores, leading to lysis (Müller-Eberhard, 1986; 
Laarman et al, 2011; Berends et al, 2013). 
 
This convertase initiates the late stages of complement activation, cleaving C5 
to form C5a and C5b. The C5-cleavage product C5a is a proinflammatory 
molecule that attracts phagocytes to the site of infection and primes them for 
bacterial uptake (Bestebroer et al, 2010), while C5b is necessary for formation 
of the membrane attack complex in the cell membrane (Rawal and Pangburn, 
2001). C5b interacts with C6 and then with C7, which induces a hydrophilic-
amphiphilic transition that allows this trimolecular complex to bind to the cell 
membrane (Müller-Eberhard, 1986). C8 binds next and this C5b-C8 complex is 
able to lyse erythrocytes but not nucleated cells. When C9 binds to the C5b-C8 
complex this induces the binding of more units of C9, forming a poly-C9 that 
can form disrupt and form a large transmembrane pore that leads to the lysis of 
the target cell (Müller-Eberhard, 1986; Ricklin et al, 2010).  
 
Due to the strong response and inflammation that this pathway can generate, a 
tight regulation system is in place. The activation of the classical pathway can 
be stopped from the start by the C1 inhibitor (C1-inh), a secreted glycoprotein 
that is able to break the C1qC1rC1s complex and turn it into C1rC1s(C1-inh)2 
complexes, leaving the C1q protein bound to the activator (Ziccardi and 
Cooper, 1979; Sim et al, 1979). The C2 receptor inhibitor trispanning (CRIT) 
can bind to C2 and inhibit its activation by the C1s protease (Inal et al, 2005). 
 
1.4.1.3.2 Lectin pathway 
 
Mannose-binding lectins (MBL) and ficolins (H-ficolin and L-ficolin) act as the 
pattern recognition molecules that activate the lectin pathway (Schwaeble et al, 
2002; Gasque, 2004; Ma et al, 2004; Seelen et al, 2005; Ricklin et al, 2010). 
They are able to recognize and bind to carbohydrates present in the bacterial 
cell wall, such as mannose and N-acetylglucosamine (Figure 1.10) (Matsushita 
et al, 2000b). 
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This binding induces the activation of the MBL-associated serine proteases or 
MASPs. These proteases share structural similarity with the C1s and C1r 
proteases from the classical pathway (Ricklin et al, 2010) and the MBL-MASPs 
complex has a strong structural and functional similarity with C1qC1rC1s, the 
recognition complex of the classical pathway (Roos et al, 2003). In human 
blood three types of MASPs have been identified, MASP-1, MASP-2, and 
MASP-3, and a truncated form of MASP-2 called sMAP (small MBL-associated 
protein) or Map19 (MBL-associated plasma protein of 19 kDa) (Takahashi et al, 
1999; Matsushita et al, 2000a; Ma et al, 2004; Takahashi et al, 2006). 
 
The binding of MBL to the ligands present in the target cells induces the 
activation of the MASPs pro-enzymes, and this activated complex is capable of 
cleaving the complement components C2 and C4, leading to the formation of 
the C3 convertase C4bC2a (Matsushita et al, 2000a; Petersen et al, 2000; 
Schwaeble et al, 2002; Ricklin et al, 2010). As in the classical pathway, this C3 
convertase is able to cleave C3, which leads to the formation of the C5 
convertase C4bC2aC3b. This leads to the late stages of complement activation, 
ending with the formation of the membrane attack complex (Matsushita et al, 
2000a; Petersen et al, 2000; Roos et al, 2003; Seelen et al, 2005). 
 
C1-inh can associate with the MBL complex and inhibit its activity (Matsushita et 
al, 2000a). The complement Factor I is one of the regulatory proteins of the 
complement system, a serine protease that can inactivate C3b and C4b through 
the cleavage of alpha chains in the components (Schlaf et al, 2001; Gasque, 
2004; Ricklin et al 2010).  
 
1.4.1.3.3 Alternative pathway 
 
This pathway of complement activation is also known as the properdin 
parthway, due to the important role that this plasma component has. The 
complement component C3 is relatively inert in its native form and has few 
ligands. In plasma C3 can turn into C3H2O via spontaneous hydrolysis, exposing 
new binding sites (Figure 1.10) (Harboe and Mollnes, 2008; Ricklin et al, 2010). 
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This form of C3 is unstable, and is either inactivated by hydrolysis or can form 
covalent bonds with the cell surface of a nearby target, allowing the 
complement activation to continue when deposited on a non-self surface or on 
immune complexes (Harboe and Mollnes, 2008). This binding to a cell surface 
favours the binding of the Factor B protease to C3H2O, and Factor D cleaves 
Factor B into Ba and Bb. The C3bBb complex is formed on the cell surface. The 
half-life of this complex is short under physiological conditions but it can be 
stabilized 5- to 10-fold by association with properdin (Fearon and Austen, 1975; 
Kemper et al, 2010). This spontaneous activation of C3 is controlled and 
inhibited by Factor H, a glycoprotein that prevents the binding of Factor B and 
promotes the dissociation of the C3Bb complex (Schlaf et al, 2010).  
 
This C3bBb complex is the C3 convertase of the alternative pathway, capable 
of cleaving C3 into C3a and C3b (Beutler, 2004; Gasque, 2004). This creates 
an efficient cycle of C3 cleavage and convertase assembly that markedly 
amplifies the immune response of the complement system. This amplification 
leads to increased density of C3b, helping the formation of the C4bC2aC3b and 
C3bBbC3b complexes, the C5 convertases. As stated previously, the formation 
of these convertases shifts the substrate specificity from C3 to C5, initiating the 
late stages of complement activation (Petersen, 2000; Seelen et al, 2005; 
Ricklin et al, 2010). The formation of C5b initiates the assembly of the terminal 
complement complex, leading to cell lysis.  
 
1.4.1.4 Phospholipase A2 
 
The phospholipase A2 (PLA2) superfamily consist in a varied group of enzymes 
that are capable of hydrolysing phospholipids in the sn-2 position of the ester 
bond. This reaction generates a free fatty acid and a lysophospholipid (Figure 
1.11) (Six and Dennis, 2000; Balsinde et al, 2002; Wu et al, 2010). The fatty 
acids, such as arachidonic acid and oleic acid, play a role in the storage of 
energy (Six and Dennis, 2000). Arachidonic acid can also be converted into 
eicosanoids, signalling molecules that play a role in immune responses, 
inflammation and pain perception (Balsinde et al, 1999; Balsinde et al, 2002; 
Schaloske and Dennis, 2006; Dennis et al, 2011). Lysophospholipids, the other 
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molecule generated by PLA2, can serve as a precursor for lipid mediators such 
as lysophosphatidic acid and platelet activating factor (PAF), and is involved in 
phospholipid remodeling, cell signalling and membrane perturbation (Six and 
Dennis, 2000; Schaloske and Dennis, 2006; Dennis et al, 2011). 
 
This superfamily can be divided into five kinds of enzymes based on their 
catalytic mechanism as well as functional and structural features: secreted 
PLA2 (sPLA2); cytosolic PLA2 (cPLA2); calcium-independent PLA2 (iPLA2); 
platelet activating factor acetylhydrolase (PAF-AH) and lysosomal PLA2 
(Schaloske and Dennis, 2006; Dennis et al, 2011). The cytosolic PLA2 (cPLA2) 
are large cytosolic proteins with a molecular weight of 85 kDa that have a serine 
residue in the catalytic site (Marshall et al, 2000, Chakraborti, 2003). These 
enzymes utilize calcium not for catalysis but for translocation to the intracellular 
membrane. These enzymes have a preference for phospholipids containing 
arachidonic acid and it has been suggested that they might be associated with 
signalling cascades associated with receptors (Six and Dennis, 2000; 
Chakraborti, 2003; Dennis et al, 2011). 
 
iPLA2 are enzymes with a molecular weight of 85 kDa and a serine residue in 
the catalytic site as for cPLA2 (Burke and Dennis, 2009). They are intracellular 
enzymes with no substrate specificity for phospholipids containing arachidonic 
acid, have no need for calcium and contain eight ankyrin repeats in the N-
terminal half of the molecule (Balsinde et al, 1999; Schaloske and Dennis, 
2006; Burke and Dennis, 2009). It has been suggested these enzymes are 
involved in bone formation, sperm development, insulin secretion, and 
monocyte recruitment and directionality (Mishra et al, 2008; Burke and Dennis, 
2009). 
 
Unlike the other PLA2s with catalytic dyads in their active sites, the PAF-AH has 
a catalytic triad formed by a serine, histidine and aspartic acid (Tjoelker et al, 
1995; Burke and Dennis, 2006). This enzyme can act on oxidized lipids and 
platelet activating factor present in the sn-2 position, and it has been shown that 
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Figure 1.11 Hydrolysis of phospholipid by phospholipase A2  
PLA2 enzymes are able to hydrolyse phospholipids in the sn-2 position generating fatty 
acids and lysophospholipids. X: head group. Adapted from (Murakami et al, 2011). 
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this enzyme has pro-inflammatory activity (Chakraborti, 2003; Burke and 
Dennis, 2006). The lysosomal PLA2 has calcium-independent PLA2 and 
transacylase activities, the same catalytic triad as PAF-AH, it localizes in 
lysosomes and shows preference for phosphatidylcholine and 
phosphatidylethanolamine (Schaloske and Dennis, 2006). 
 
The secreted PLA2 (sPLA2) is a group of small secreted proteins (14-16 kDa) 
that usually contains 6 to 8 sulphide bonds (Schaloske and Dennis, 2006; 
Dennis et al, 2011). Calcium is required for their activity due to the 
histidine/aspartic acid catalytic dyad (Dennis et al, 2011; Murakami et al, 2011; 
Murakami and Lambeau, 2013). There are other conserved residues that 
participate in the active site hydrogen bonding networks, including tyrosines and 
glycines in the calcium binding loop and a second aspartate residue that can 
activate and orient the catalytic histidine (Six and Dennis, 2000; Murakami et al, 
2011).  
 
The sPLA2 enzymes can be found in mammals and snake venoms, and have 
also been isolated from plants, invertebrates and fungi (Schaloske and Dennis, 
2006; Nevalainen et al, 2008). In mammals these enzymes can be found in 
several fluids, including tears, blood, seminal plasma, inflammatory exudates 
and the intestinal lumen (Kunze and Bohn, 1978; Tayakama et al, 1991; 
Weinrauch et al, 1996; Qu and Lehrer, 1998; Mennschikowski et al, 2006). 
They are capable of acting on cellular membranes, microbial membranes, 
lipoproteins, pulmonary surfactant and microvesicles (Murakami et al, 2011), 
but show differential selectivity towards different cell types: Gram-positive 
bacteria > Gram-negative bacteria >> eukaryotic cells (Nevalainen et al, 2008). 
sPLA2 do not show specificity for particular sn-2 position fatty acids,  but 
instead for certain head groups of the phospholipids (Schaloske and Dennis, 
2006; Dennis et al, 2011).  
 
These enzymes play a role in inflammatory diseases such as rheumatoid 
arthritis (Schaloske and Dennis, 2006), in the development of atherosclerosis 
(Webb, 2005), exocytosis (Lambeau and Gelb, 2008; Harris and Scott-Davey, 
2013) and are involved in coagulation (Schaloske and Dennis, 2006; Lambeau 
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and Gelb, 2008). They also play a role in the immune system of the host due to 
their antifungal (Moerman et al, 2002; Samy et al, 2007) and antiviral activities 
(Dennis et al, 2011), but mostly through their well known antibacterial activity 
against Gram-positive and Gram-negative bacteria (Weiss et al, 1994; 
Weinrauch et al, 1996; Qu and Lehrer, 1998; Laine et al, 1999; Buckland and 
Wilton, 2000).  
 
 
1.4.2 Adaptive immune system 
 
As stated above (Chapter 1.4.1), the innate immune system can fight infection 
very efficiently, but is also capable of causing important collateral damage. The 
emergence of vertebrates with jaws (gnathostomes) was accompanied by the 
appearance of the adaptive immune system (Cooper and Alder, 2006; Boehm 
et al, 2012). The adaptive immune system increases the efficacy of the immune 
response by focusing the response in an antigen-specific manner using highly 
specific receptors, minimizing collateral damage (Palm and Medzhitov, 2009). 
This system can recognize bacteria, viruses, fungi and parasites (Cooper and 
Alder, 2006). 
 
An important difference with the innate immunity is that adaptive immunity is 
able to generate long lasting immunological memory. This provides protection 
from future infections with the same pathogen via an accelerated response 
upon a new encounter (Usharauli, 2010). Another difference is that the adaptive 
immune response is relatively slow in comparison with the innate immunity 
(Hedrick, 2004). One problem with the adaptive system is that because the 
receptors are randomly generated they can potentially lead to autoimmunity or 
to allergies (Palm and Medzhitov, 2009).  
 
The adaptive immune system uses randomly generated, clonally expressed and 
highly specific receptors of unlimited specificity to recognize microbial invaders 
(Palm and Medzhitov, 2009), allowing this system to focus the response and 
minimize the collateral damage. The lymphocytes are the specialized cell type 
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of the adaptive immune system, they generate from progenitor cells within the 
bone marrow with receptors in their cell surface that are able to recognize 
different antigen configurations of specific pathogens (Parking and Cohen, 
2001). Once this recognition takes place a clonal amplification is triggered, 
leading to cell differentiation and antibody production that has the same antigen 
binding specificity of the receptor in the lymphocyte that interacted with the 
pathogen in the first place (Figure 1.12) (Parkin and Cohen, 2001; Cooper and 
Alder, 2006). 
 
The response of the adaptive immune system is a multistep process with 
several checkpoints that can control different aspects of the response and 
integrate information from different signals. These checkpoints help the 
response to determine the origin of the infection and its type, the extent and 
duration of the infection and the requirement for immediate or future defence 
(Iwasaki and Medzhitov, 2004; Pasare and Medzhitov, 2004; Palm and 
Medzhitov, 2009). 
 
Adaptive immunity is mediated by a large number of immunoglobulins and B 
and T cell receptors (BCRs and TCRs, respectively), which are generated 
through recombinaton of variable (V), diversity (D) and joining (J) gene 
segments (Litman et al, 2010). Molecules encoded by the major 
histocompatibility complex (MHC) alleles control the TCR-mediated response 
through the presentation of the antigenic peptides (Vivier and Malissen, 2005). 
Each TCR has an a priori ligand (Vivier and Malissen, 2005). The 
immunoglobulins function as membrane-bound receptors on the B cells and 
their precursor cells, and they are selected by their antigen-binding specificity 
and affinity during their development (Vivier and Malissen, 2005; Palm and 
Medzhitov, 2009). 
 
It is known that the complement system is able to modulate adaptive immunity 
(Ricklin et al, 2010). The activation and deposition of complement components 
within immune complexes helps to target them to cells that have receptors 
against these antigens, such as B lymphocytes (Parkin and Cohen, 2001). The
   
 42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12 Components of the adaptive immune system 
When antigens are recognized by specific receptors present in B and T cells, these 
cells are activated and differenciated within lymphoid tissue. This leads to the effector 
response through antibodies released into the blood by activated B cells or through 
effector T cells travelling to the infection site.  
Adapted from (Parkin and Cohen, 2001). 
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antibody response is also controlled by complement-derived fragments, as 
shown in experiments where animals without C3 had a reduced formation of 
antibodies against T cell-dependent antigens (Pepys, 1974; Gasque, 2004). It 
has also been reported that the alpha chain of the C4b protein can activate B-
lymphocytes through the CD40 receptor (Brodeur et al, 2003). The C1q 
component of the classical pathway of complement activation also acts in 
adaptive immunity after binding to natural IgM complexes to antigens (Heyman, 
2000).  
 
1.4.3 Rabbit immune system 
 
The European laboratory rabbit (Oryctolagus cuniculus) belongs to the 
Leropidae family of the Lagomorpha order (Okerman, 1989). Originally they 
could be found in the Iberian Peninsula, western France and northern Africa 
(Gibb, 1990), but currently their presence is widespread throughout the world 
(Thompson and King, 1994). 
 
The rabbit was an important model species during the early times of 
immunology and the first studies about allelic exclusion and inheritance of 
idiotypes were carried out in rabbits (Davie et al, 1971; Hague and Kindt, 1998). 
They were also used in early studies of transplantation and histocompatibility 
(Ehlers and Ahrons, 1971; Goldstein et al, 1975; Hague and Kindt, 1998). This 
species has also been used as a model for the study of rheumatoid arthritis 
(Beischer et al, 2002), atherosclerosis (Yanni, 2004; Phinikaridou et al, 2009), 
syphilis (Froberg et al, 1993), herpes virus (Schlitt et al, 1986), adult T cell 
leukemia-lymphoma (Simpson et al, 1996) and human immunodeficiency virus 
(Kulaga et al, 1989), among others. Currently rabbit is the preferred animal for 
antibody production due to their convenient size, life span, ease of handling and 
bleeding, and because the rabbit can produce sufficient high-titer, high-affinity, 
precipitating antiserum (Hanly et al, 1995; Leenaars and Hendriksen, 2005).  
 
The immune system of the rabbits is similar to the human, with small 
differences. It has been shown that mammals with gestation periods longer than 
60 days have mature immune systems before birth (Solomon, 1970). Rabbits 
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have relatively short gestation periods of 31-32 days (Patton, 1994) and at the 
time of birth they are physiologically immature with not fully developed lymphoid 
organs (Jeklova et al, 2007). 
 
The role of the appendix is another difference between humans and rabbits. 
The appendix is an appendage located from the postero-medial wall of caecum 
without any known function in humans and is regarded as a vestigial remnant of 
our herbivorous ancestors (Malla, 2003; Ansaloni et al, 2009). On the other 
hand, in rabbits the appendix has a role as primary lymphoid organ involved in 
the maturation and production of B cells (Hague and Kindt, 1998; Drouet-Viard 
and Fortun-Lamothe, 2002). These newly generated B cells undergo a selection 
process in the appendix, involving self and foreign antigens (Pospisil and Mage, 
1998). Studies of rabbit blood lymphocytes showed that they have a very 
heterogenous population spite their morphologically homogenous appearance 
(Sell, 1979). 
 
Differences also can be found between human and rabbit immunoglobulins. In 
human serum five immunoglobulin classes can be found: IgG, IgM, IgA, IgE and 
IgD (Janeway et al, 2001). Rabbit immunoglobulins include IgE and IgM, with 
only one gene for IgE and 13 IgA genes with no IgD gene reported (Hague and 
Kindt, 1998). An important feature of these immunoglobulins are the differences 
in structure between allelically determined immunoglobulins. Somatic gene 
conversion is responsible for antibody diversity in rabbits (Hague and Kindt, 
1998; Drouet-Viard and Fortun-Lamothe, 2002).  
 
 
1.5 Staphylococcus aureus immune evasion strategies 
 
In order to successfully colonize the host, S. aureus expresses many virulence 
factors that interact with the environment and facilitate the adherence to host 
tissue (Tompkins et al, 1990; van Belkum et al, 2009). S. aureus also produces 
several wall associated and excreted proteins that contribute to its escape from 
the immune system of the host (Foster, 2004). The bacterium is capable of 
defensin evasion, neutrophil migration evasion, complement evasion and 
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reactive oxygen species attack evasion (Rooijakkers et al, 2005a). The majority 
of the described evasion proteins appear to be involved in avoiding complement 
attack (Rooijakkers et al, 2005a). 
 
Antimicrobial peptides are an essential part of the host innate immune system 
and they are responsible for the first line of defence against pathogens (Jin et 
al, 2004; Ryu et al, 2014). Most of these peptides are cationic and are able to 
interact with the anionic microbial cell wall, leading to the disruption of the 
integrity of bacterial cell membrane (Rooijakkers et al, 2005a; Ryu et al, 2014). 
S. aureus can change the composition and the net charge of its cell wall 
allowing the repulsion of the cationic peptides through the incorporation of D-
alanine and L-lysine into its teichoic acids or phospholipids using the dltABCD 
operon and the mprF gene product, respectively (Peschel et al, 1999; Collins et 
al, 2002; Yeaman and Yount, 2003; Bera et al, 2005; Rooijakkers et al, 2005a).  
 
Staphylokinase is a protein secreted by S. aureus that has fibrinolytic activity 
and can bind to defensins from human neutrophils, inhibiting its bactericidal 
effect (Jin et al, 2004; Peschel and Sahl, 2006; Ryu et al, 2014). This protein 
also has anti-opsonic properties, preventing Fc receptor-mediated phagocytosis 
(Rooijakkers et al, 2005b). S. aureus produces peptidases and proteases, such 
as metalloproteinase and aureolysin, that have the ability to cleave cationic 
antibacterial peptides (Shaw et al, 2004; Sieprawska-Lupa et al, 2004; Ryu et 
al, 2014).  
 
S. aureus is also resistant to lysozyme via the O-acetylation of the N-
acetylmuramic acid on its peptidoglycan (Bera et al, 2005; Bera et al, 2007). 
Resistance to lysozyme allows the bacteria not only to avoid direct 
peptidoglycan degradation, but also the production of IL-1β. Peptidoglycan 
degradation leads to the secretion of IL-1β by macrophages and the primary 
role of this interleukin in host defence is the regulation of the recruitment of 
neutrophils to the sites of infection (Shimada et al, 2010). 
 
As one of the major components of the innate immune system, neutrophils are 
the primary defence against invading organisms and provide a fast, non-specific 
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and potent response (Rigby and De Leo, 2012). S. aureus produces surface 
components and secreted molecules that can act as neutrophil chemotactic 
molecules directly or via complement cascade components (Standiford et al, 
1994; Yao et al, 1996; McLoughlin et al, 2006). Simultaneously, S. aureus can 
evade host defence used by neutrophils, including the ability to modulate 
normal neutrophil turnover, causing a delay in neutrophil apoptosis or 
accelerated neutrophil lysis (De Leo, 2004; Rigby and De Leo, 2004). This 
alteration facilitates the survival of the pathogen and promotes infection (Rigby 
and De Leo, 2012).  
 
Inside the neutrophils, pathogens are killed by reactive oxygen species 
contained within granules (Beutler, 2004; Chaplin, 2010; Kumar and Sharma, 
2010). S. aureus produces several molecules that help with the evasion of 
reactive oxygen species attack, such as catalase. This protein is able to 
inactivate toxic hydrogen peroxide and free radicals that are produced within 
phagocytic cells (Rooijakkers et al, 2005a; Kim et al, 2012). S. aureus produces 
a yellow carotenoid pigment that can scavenge oxygen free radicals (Foster, 
2005, Liu et al, 2005), and also expresses two superoxide dismutase enzymes 
that remove the superoxide radicals (O2-) (Karavolos et al, 2003). S. aureus 
also secretes cytolytic toxins that can damage the neutrophils that attempt to 
engulf and kill this pathogen (Foster, 2005).  
 
S. aureus can produce proteins that are capable of inhibiting neutrophil 
recruitment to the site of infection (Foster, 2005). One of these proteins is the 
extracellular adherence protein (Eap), capable of blocking recruitment by 
interfering with several interactions of adhesion receptors and ligands, such as 
intracellular adhesion molecule-1 (ICAM-1) present on the surface of 
endothelial cells (Chavakis et al, 2002). This binding prevents leukocyte 
adhesion, diapadesis and extravasation (Foster, 2005; Hammel et al, 2007a). 
This suggests that this protein has anti-inflammatory activity (Chavakis et al, 
2002; Chavakis et al, 2005).  
 
Another protein that can affect the recruitment of neutrophils is chemotaxis 
inhibitory protein of S. aureus (CHIPS). CHIPS can bind the formyl peptide 
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receptor (FPR) and the C5a receptor (C5aR) present in neutrophils, inhibiting 
the binding of their normal agonist (de Haas et al, 2004; Postma et al, 2004; 
Foster, 2005). It has been suggested that CHIPS plays a role in the early 
stages of bacterial infection (de Haas et al, 2004).  
 
Another S. aureus immune evasion strategy is its ability to minimize or inhibit 
host recognition by modifying its surface (Rigby and De Leo, 2012). The 
expression of capsule has been associated with an increase in the virulence in 
animal models. The capsular polysaccharides are able to modify the negative 
charge of the bacterial surface (O’Riordan and Lee, 2004; Vuong et al, 2004) 
and in vitro assays have revealed that the presence of capsule reduces the 
phagocytosis of the pathogens by neutrophils in the presence of normal serum 
opsonins, indicating that the capsule has anti-opsonic properties (Thakker et al, 
1998; Foster, 2005).  
 
S. aureus produces Protein A, which has the ability to bind to the Fc region of 
immunoglobulins, coating the bacteria with antibodies in a nonopsonic 
orientation. This provides a disguise that disrupts the opsonization and 
phagocytic uptake (Nizet, 2007; Rigby and De Leo, 2012). Clumping factor A 
(ClfA), a fibrinogen-binding protein that is present in the surface during 
stationary phase, is produced by S. aureus (McDevitt et al, 1997) and this helps 
the bacteria to become coated with fibrinogen inhibiting the access and 
deposition of opsonins (Foster, 2005). This protects S. aureus from 
phagocytosis by macrophages and neutrophils (Palmqvist et al, 2004; Higgins 
et al, 2006). S. aureus produces serine proteases (SspA), cysteine proteases 
(SspB) and metalloproteases that are also capable of cleaving the 
immunoglobulins in solution and bound to the cell surface (Shaw et al, 2004; 
Nizet et al, 2007; Fernández Falcon et al, 2011). 
 
S. aureus makes cytolytic toxins that target the leukocytes and form pores that 
lead to cell lysis (Foster, 2005; Nizet, 2007). Whilst the Panton-Valentine 
leukocidin (PVL) is toxic just for leukocytes, the γ-hemolysyn or γ-toxin also 
affects erythrocytes (Foster, 2005). It has been shown that S. aureus can also 
avoid the action of leukocytes via the production of adenosine from AMP, ADP 
 48 
or ATP, as adenosine receptor-mediated signalling on phagocytes interferes 
with phagocytosis by polymorphonuclear leukocytes (Kim et al, 2012). 
 
S. aureus has a large number of complement system evading strategies. 
Protein A and its ability to bind antibodies at the bacterial surface can also block 
the classical pathway of complement activation by interrupting pathogen 
recognition. Protein A can bind to the Fc region of immunoglobulin G, blocking 
the Fc-receptor-mediated complement activation via C1q (Rooijakkers et al, 
2005a; Rooijakkers and van Strijp, 2007). 
 
The bacteria excrete extracellular fibrinogen binding protein (Efb). This 
molecule is able to bind to the C3d region of complement component C3, 
blocking its deposition on the bacterial cell surface and subsequent 
phagocytosis of the pathogen (Lee et al 2004a; Jongerius et al, 2007), or further 
activation beyond C3b (Lee et al, 2004b). This allows Efb to block the 
alternative pathway convertase (C3bBb) and the C5 convertases of the 
lectin/classical pathway (C4b2a3b) and of the alternative pathway (C3bBb3b) 
(Rooijakkers et al, 2005a; Jongerius et al, 2007). Another excreted protein 
involved in immune evasion is the extracellular complement-binding protein 
(Ecb), also known as Ehp (Hammel et al, 2007b; Jongerius et al, 2012). This 
protein is a homologue of Efb that can also bind to C3b and inactivate the C3b 
containing convertases, blocking all the activation pathways of complement 
activation (Jongerius et al, 2007; Jongerius et al, 2012). 
 
The surface protein SdrE of S. aureus has been implicated in human platelet 
aggregation (O’Brien et al, 2002) and is capable of recruiting the complement 
regulatory protein Factor H and inhibiting the alternative pathway of 
complement (Sharp et al, 2012). Factor H is able to accelerate the dissociation 
of the alternative pathway C3 convertase (C3bBb) and acts as a cofactor for the 
Factor I mediated cleavage of C3b into C3bi, the inactive form of this 
complement component (Foster 2005; Jozsi y Zipfel, 2008). The bacteria use 
the surface protein ClfA to recruit Factor I (Hair et al, 2010) and it has been 
shown that the Ecb protein enhances the acquisition of Factor H from the serum 
(Amdahl et al, 2013).  
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Another immune evasion protein produced by S. aureus is the staphylococcal 
Ig-binding protein (Sbi) (Upadhyay et al, 2008). This protein has four domains 
and is able to affect the adaptive and innate immune systems of the host. The 
two N-terminal domains (Sbi-I and Sbi-II) are IgG-binding-domains that allow 
the protein to interfere directly with adaptive immunity (Zhang et al, 1998; Atkins 
et al, 2008), while the Sbi-III and Sbi-IV domains can modulate the complement 
system through binding with C3 (Burman et al, 2008; Upadhyay et al, 2008). 
 
SCIN, or staphylococcal complement inhibitor, is a protein secreted by S. 
aureus and is considered the most efficient complement inhibitor because is 
able to block all the complement pathways, efficiently preventing the 
phagocytosis of S. aureus and the production of C3a (Rooijakkers et al, 2005c; 
Rooijakkers et al, 2006; Rooijakkers and van Strijp, 2007). SCIN is produced 
during the early stages of growth, making the protein an effective immune 
modulator (Rooijakkers et al, 2006). SCIN can block complement through the 
binding and stabilization of the membrane-bound C3 convertases (C4bC2a and 
C3bBb), which affects the complement cascade in different ways (Foster, 2005; 
Rooijakkers et al, 2005c). 
 
The dissociation of the C3 convertases leaves the membrane-bound 
components C4b and C3b available to act as cofactors for the cleavage of C2 
and Factor B, respectively. The stabilization of C3bBb and C4b2a on the 
surface of S. aureus prevents the generation of additional convertases (Foster, 
2005; Rooijakkers et al, 2005c; Ricklin et al, 2009). The binding of SCIN also 
affects the enzymatic activity of these complexes, making the convertases no 
longer able to cleave C3 (Rooijakkers and van Strijp, 2007). Finally, SCIN is 
able to prevent further C3b deposition in the bacterial surface, interfering with 
the amplification loop of the alternative pathway of complement activation 
(Foster, 2005; Rooijakkers et al, 2005c). As the C5 convertases are no longer 
being formed, SCIN attenuates the neutrophil response induced by the release 
of C5a and also the formation of the membrane attack complex on the bacteria 
(Rooijakkers et al, 2006; Rooijakkers et al, 2007). 
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The staphylococcal superantigen-like proteins (SSLs) have structural similarity 
to superantigens (Rooijakkers et al, 2005a; Hermans et al, 2012). While 
superantigens bind to T-cell receptors and major histocompatibility complex 
class II molecules, SSLs bind to components of the innate immunity such as 
complement, Fc receptors and myeloid cells (Rooijakkers et al, 2005a; 
Bestebroer et al, 2010; Hermans et al, 2012). For example, SSL-10 is able to 
bind to the Fc region of human IgG1 blocking phagocytosis mediated by the 
FcγR (Patel et al, 2010), while SSL5 and SSL11 are able to bind to neutrophils 
and inhibit neutrophil rolling (Bestebroer et al, 2007). 
 
The staphylococcal superantigen-like 7 (SSL-7) can bind to IgA, blocking its 
binding to FcαR, inhibiting the IgA-mediated anti-staphylococcal mechanism at 
the mucosal surface of epithelial cells (Langley et al, 2005; Langley et al, 2010). 
SSL-7 is also able to bind to C5, inhibiting the formation of the membrane 
attack complex of the complement and the production of C5a (Langley et al, 
2005; Bestebroer et al, 2010; Langley et al, 2010). 
 
 
1.6 Mechanisms of host adaptation by S. aureus 
 
The ability of a microbial pathogen to colonize and infect a host organism is 
known as host specificity or tropism (Pan et al, 2014). Pathogenic bacteria 
exhibit different levels of host specificity, from extreme diversity such as 
Yersinia pestis (Perry and Fetherston, 1997; Anisimov et al, 2004), intermediate 
levels of host tropism like Listeria monocytogenes (Lecuit, 2005; Hamon et al, 
2006) or strict host selectivity, like Streptococcus pneumoniae and Neisseria 
meningitidis have for humans (Lu et al, 2005; Hill et al, 2010; Achila et al, 
2015).  
 
Along with being a major human pathogen, S. aureus is able to infect domestic 
animals such as cows, sheep, poultry and rabbits (Vancraeynest et al, 2006; 
Fitzgerald, 2012; Viana et al, 2015). It has been reported that host-specialized 
clones of S. aureus resulted from human to animal host jumps, but the 
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molecular basis for this adaptation is not completely understood (Herron-Olson 
et al, 2007; Sung et al, 2008; Viana et al, 2015). However, it has been reported 
that most of the host tropisms are associated with genes involved in interactions 
with the immune system such as virulence factors and cell adhesion proteins 
(Smyth et al, 2009; Guinane et al, 2010; Shepheard et al, 2013). 
 
As stated above, most of the mutations that are involved in host tropisms can 
be found in genes involved in interactions with the immune system, like toxins, 
complement inhibitors and proteins involved in biofilm formation. It has been 
found that mobile genetic elements (MGE), such as bacteriophages and 
pathogenicity islands play a role in this process (Herron-Olson et al, 2007; 
Viana et al, 2010; McCarthy et al, 2011; Resch et al, 2013).  
 
The use of different sequencing techniques, in particular Multilocus Sequence 
Typing (MLST), revealed strains mostly associated with a single host species 
(Enright and Spratt, 1999; Fitzgerald, 2012; Shepheard et al, 2013). Mutations 
found in the sequenced genes allow identification of sequence types (STs), 
which represent different S. aureus genotypes. However, some STs have the 
ability to infect more than one host organism, such as the ST121 strain capable 
of infecting both humans and rabbits (Viana et al, 2007; Viana et al, 2015) and 
the ST398 MRSA strain, generally pig-associated but also found in cows, 
poultry and humans (van Loo et al, 2007; Fitzgerald, 2012). The STs can be 
grouped into clonal complexes (CC), which are comprised by STs that differ in 
no more than two of the seven MLST alleles (McGavin et al, 2012). 
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1.7 Aims of this project 
 
This project aimed to identify the bacterial component(s) that act as a receptor 
for the bactericidal activity of the naive rabbit serum and the mechanism that is 
responsible for the antibacterial properties of the serum. 
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2 CHAPTER 2: 
Materials and Methods 
2.1 Growth Media 
All media were prepared using distilled water and sterilized by autoclaving at 
121ºC, 15 pounds per square inch for 20 minutes.  
 
2.1.1 Blood Agar  
Blood agar base #2 (Oxoid)    40 g/L 
The agar was resuspended in dH2O, boiled to ensure dissolving and 
autoclaved. The agar was cooled to 50ºC before adding 7% (v/v) Oxoid 
defibrinated sheep blood. 
 
2.1.2 Brain Heart Infusion (BHI)  
Brain heart infusion (Oxoid)     37 g/L 
1.5% (w/v) Oxoid Agar was added to make BHI agar. 
 
2.1.3 Luria-Bertani (LB) 
Tryptone (Oxoid)      10 g/L 
Yeast extract (Oxoid)     5 g/L 
NaCl        5 g/L 
The pH was adjusted to 7.2 using 5M NaOH. 1.5% (w/v) Oxoid Agar was added 
to make LB agar. 
 
2.1.4 Tryptic Soy Broth (TSB) 
Tryptic soy broth (Oxoid)     30 g/L 
1.5% (w/v) Oxoid Agar was added to make Tryptic soy agar (TSA). 
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2.2 Antibiotics 
The antibiotics that were used in this study are listed in Table 2.1. They were 
prepared from stock solutions, which were prepared in different solvents, filter 
sterilised (0.2µm pore size) and stored in aliquots at -20ºC. For liquid media, 
antibiotic stock solution was added just before use. For agar plates, the media 
were cooled to approximately 50ºC before adding the antibiotic stock. 
 
2.3 Bacterial strains 
2.3.1 S. aureus strains 
The bacteria used in this study are listed in Table 2.2. For growth in liquid 
media, a single colony was used to inoculate 5 ml of media and the culture was 
grown overnight aerobically at 37ºC shaking at 250 rpm. This culture was used 
to inoculate fresh media until it reached a known OD600. The strains were also 
cultured on BHI agar plates with the appropriate antibiotics for an overnight at 
37ºC and stored at 4ºC for up to three weeks. For long-term storage, a single 
colony was used to inoculate 5 ml of media and grown up to an OD600 of 0.5. 
Two ml of the culture were then centrifuged and the pellet was used to inoculate 
Microbank beads that were stored at -80ºC. 
2.3.2 E. coli strains 
The E. coli strain used in this study is shown in Table 2.3. The growth and 
storage conditions were the same as for the S. aureus strains (Chapter 2.3.1), 
except that LB broth or agar was used as growth media. 
 
2.4 Buffers and solutions 
All buffer and solutions were prepared using distilled water unless otherwise stated. 
They were sterilized if necessary and stored at room temperature or 4ºC.  
Phosphate buffered saline (PBS) 
NaCl        8 g/L 
Na2HPO4       1.4 g/L 
KCl        0.2 g/L 
KH2PO4       0.2 g/L 
The pH was adjusted to 7.4 using NaOH 
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Table 2.1 Antibiotic stock solutions and concentrations 
Antibiotic Solvent 
Stock 
concentration 
(mg/ml) 
Working 
concentration 
(µg/ml) 
Chloramphenicol 
(Cm) 
100% (v/v) 
ethanol 
5 10 
Erythromycin 
(Ery) 
100% (v/v) 
ethanol 
5 2.5 
Spectinomycin 
(Spec) 
dH2O 50 100 
Tetracycline 
(Tet) 
dH2O 5 5 
 
Table 2.2 S. aureus strains used in this study 
Strain Relevant genotype/Marker Source 
SH1000 Functional rsbU+ derivative of 8325-4  Horsburgh et al, 2002 
CH 3934 J strain, ST121 clone rabbit origin Viana et al,  2015 
CH 9982 J strain, dltB deleted Viana et al,  2015 
CH 8348 J strain, rot from human isolates Viana et al,  2015 
CH 9548 J strain, dltB from human isolates Viana et al,  2015 
CH 7705 F strain, ST121 clone human origin Viana et al,  2015 
CH 8569 F strain, rot mutation present in rabbit isolates (K103*) 
Viana et al, 
 2015 
CH 9692 F strain, dltB 1SNP (*405Y) Viana et al,  2015 
CH 9700 F strain, rot 1SNP (K103*) and dltB 1SNP (*405Y) 
Viana et al,  
2015 
CH 9897 
F strain, rot 1SNP (K103*) and dltB 
1SNP (*405Y), cured from the prophage 
inserted in the β-toxin gene 
Viana et al,  
2015 
CH 10310 F strain, dltB 3SNPs (T113K, Y250H, *405Y) 
Viana et al,  
2015 
CH 10311 F strain, dltB 3SNPs (T113K, Y250H, *405Y) and rot 1SNP (K103*) 
Viana et al,  
2015 
CH 10320 F strain, dltB 2SNPs (T113K, Y250H) Viana et al, 2015 
DL 9 ST96 clone, rabbit origin. Viana et al, 2015 
BK 4337 ST96 clone, human origin Viana et al, 2015 
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RN4220 Restriction deficient derivative of 8325-4 Kreiswirth et al, 1983 
RN4220 ΔtarM RN4220 with deletion of tarM, unmarked Brown et al, 2012 
RN4220 ΔtarS RN4220 with deletion of tarS, unmarked Brown et al, 2012 
RN4220 ΔtarM 
ΔtarS 
RN4220 with deletion of tarM and tarS, 
unmarked 
Brown et al, 
2012 
RN4220 ΔtarM 
ΔtarS pRB-tarS 
RN4220 with deletion of tarM and tarS, 
with complementation of tarS, CmR 
Brown et al, 
2012 
Sa113 Restriction deficient mutant of NCTC 8325. 
Iordanescu and 
Surdeanu, 1976 
Sa113 ΔdltA Sa113 with dltA gene replaced by spectinomycin resistance gene, SpecR 
Peschel et al, 
1999 
Sa113 ΔmprF:ermB 
Sa113 with mprF gene replaced by 
erythromycin resistance cassette (ermB), 
EryR 
Weidenmaier et al, 
2005a 
Sa113 ΔmprF:ermB 
pRB474-mprF 
Sa113 with mprF replaced by ermB, 
complemented. EryR CmR  
Weidenmaier et al, 
2005a 
Sa113 ΔypfP:ermB 
Sa113 with ypfP gene replaced by 
erythromycin resistance cassette (ermB), 
EryR 
Fedtke et al, 
2007 
Sa113 ΔypfP:ermB 
pRB473-ypfP 
Sa113 with ypfP replaced by ermB, 
complemented. EryR CmR 
Fedtke et al, 
2007 
15981 Clinical strain, biofilm positive Lab collection, gift from I. Lasa 
15981 ΔtagO 15981 with deletion of tagO, unmarked  Vergara-Irigaray et al, 2008. 
CmR, chloramphenicol resistant; EryR, erythromycin resistant; SpecR, 
spectinomycin resistant 
 
 
Table 2.3 E. coli strains used in this study 
Strain Relevant genotype/Marker Source 
MC1061 
F- Δ(ara-leu)7697 [araD139]B/r Δ(codB-
lacI)3 galK16 galE15 λ- e14- mcrA0 relA1 
rpsL150(strR) spoT1 mcrB1 hsdR2(r-m+) 
Lab collection 
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2.4.1 Peptidoglycan purification 
2.4.1.1 5% (w/v) SDS solution 
Sodium dodecyl sulphate     5% (w/v) 
Sterile MilliQ water was used to reach the desired volume. 
 
2.4.1.2 4% (w/v) SDS solution 
Sodium dodecyl sulphate     4% (w/v) 
Sterile MilliQ water was used to reach the desired volume. 
 
2.4.1.3 Washing solution 
Tris-HCl       50 mM 
The pH was adjusted to 7.0 using NaOH and sterile MilliQ water was used to 
reach the desired volume. 
 
2.4.2 Wall teichoic acid purification 
2.4.2.1 MES Buffer 1 
2-(N-morpholino) ethanesulfonic acid (MES)   50 mM 
The pH was adjusted to 6.5 using NaOH 
 
2.4.2.2 MES Buffer 2 
2-(N-morpholino) ethanesulfonic acid (MES)   50 mM 
SDS         4% (w/v) 
The pH was adjusted to 6.5 using NaOH 
 
2.4.2.3 MES Buffer 3 
2-(N-morpholino) ethanesulfonic acid (MES)   50 mM 
NaCl         2% (v/v) 
The pH was adjusted to 6.5 using NaOH 
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2.4.3 Lipoteichoic acid purification 
2.4.3.1 Sodium citrate washing solution 
Sodium citrate       0.1M 
The pH was adjusted to 4.7 with HCl. 
 
2.4.3.2 Dialysis buffer 
Sodium citrate       20mM 
The pH was adjusted to 4.7 with HCl. 
 
2.4.3.3 Hydrophobic Interaction Chromatography 
The buffers were filtered and degassed before use.  
 
Buffer A (0.1M sodium citrate (pH 4.7), 15% (v/v) 1-propanol) 
0.5 M sodium citrate (pH 4.7)    200 ml 
1-propanol       150 ml 
dH2O        650 ml 
 
Buffer B (50mM sodium citrate (pH 4.7), 65% (v/v) 1-propanol) 
0.5 M sodium citrate (pH 4.7)    100 ml 
1-propanol       650 ml 
dH2O        250 ml 
 
2.4.4 SDS-PAGE solutions 
2.4.4.1 SDS-PAGE Reservoir buffer (10x) 
Glycine       144 g/L 
Tris Base       30.3 g/L 
SDS        10 g/L 
The buffer was diluted with dH2O to 1:10 before use. 
 
2.4.4.2 Loading buffer (5x) 
Tris-HCl pH 6.8      250 mM 
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SDS        10% (w/v) 
Bromophenol blue      0.5 % (w/v) 
Glycerol       50% (v/v) 
2-mercaptoethanol      10% (v/v) 
 
2.4.4.3 Coomassie Blue stain 
Coomassie Blue      0.1% (w/v) 
Methanol       5% (v/v) 
Glacial acetic acid      10% (v/v) 
2.4.4.4 Coomassie Blue destain 
Methanol       5% (v/v) 
Glacial acetic acid      10% (v/v) 
 
2.4.4.5 Silver Staining 
The Pierce Silver Staining Kit from Life Technologies was used and the 
Sensitizer Solution, Stain Solution and Developer Solution were prepared using 
the reagents and protocol provided. The rest of the solutions were prepared as 
follows: 
 
Fixing Solution 
Acetic acid       10% (v/v) 
Ethanol       30% (v/v) 
MilliQ water       to 50 ml 
 
Ethanol Solution 
Ethanol       10% (v/v) 
MilliQ water       to 50 ml 
 
Stop Solution 
Acetic acid       5% (v/v) 
MilliQ water       to 50 mL 
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2.4.5 Native polyacrylamide gel electrophoresis solutions 
2.4.5.1 Running buffer 
Tris Base        3.02 g/L 
Glycine       14.41 g/L 
Distilled water      to 1L 
 
2.4.5.2 Loading buffer (2x) 
Tris-HCl pH 6.8      62.5 mM 
Glycerol       25% (v/v) 
Bromophenol blue      1% (w/v) 
 
2.4.6 Western Blotting buffers 
2.4.6.1 Blotting buffer 
Tris Base       2.4 g/L 
Glycine       11.26 g/L 
Ethanol       20% (v/v) 
The buffer was chilled at 4ºC for 60 minutes before use. 
 
2.4.6.2 TBST buffer (20x) 
Tris-HCl pH 7.4      48.4 g/L 
NaCl        20 g/L 
Tween-20       2% (v/v) 
The Tris-HCl solution was autoclaved before adding the rest of the components. 
The pH of the solution was adjusted to 7.6 and the buffer was diluted 1:20 with 
dH2O before use. 
 
2.4.6.3 Blocking Solution 
Skim milk powder (Oxoid)     5% (w/v) 
The powder was dissolved in 1xTBST Buffer. 
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2.4.7 Purified Phospholipase A2 Buffer 
Tris Base       12.11 g/L 
CaCl2        0.14 g/L 
Fatty acid free BSA      1.0 g/L 
 
The solution was prepared with sterile MilliQ water and its pH was adjusted to 
8.0 with HCl. The solution was filtered (0.2µm pore size) before use and stored 
at room temperature. 
 
2.4.8 Fluorescence Microplate Assay for Phospholipase A2 
2.4.8.1 Assay Buffer 
Tris Base       6.06 g/L 
NaCl        5.80 g/L 
CaCl2-2H2O       0.15 g/L 
The solution was prepared using sterile MilliQ water and the pH was adjusted 
with HCl to 8.9. The solution was filtered (0.2µm pore size) before use and 
stored at 4ºC. 
 
2.5 Stock solutions 
All the chemicals used in this study were of analytical grade quality and were 
purchased from Sigma, Fisher Scientific, MP Biomedicals or Roche unless 
otherwise stated. Concentrations and storage conditions of the stock solutions 
are shown in Table 2.4. 
 
The origins of the different types of mammalian sera tested in this study are 
shown in Table 2.5. Protein ladders for SDS-PAGE were purchased from New 
England Biolabs. The antibodies used in this study were purchased from 
Sigma, Abcam and Genscript and are shown in Table 2.6 and Table 2.7.  
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Table 2.4 Chemical stock solutions used in this study 
RT: Room temperature. 
 
  
Stock Solution Concentration Dissolved in Storage conditions 
2,4-dinitrophenylhydrazine 0.1% (w/v) 2M HCl 
RT, 
aluminium-
covered 
Ammonium acetate 1 M MilliQ water RT 
Ammonium carbonate 1 M MilliQ water RT 
Ammonium chloride 1 M MilliQ water RT 
Ammonium hydroxide 1 M MilliQ water RT 
Ammonium persulfate (APS) 10%( w/v) MilliQ water -20ºC 
Calcium chloride (CaCl2) 0.1 M MilliQ water RT 
D-amino acid oxidase 2.5 mg/ml 0.2M Tris-HCl pH 8.4 
RT, 
aluminium-
covered 
Dithiothreitol (DTT) 100 mM MilliQ water 4ºC 
1,2- Dioleoyl-sn- glycero-3-
phosphocholine (DOPC) 10 mM Ethanol -20ºC 
1,2-Dioleoyl-sn-glycero-3-
phospho-rac-(1-glycerol) 
(DOPG) 
10 mM Ethanol -20ºC 
Ethylene glycol tetraacetic 
(EGTA) 0.1 M MilliQ water RT 
Honey Bee (Apis mellifera) 
PLA2 5 mg/ml Sterile PBS -20ºC 
Magnesium chloride (MgCl2) 0.1 M MilliQ water RT 
Pronase 2 mg/ml MilliQ water -20ºC 
Proteinase K 20 µg/ml 
20mM TrisHCl 
(pH 8.0), 0.5% 
(w/v) SDS 
-20ºC 
Red/Green BODIPY PC-A2 1 mM DMSO 
-20ºC, 
aluminium 
covered 
Spitting Cobra (Naja 
mossambica mossambica) 
PLA2 
1 mg/ml Sterile PBS -20ºC 
Trypsin 1 mg/ml 1mM HCl 4ºC 
Zymosan 10 mg/ml Sterile PBS -20ºC 
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Table 2.5 Mammalian sera used in this study 
Animal source Source 
Naive rabbit blood 
New England White female rabbits as explained in 
Chapter 2.8 
Adult human blood 
Healthy adult volunteers as explained in Chapter 
2.13 
Infant human blood 
Healthy infant volunteers under 12 months of age as 
explained in Chapter 2.14 
Mouse blood Balb/c strain, gift from Dr Cristina Teles 
Defibrinated Horse blood E&O Laboratories 
Defibrinated Sheep blood E&O Laboratories 
Bovine calf blood Fisher Scientfics 
Porcine serum Sigma-Aldrich 
Bovine adult serum MP Biomedicals 
Rat blood  Sigma-Aldrich 
 
 
Table 2.6 Primary antibodies used in this study 
Antibody Dilution used 
Anti- MBL rabbit complement component, raised in 
chicken (Genscript) 
WB: 1:1000 
SB: 1: 5000 
Anti-C4b rabbit complement component, raised in 
chicken (Genscript) 
WB: 1:1000 
SB: 1: 5000 
Anti-C5b rabbit complement component, raised in 
chicken (Genscript) 
WB: 1:1000 
SB: 1: 5000 
Anti-C9 rabbit complement component, raised in 
chicken (Genscript) 
WB: 1:1000 
SB: 1: 5000 
Chicken IgY control, whole molecule (Genscript) SB: 1:10,000 
Chicken IgY control immunoglobulin (Promega) Inactivation assays only 
Anti-MBL human complement component, raised in 
mouse (Abcam) 
WB: 1:5000 
SB: 1:10,000 
Anti-C4b human complement component, raised in 
mouse (Abcam) 
WB: 1:5000 
SB: 1:10,000 
Anti-C5b human complement component, raised in 
mouse (Abcam) 
WB 1:5000 
SB: 1:10,000 
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Anti-C9 human complement component, raised in 
mouse (Abcam) 
WB: 1:5000 
SB: 1:10,000 
Anti-low molecular weight phospholipase A2 antibody 
(Merk Millipore) 
WB: 1:5000 
SB: 1:10,000 
Anti-low molecular weight phospholipase A2 antibody 
(Abcam) 
WB: 1:5000 
SB: 1:10,000 
Rat control antibody, whole molecule (Sigma-Aldrich) Inactivation assays only 
Anti-annexin A1 antibody, mouse polyclonal (Sigma-
Aldrich) 
WB: 1:5000 
SB: 1:10,000 
Anti-lipoteichoic acid monoclonal antibody, raised in 
mouse (Hycult Biotechnology) 
SB: 1:1,000 
Anti-cobra venom polyclonal antibody, raised in duck 
(Abcam) 
WB: 1:5,000 
WB: Western blot; SB: Slot blot 
 
Table 2.7 Secondary antibodies used in this study 
Antibody Dilution used 
Anti-chicken IgG (H+L), F(ab) fragment, HRP antibody 
produced in goat (Sigma-Aldrich) 
1:10,000 
Anti-mouse antibody, HRP antibody produced in goat 
(Sigma-Aldrich) 
1:10,000 
Anti-rabbit IgG1 (H) HRP antibody produced in goat 
(Sigma-Aldrich) 
1:10,000 
Anti-bird IgY H&L HRP antibody produced in goat (Abcam) 1:10,000 
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2.6 Centrifugation 
The following centrifuges were used to harvest cells and precipitated material: 
I. Eppendorf centrifuge 5418, rotor capacity 18 x 1.5/2 ml, max speed 16,873g 
(14,000 rpm). 
II. Eppendorf centrifuge 5424, rotor capacity 24 x 2ml, max speed 20,238g 
(14,680 rpm). 
III. Sigma 4K15C centrifuge, max capacity 4x500 ml, max speed 15,000 rpm. 
IV. Sigma 3K15 centrifuge, max capacity 4x200 ml, max speed 5410g. 
V. Avanti High Speed J25 centrifuge, Beckman. 
a. Rotor JA-20: max capacity 8x50ml, max speed 48,400g (20,000 rpm). 
b. Rotor JLA-10.500: max capacity 3L, max speed 18.500g (10,000 
rpm) 
The temperature at which the centrifugation was carried out is noted in each 
protocol. 
 
2.7 Determination of bacterial density 
To quantify the bacterial yield spectrophotometric measurements were carried 
out at 600 nm (OD600) using WPA Biowave DNA Spectrophotometer and Semi-
micro PS cuvettes (Fisherbrand). Culture samples were diluted 1:10 and 1:20 in 
sterile culture medium when necessary.  
 
2.8 Preparation of Naive Rabbit Serum (NRS) 
Blood was collected directly in 50 ml Falcon tubes from New Zealand White 
female rabbits immediately post mortem and left at room temperature for one 
hour before being placed at 4ºC overnight on ice. The tubes containing the 
blood were then centrifuged twice (5000 rpm, 10 minutes, 4°C) and the 
supernatant was collected, filtered (0.2µm pore size), aliquoted (1 ml) and 
stored at -80ºC.  
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2.9 Effect of Naive Rabbit Serum (NRS) on S. aureus 
One colony of the bacterial strain to test was used to inoculate 5 ml of media in 
a 25 ml sterile universal and grown overnight at 37ºC on a rotary shaker at 250 
rpm. This culture was used to inoculate 5 ml of fresh media and grown at 37ºC 
and 250 rpm until it reached exponential phase. The cells were washed twice 
with sterile PBS by centrifugation (14,000 rpm, 3 minutes, room temperature) 
and then resuspended in PBS.  
 
An aliquot of NRS was inoculated with 105-106 cells/ml of this culture and 
incubated at 37ºC with rotation. Samples were taken from this culture at 
appropriate times (0, 0.5, 1, 2, 3 and 4 hr), 10-fold serial dilutions were made in 
sterile PBS and two 10 µl aliquots of each dilution were directly spotted on BHI 
plates. The ‘zero’ time point represents to a time point between 5 or 10 minutes 
after the inoculation of the bacteria into the serum, considering the time that 
took to set each experiment. After overnight incubation at 37ºC the number of 
colony forming units was determined (CFU/ml). Unless otherwise stated, all 
experiments were carrieds out in biological triplicates. 
 
2.9.1 Statistical Analysis 
Survival curves from bactericidal killing experiments were compared using 
Student t-test and the analysis were carried out using GraphPad Prism (version 
6). Statistical significance was determined using the Holm-Sidak method as 
recommended by GraphPad, and results were considered significant at a p-
value below 0.05. One asterisk (*) denotes p-value below 0.05; ** a p-value 
below 0.01; and *** a p-value below 0.001. Experiments were carried out on 
triplicate and error bars correspond to the standard deviation of the means.  
 
2.10 Inactivation of NRS 
2.10.1 Heat treatment 
The rabbit serum was heated at 56ºC for 30 minutes in a water bath before 
inoculating with 105 cells/ml of an exponential phase bacterial culture. Killing 
assays as described in Chapter 2.9 were carried out. 
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2.10.2 Ethylene glycol tetraacetic acid (EGTA) treatment 
The stock solution of EGTA was prepared using dH2O and it was autoclaved 
before being mixed with the serum. An aliquot 150 µl of rabbit serum was gently 
mixed with 15 µl of 0.1M EGTA to a final concentration of 10 mM, and 
incubated for 60 minutes at 37ºC before the addition of 105 cells/ml of an 
exponential phase culture of S. aureus SH1000 to the mix. Killing assays were 
carried out as explained in Chapter 2.9. 
 
For the experiments with the E. coli MC1061 strain, 50µM EGTA was used 
instead and the samples were spotted on LB agar plates.  
 
2.10.3 Pre-incubation with zymosan A from Saccharomyces cerevisiae  
Zymosan A was activated before the pre-incubation with NRS. Zymosan was 
resuspended to a concentration of 0.1% (w/v) in 0.15 M sodium chloride and 
boiled for 60 minutes in a water bath. This solution was centrifuged for 30 
minutes at 4000 rpm and the supernatant was discarded. The insoluble material 
was resuspended in sterile PBS to the desired stock concentration of 10 mg/ml. 
This material was stored at 4ºC until further use. 
 
An aliquot of 100 µl of rabbit serum was mixed with 10 µl of the activated 
zymosan A to a final concentration of 1 mg/ml, and incubated for 60 minutes at 
37ºC with rotation. This mixture was then centrifuged for 5 minutes at 4000 rpm 
at room temperature and the supernatant was recovered for killing assays using 
105 cells/ml of an exponential phase culture of S. aureus SH1000 for the 
inoculation and following the protocol explained in Chapter 2.9. 
 
2.10.4 Ammonium salts and ammonium hydroxide pre-incubation 
The ammonium solutions were prepared using sterile MilliQ water and sterilised 
using a 0.2 µm pore size filter. Aliquots of 150 µl of rabbit serum was treated 
with 25 µl of ammonium acetate, ammonium carbonate, ammonium chloride 
and ammonium hydroxide (final concentration 150 mM) for 45 minutes at 37ºC, 
and afterwards these solutions had their pH adjusted to 7.4 using HCl. The 
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mixtures where then inoculated with 105 cells/ml of an exponential phase 
culture of S. aureus SH1000 and killing assays were carried out (Chapter 2.9) 
 
2.10.5 Dithiothretiol pre-incubation 
A 100 mM stock solution of dithiothretiol (DTT) was prepared with sterile MilliQ 
water and it was filtered using a 0.2 µm pore size filter. Aliquots of 100 µl of 
rabbit serum were treated with 10 µl of the stock solution of DTT (10 mM final 
concentration) and preincubated at 37ºC for 30 minutes. This mixture was 
inoculated with 105 cells/ml of an exponential phase culture of S. aureus 
SH1000. Killing assays were carried out (Chapter 2.9) 
 
2.11 Reactivation of NRS with magnesium chloride and calcium chloride 
The different stock solutions used in the reactivation of the bactericidal activity 
of rabbit serum experiments were prepared using dH2O and were autoclaved 
before used. 
 
For the reactivation of rabbit serum with magnesium chloride, a liquid culture of 
S. aureus SH1000 or E. coli MC1061 was grown at 37ºC and 250 rpm until it 
reached exponential phase (OD600= 0.5). An aliquot of NRS was mixed with 
equimolar concentrations of EGTA and magnesium chloride (final concentration 
10 mM for S. aureus and 50 µM for E. coli) and was incubated for 60 minutes at 
37ºC before the addition of 105 cells/ml, after which killing assays were carried 
out (Chapter 2.9).  
 
The same protocol was used for the reactivation of NRS with magnesium 
chloride and calcium chloride. The only difference was that the rabbit serum 
was mixed with EGTA, MgCl2 and CaCl2 (final concentration 50 µM or 10 mM) 
before incubation of this mixture for one hour at 37ºC, after which the solution 
was inoculated with E.coli MC1061 or S. aureus SH1000, respectively. 
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2.12 Inactivation of the bactericidal activity of NRS using pre-incubation 
with antibodies 
2.12.1 Antibodies against complement components 
Stock solutions at 2 mg/ml of antibodies against complement components 
(Table 2.6) were used for inactivation of rabbit serum experiments. Aliquots 100 
µl of NRS were mixed with 5, 10, 15 and 20 µl of the stock solution of each 
antibody (final concentration 100, 200, 300 and 400 µg/ml, respectively) and 
incubated for 1 hour at 37ºC with rotation. After this incubation the solution was 
inoculated with 105 cells/ml of an exponential phase culture of S. aureus and 
killing assays were carried out (Chapter 2.9). 
 
The same protocol was followed for the inactivation with the control whole 
chicken molecule antibodies (Table 2.6). 
 
2.12.2 Antibodies against phospholipase A2 
Stock solutions at 1 mg/ml of antibodies against phospholipase A2 (Table 2.6) 
were used to inactivate rabbit serum. Aliquots of 100 µl of rabbit serum were 
inoculated with different volumes of the stock solution of anti-phospholipase A2 
antibodies (final concentrations 10-100 µg/ml) and incubated for 60 minutes at 
37ºC with rotation. The solution was then inoculated with 105 cells/ml of an 
exponential phase culture of S aureus and killing assays were carried out 
(Chapter 2.9). 
 
The same protocol was followed for the inactivation with the whole rabbit control 
antibody (Table 2.6). 
 
2.13 Preparation of Adult Human Serum and effect on S. aureus 
2.13.1 Preparation of adult human serum 
The South Sheffield Ethics Committee approved the protocol for phlebotomy 
(Reference Number STH13927). 100 ml of blood was collected directly from 
four healthy volunteers in 50 ml Falcon tubes and the samples were left at room 
temperature for 60 minutes before transferring the tubes to 4ºC on ice for an 
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overnight. The supernatant was taken from the tubes and centrifuged twice at 
4ºC for 10 minutes at 5000 rpm. The supernatant was then collected, filtered 
(0.2 µm pore size), aliquoted (1 ml) and stored at -80ºC. 
 
2.13.2 Effect of adult human serum on S. aureus 
Aliquots of 100 µl of adult human serum were inoculated with 105 cells/ml of an 
exponential phase culture of different strains of S. aureus and killing assays 
were carried out (Chapter 2.9) 
 
2.14 Preparation of Infant Human Serum and effect on S. aureus 
2.14.1 Preparation of infant human serum 
Blood was collected from healthy infants under 12 months of age with their 
parents’ authorization from the Royal Hallamshire Children’s Hospital with the 
help of Dr Fiona Shackley under Case Number CA11011. The samples were 
left at room temperature for 60 minutes before transferring the tubes to 4ºC on 
ice for 60 minutes. The supernatant was taken and centrifuged at 4ºC for five 
minutes at 4000 rpm and then for one minute at 5000 rpm. The serum was then 
removed from the tubes, filtered (0.2 µm pore size), aliquoted (50 µl) and stored 
at -80ºC. 
 
2.14.2 Effect of infant human serum on S. aureus 
Aliquots of 50 µl of infant human serum were incubated with 105 cells/ml of an 
exponential phase culture of S. aureus SH1000 and killing assays were carried 
out (Chapter 2.9). 
 
2.15 Purification of human and rabbit serum components by centrifugal 
filtration 
2.15.1 Fractionation of human and rabbit serum 
2 ml of NRS were used to obtain different fractions using Amicon Ultra 0.5ml 
centrifugal filters, Ultracel (Millipore). The filters used had a molecular weight 
cut-off of 10, 30 and 50 kDa. For this purification the protocol from Millipore was 
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followed with a few modifications. The sample reservoir with the filter was 
placed into the vial. 0.5 ml of serum was placed into the sample reservoir 
without touching the membrane and the cap was sealed. The sample was 
centrifuged for 10 minutes at 14000 rpm at room temperature, and the fraction 
collected in the vial (components smaller than the cut-off) was taken. The 
sample reservoir with the components bigger than the cut-off molecular weight 
was carefully placed upside down in a new vial and centrifuged for 3 minutes at 
3000 rpm and room temperature. The vials were carefully labelled and they 
were stored at -80ºC until further use in NRS killing assays and protein analysis. 
The same protocol was used for the fractionation of human serum. 
 
2.15.2 Bactericidal activity of purified fractions of human and rabbit serum 
against S. aureus 
The Amicon Ultra 0.5ml centrifugal filters, Ultracel (Millipore) also concentrated 
the fraction containing the bigger component for each filter. This concentration 
of components was taken into consideration before inoculating the fractions 
with the bacteria: the fraction containing the components smaller than the 
molecular weight cut-off was used directly but the fractions containing the 
components bigger than the molecular weight cut-off were diluted accordingly 
using sterile PBS.  
 
Aliquots of 100 µl of the different fractions were inoculated with 105 cells/ml of 
an exponential phase culture of S. aureus SH1000 and killing assays were 
carried out as explained in Chapter 2.9.  
 
2.15.3 Combination of different purified fractions from rabbit and human 
serum 
Appropriate volumes of the different fractions were mixed and rabbit serum 
killing assays were carried out as explained in Chapter 2.9. Aliquots of 100 µl of 
total volume of combined fractions were inoculated with 105 cells/ml of an 
exponential phase culture of S. aureus SH1000 and killing assays were carried 
out (Chapter 2.9). 
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2.16 Purification of peptidoglycan from S. aureus strains 
2.16.1 Purification of peptidoglycan 
A single colony of S. aureus from a BHI agar plate was used to inoculate 10 ml 
of BHI broth that was incubated at 37ºC with 250 rpm for an overnight. The 
OD600 of this overnight culture was determined and an appropriate volume was 
used to inoculate 500 ml of fresh BHI broth with an initial OD600=0.01. This 
culture was grown until it reached exponential phase (OD600=0.5) at 37ºC and 
200 rpm shaking. The culture was then chilled to 4ºC on ice for 10 minutes to 
stop growth. The cells were then harvested by centrifugation (15000g, 10 
minutes, 4ºC) and the pellet was resuspended in 30 ml of ice cold sterile PBS. 
This mixture was boiled in a water bath for 7 minutes and then chilled to 4ºC on 
ice. The cells were centrifuged (13000g, 10 minutes, 4ºC) and the pellet was 
resuspended in 3 ml of PBS sterile.  
 
Next, the cells were broken by homogenization using lysing matrix B, 
RNAse/DNAse free tubes with silica beads (MP Biomedicals) in a Fast Prep-24 
machine (MP Biomedicals): 24x at speed 6 for 30 seconds with 60 seconds 
pause on ice between each run. To remove the silica beads the tubes were 
centrifuged (2000 rpm, 30 seconds, room temperature) and the broken cell 
suspension was carefully transferred to a 15 ml Falcon tube. The suspension 
was centrifuged (5000 rpm, 8 minutes, 4ºC), the pellet was fully resuspended 
into 7 ml of pre-warmed (55ºC) 5%(w/v) SDS and then boiled for 30 minutes in 
a water bath, after which the solution was chilled on ice. The insoluble material 
was collected by centrifugation (5000 rpm, 8 minutes, 4ºC), resuspended into 7 
ml of pre-warmed (55ºC) 4% (w/v) SDS and then boiled for 15 minutes in a 
water bath.  
 
The solution was chilled on ice and the insoluble material was collected by 
centrifugation (5000 rpm, 8 minutes, 4ºC). The pellet was washed five times 
with 7 ml of sterile MilliQ water (60ºC) until free of SDS (500 rpm, 8 minutes, 
4ºC). Covalently attached proteins were removed by treatment with 4 ml of 50 
mM Tris-HCl (pH 7.0) containing 2mg/ml pronase for 90 minutes at 60ºC. The 
sacculi were washed repeatedly, once with 50 mM Tris-HCl (pH 7.0) and five 
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times with cold sterile MilliQ water. The peptidoglycan was then lyophilized 
using a Freeze Dryer Scanvac Cool Safe. 
 
The stripped peptidoglycan (peptidoglycan without wall teichoic acid) used 
during this project came from laboratory stocks. To obtain it, the wall teichoic 
acids were removed using 48% (v/v) hydrofluoric acid (HF) treatment. This acid 
was added to the peptidoglycan and incubated for 24 hours at 4ºC, after which 
the mixture was repeatedly washed by centrifugation (9000g, 10 minutes at 
room temperature) using 50 mM Tris-HCl (pH 7.0) once and cold sterile MilliQ 
water five times, until the pH of the solution was neutral. This pure 
peptidoglycan was lyophilized using a Freeze Dryer Scanvac Cool Safe, 
resuspended in sterile PBS, aliquoted and stored at -20ºC until used. 
 
2.16.2 Treatment of NRS with purified peptidoglycan 
The lyophilized peptidoglycan samples were resuspended in PBS in order to 
obtain stock solutions with a final concentration of 10 mg/ml. An aliquot of NRS 
was mixed with this purified cell wall material (final concentration 1 mg/ml) and 
incubated for 30 minutes at 4ºC with rotation. The tubes were then centrifuged 
(10000 rpm, 3 minutes, room temperature) and the supernatant was collected 
and used for rabbit serum killing assays as described in the Chapter 2.9. The 
insoluble material obtained was washed three times with sterile MilliQ water and 
after a final centrifugation (14000 rpm, 3 minutes, room temperature) was 
resuspended in 30 µl of MilliQ water. These samples were stored at -20ºC until 
further use.  
 
2.17 Purification of wall teichoic acid (WTA) from S. aureus strains 
2.17.1 Purification of wall techoic acid 
Following an overnight culture of S. aureus in BHI broth, the OD600 was 
determined and an appropriate volume was used to inoculate 500 ml of fresh 
BHI broth with an initial OD600=0.01. This culture was grown until exponential 
phase (OD600=0.5) at 37ºC with 200 rpm shaking. The culture was chilled on ice 
for at least 10 minutes to stop growth. The cells were harvested (15000g, 10 
minutes, 4ºC), the pellet was washed with 60 ml of MES Buffer 1 and the cells 
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were centrifuged at 13000g for 10 minutes at room temperature. The cells were 
resuspended in 60 ml of MES Buffer 2 and placed in a boiling water bath for 60 
minutes. The cells were chilled on ice before centrifugation (13000g, 10 
minutes, 4ºC) and the pellet was resuspended in 10 ml of MES Buffer 2, 
transferred to Eppendorf tubes and centrifuged for 10 minutes at room 
temperature.  
 
Next, the pellet was washed once with 20 ml of MES Buffer 2, once with MES 
Buffer 3 and once with MES Buffer 1 (4600g, 10 minutes, 4ºC), and then the 
sample was treated with 20 µg/ml Proteinase K at 50ºC for 4 hours. The sample 
was then washed with 20 ml of MES Buffer 3 and three times with sterile MilliQ 
water. 
 
To release the wall teichoic acid, the sample was thoroughly resuspended in 10 
ml 0.1 M NaOH and mixed by inversion at room temperature for 16 hours. The 
insoluble cell wall fragments were removed by centrifugation (13000g, 10 
minutes, 4ºC) and the supernatant was recovered. Neutralization was carried 
out with 0.1 M acetic acid and then extensively dialysed against MilliQ water 
using Spectra/Por CE Dialysis Tubing, 500-1000 MWCO from Spectrum (VWR 
Jencons) and then lyophilized to obtain a white powder using a Freeze Dryer 
Scanvac Cool Safe. 
 
2.17.2 Treatment of NRS with purified wall teichoic acid 
The lyophilized wall teichoic acid samples were resuspended in PBS in order to 
obtain stock solutions with a final concentration of 10 mg/ml. Aliquots of rabbit 
serum were mixed with 1 mg/ml (final concentration) of purified WTA and 
incubated for 30 minutes at 4ºC with rotation. The tubes were then centrifuged 
(10000 rpm, 3 minutes, room temperature). Due to the soluble nature of WTA 
there was no visible pellet after the centrifugation step. The supernatant was 
carefully collected and used for rabbit serum killing assays as described in the 
Chapter 2.9. Any insoluble material was washed three times with sterile MilliQ 
water and after a final centrifugation (14000 rpm, 3 minutes, room temperature) 
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was resuspended in 30 µl of MilliQ water. These samples were stored at -20ºC 
until further use.  
 
2.18 Purification of lipoteichoic acids (LTA) from S. aureus strains 
2.18.1 Purification of lipoteichoic acids 
This protocol was modified from Grundling and Schneewind, 2007a. A single 
colony was used to inoculate 10 ml of BHI broth that was incubated overnight at 
37ºC. The OD600 of this culture was determined and an appropriate volume was 
used to inoculate 500 ml of fresh BHI broth with an initial OD600= 0.01. The 
culture was incubated at 37ºC with 200 rpm shaking until it reached exponential 
phase (0D600=0.5). The cells were placed on ice for 10 minutes to stop bacterial 
growth and then they were centrifuged (6000g, 10 minutes, 4ºC). The pellet was 
resuspended in 90 ml of 0.1 M sodium citrate (pH 4.7), centrifuged (6000g, 10 
minutes, 4ºC) and the pellet was stored at -80ºC until used. 
 
To extract the LTA, the pellet was thawed on ice and resuspended in 4 ml of 0.1 
M sodium citrate (pH 4.7). The cells were broken using a Fast Prep-24 (MP 
Biomedicals) and lysing matrix B, RNAse/DNAse free tubes with silica beads 
(MP Biomedicals): 24 times at speed 6 for 30 seconds with 60 seconds pause 
on ice between each run. The silica beads were removed by centrifugation 
(2000 rpm, 30 seconds, room temperature) and the broken cells were carefully 
recovered into a new centrifugation tube. The silica beads were washed once 
with 1ml of 0.1 M sodium citrate (pH 4.7) and the supernatant was mixed with 
the broken cells. This suspension was centrifuged at 13000g and 4 ºC for 60 
minutes.  
 
The pellet was washed once with 0.1 M sodium citrate (pH 4.7) and centrifuged 
again at 13000g and 4 ºC for 60 minutes. The pellet was washed with 10 ml of 
0.1 M sodium citrate (pH 4.7) and 10 ml of 1-butanol was added. This solution 
was mixed by inversion at room temperature for 30 minutes. The insoluble 
material was separated by centrifugation (13000g, 20 minutes, 4ºC), the extract 
was transferred into a new tube and the phases were separated by 
centrifugation (13000g, 20 minutes, 4ºC).  
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The aqueous phase contains the LTA and it was recovered and dialysed 
thoroughly using 20 mM sodium citrate (pH 4.7) and Spectra/Por CE Dialysis 
Tubing, 500-1000 MWCO from Spectrum (VWR Jencons). The protein content 
of the dialysed samples was determined and the samples were adjusted to 
contain 0.088 mg/ml of protein in a 0.1 M sodium citrate (pH 4.7) and 15% (v/v) 
1-propanol buffer. The samples were then filtered using Acrodisc 13 mm 
Syringe Filter with 0.45µm pore size Nylon Membrane, HPLC certified (Life 
Sciences). The samples were loaded in a HiTrap Octyl Sepharose Fast Flow 
Column (GE Healthcare) for the hydrophobic interaction chromatography step. 
The LTA was eluted using a linear 15-65% (v/v) 1-propanol gradient in 50 mM 
sodium citrate (pH 4.7) and 0.5 ml/min flow rate. 750 µl fractions were collected. 
The fractions were then lyophilized to obtain a white powder using a Freeze 
Dryer Scanvac Cool Safe. To verify that LTA was present in the fractions, they 
were analysed through immunoblot using a specific anti-LTA antibody. 
 
2.18.2 Treatment of NRS with purified lipoteichoic acids 
The lyophilized lipoteichoic acid samples were resuspended in sterile PBS to 
obtain 10mg/ml stock solutions. Aliquots of rabbit serum were mixed with 
1mg/ml of this purified material and incubated at 4ºC for 30 minutes with 
rotation. The samples were centrifuged (10000 rpm, 3 minutes, room 
temperature), the supernatant was recovered and used for NRS killing assays 
as described in Chapter 2.9. The insoluble material was washed three times 
with sterile MilliQ water and after a final centrifugation (14000 rpm, 3 minutes, 
room temperature) was resuspended in 30 µl of MilliQ water. These samples 
were stored at -20ºC until further use.  
 
2.18.3 Measurement of D-alanylation of WTA and LTA 
In order to release teichoic acids from peptidoglycan to measure the D-alanine 
content of the SH1000 strain, the peptidoglycan was incubated in trichloroacetic 
acid 10% (final concentration) for 18 hrs at 4ºC, after which it was removed by 
centrifugation (Bernal et al, 2009; Bertsche et al, 2013; Reichmann et al 2013). 
The D-alanine content of the supernatant was measure as follows.   
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This protocol was modified from Peschel et al, 1999. Wall teichoic acid and 
lipoteichoic acid samples were adjusted to pH 9-10 with sodium hydroxide and 
these 10 µl were incubated for 60 minutes at 37ºC. 20 µl of 0.2 M Tris-HCl (pH 
8.4) containing 2.5 mg of D-amino acid oxidase/ml was added to the solution 
and the samples were incubated for one hour at 37ºC. This reaction was 
stopped with 10 µl of 30% (v/v) trichloroacetic acid and the precipitated material 
was removed by centrifugation (10000 rpm, 5 minutes, room temperature). The 
supernatant was placed in a new tube, 10 µl of a 0.1% (w/v) 2,4-
dinitrophenylhydrazine prepared in 2 M HCl was added and incubated for 5 
minutes at room temperature. After the addition of 20 µl of 2.5 M NaOH to the 
solution, the absorbance at 525 nm (A525) was determined using WPA Biowave 
DNA Spectrophotometer and a Ultra-micro cell 105.202-QS LP 10mm, vol.50 
µl, CH 15mm quartz cuvette. For the calibration curve, a stock solution of 
100mg/ml D-alanine (98% w/v) was prepared using sterile MilliQ water (Figure 
2.1). 
 
2.19 Use of purified cell wall material as affinity matrices 
The lyophilized purified cell wall material was resuspended in sterile PBS to 
obtain 10 mg/ml stock solutions. 1 ml of rabbit serum was mixed with 1 mg/ml 
(final concentration) of the different purified material and incubated for 30 
minutes at 4ºC with rotation. After incubation the samples were centrifuged 
(10000 rpm, 3 minutes, room temperature) and the insoluble material was 
washed three times with sterile MilliQ water. After a final centrifugation (14000 
rpm, 3 minutes, room temperature) the insoluble material was resuspended in 
30 µl of MilliQ water. The samples were stored at -20ºC until further use in 
protein analysis via mass spectrometry, SDS-PAGE and 24-well slot blotting. 
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Figure 2.1 Calibration curve used for the determination of D-alanine content  
The calibration curve was prepared using a stock solution of 100 mg/ml D-alanine 
(98% [w/v], Sigma-Aldrich) and 10-fold serial dilutions between 10 mg/ml to 1µg/ml in 
sterile MilliQ water. The different solutions were made in duplicate and the absorbance 
was determined at 525 nm using the WPA Biowave DNA Spectrophotometer and Ultra-
micro cell 105.202-QS LP 10mm, vol.50 µl, CH 15mm quartz cuvette. 
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2.20 Mass Spectrometry 
2.20.1 Preparation of samples for MS 
Aliquots of 50 µl of the samples were boiled in a water bath for 5 minutes. They 
were cooled to room temperature before adding 150 µl of 50 mM ammonium 
bicarbonate. 1mg/ml of trypsin from porcine pancreas resuspended in 1mM HCl 
was added to the mixture and the tubes were incubated for 16 hours at 37ºC. 
The samples were then centrifuged (10000 rpm, 5 minutes, room temperature), 
the supernatant was transferred to a new tube and kept at -20ºC until they were 
used. 
 
2.20.2 Liquid Chromatography-Mass Spectrometry Analysis (LC-MS) 
The LC-MS analysis was carried out by Dr. Richard Beniston at the biOMICS 
Facility from the University of Sheffield. After the tryptic digestion of the 
samples, the peptides were vacuum dried and subsequently solubilized in 
Switchoss Solution (0.1% [v/v] formic acid, 3% [v/v] acetonitrile).  
 
10% of the material was injected, using a Dionex Ultimate 3000 uHPLC, onto a 
PepMap100 C18 2cm x75µm I.D. trap column (ThermoFisher Scientific) at 
5µL/min in 0.1% (v/v) formic acid, 2% (v/v) acetonitrile and 35°C in the column 
oven and 6°C in the autosampler. The sample was separated, over a 64 minute 
uHPLC run of increasing acetonitrile from 2.4% (v/v) up to 72% (v/v), in 0.1% 
(v/v) formic acid, using a EasySpray 15cm PepMap100 C18 analytical column 
(2µm particle size, 100Å pore size 75µm I.D) (ThermoFisher Scientific) at 
250nL/min and 35°C. 
 
Table 2.8 Sample separation parameters 
Data collection occurred between retention time 8.1 to 63.1 minutes, and the main 
sample separation took place for 28 minutes, between RT 13 to 41 minutes. Buffer A: 
Ultrapure water with 0.1% (v/v) formic acid; Buffer B: 20% (v/v) ultrapure water, 80% 
(v/v) acetonitrile with 0.1% formic acid (v/v). 
 
Retention Time 
(RT) (min) 
Flow rate 
(µL/min) 
% Buffer B Column Valve 
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0 0.250 3.0 1-2 
8.0 0.250 3.0 10-1 
8.1 0.250 3.0 10-1 
13 0.250 10.0 10-1 
41 0.250 60.0 10-1 
42 0.250 90.0 10-1 
47 0.250 90.0 10-1 
48 0.250 3.0 10-1 
61 0.250 3.0 1-2 
63.1 0.250 3.0 1-2 
64 0.250 3.0 1-2 
 
The mass spectrometer analyser used was the electron transfer dissociation 
(ETD) enabled Thermo Fisher-Scientific Orbitrap Elite, equipped with an 
Easyspray ESI source (ThermoFisher Scientific). Nanospray ionization was 
carried out at 1.8 kV, with the ion transfer capillary at 250°C, and S-lens setting 
of 60%. MS1 spectra were acquired at a resolving power of 60,000 with an 
automatic gain control (AGC) target value of 1x106 ions by the Orbitrap 
detector, with a range of 350-2000m/z. Following MS1 analysis the top 20 most 
abundant precursors were selected for data dependant activation (MS2 
analysis) using collision induced dissociation (CID), with a 10ms activation time, 
and an AGC setting of 10,000 ions in the dual cell linear ion trap on normal 
scan rate resolution, with wideband isolation active and an ion intensity 
threshold of 5000. Ion injection time prediction and FTMS preview mode were 
enabled. Charge state screening and monoisotopic precursor selection were 
enabled with precursor ions of single charge rejected, and a 30 second dynamic 
exclusion window setting was used after a single occurrence of an ion with a +/- 
10ppm tolerance. 
 
The resulting spectra were searched with Mascot (Matrix Science) against the 
Swissprot database (Rodentia taxonomic filter) and a decoy database, within 
the Proteome Discoverer 1.3 software package (ThermoFisher Scientific). Full 
trypsin enzymatic specificity was required with up to 2 missed cleavages 
permitted. Instrument was set to ESI-TRAP. A mass tolerance of 5ppm was 
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used for precursors and 0.2Da for fragment ions. Carbamidomethylation of 
cysteine (+57.021Da) was specified as a fixed modification and oxidation of 
methionine (+15.995Da) was specified as variable modification. False discovery 
rates (FDRs) were set at 1% (strict) and 5% (relaxed) by Target Decoy PSM 
Validator (workflow node within Proteome Discoverer) and were used to 
distribute the confidence indicators for the peptide spectral matches. Proteins 
required a minimum of two peptides with a 95% confidence interval or above in 
order to be reported. 
 
2.21 Protein Analysis 
2.21.1 24-well slot blot system 
The AmershamTM Hybond-ECL nitrocellulose blotting membrane (GE 
Healthcare) was cut to the same size as the 24-well slot blotting apparatus 
(CORE Life Sciences) and equilibrated in blotting buffer for 15 minutes before 
use. The wet membrane was placed between the two parts of the apparatus, 
and the screws of blotting apparatus were secured before turning on the 
vacuum. 200 µl of PBS were passed through the slots as preparation and then 
200 µl of the samples were loaded into the slots, ensuring that the sample really 
goes through the membrane.  
 
After loading the membrane, it was removed from the 24-well slot blotting 
apparatus and incubated in blocking buffer for 1 hour at room temperature with 
gentle shaking. The membrane was washed three times with TBST before 
incubating it for 1 hour at room temperature with blocking buffer containing the 
primary antibody at appropriate dilution (Table 2.6). After the incubation the 
membrane was washed 3 times with TBST before incubating it for 1 hour at 
room temperature and shaking with blocking buffer containing the suitable 
horseradish peroxidase conjugated secondary antibody (Table 2.7) at 1:10,000 
dilution. The membrane was washed three times with TBST before its 
development.  
 
For the development of the membrane equal volumes of SuperSignal® West 
Pico (Thermo Scientific) Enhanced Chemiluminescent (ECL) substrate reagent 
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1 and ECL reagent 2 were mixed and poured over the entire surface of the air-
dried membrane and incubated for 5 minutes at room temperature in a dark 
room. The membrane was then dried and placed between two sheets of plastic 
that were inside of a film cassette. AmershamTM Hyperfilm-ECL (GE 
Healthcare) was placed on top of the nitrocellulose membrane and exposed for 
different times, depending on optimal detection of the proteins. After the 
exposure the film was washed in developer solution until the bands appeared, 
then the film was submerged immediately in fixer solution and rinsed in distilled 
water twice. The developed films were then air-dried. 
 
2.21.2 SDS-PAGE 
The samples were prepared as follows. The protein concentration was 
measured using Bradford protocol and adjusted using sterile PBS. These 
samples were mixed with Loading Buffer and boiled for five minutes in a heating 
block, after which they were cooled down to room temperature before loading 
them in the gels. The samples were stored at -20ºC between uses. 
 
The resolving gels were prepared as follows. The ammonium persulfate (APS) 
and tetramethylethylenediamine (TEMED) were added immediately before 
pouring the gels.  
 
10% (w/v) resolving gel  
dH2O         3.2 ml 
50 mM Tris-HCl (pH 8.4)      2.0 ml 
SDS 10% (w/v)       80 µl 
30% (w/v) acrylamide/2.6% (w/v)bis (BioRad)   2.67 ml 
10% (w/v) APS       80 µl 
TEMED        10 µl 
 
12% (w/v) resolving gel  
dH2O         1.75 ml 
50 mM Tris-HCl (pH 8.4)      1.25 ml 
SDS 10% (w/v)       50 µl 
30% (w/v) acrylamide/2.6% (w/v) bis (BioRad)   2.0 ml 
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10% APS        25 µl 
TEMED        10 µl 
 
The components were gently mixed in a Falcon tube and loaded into the 
BioRad Mini-Protean II gel casting apparatus, selecting a spacer plate of the 
desired gel thickness. A layer of isopropanol was pipetted on the top of the gel 
to isolate it from the air and to make sure it was even. Once the gel had 
solidified, the isopropanol was drained using filter paper. The stacking gel was 
made up as follows and applied on top of the resolving gel. 
4% (w/v) stacking gel  
dH2O         3.05 ml 
50 mM Tris-HCl (pH 8.4)      1.25 ml 
SDS 10% (w/v)       50 µl 
30% (w/v) acrylamide/2.6% (w/v) bis (Biorad)   0.65 ml 
10% (w/v) APS       25 µl 
TEMED        10 µl 
 
A BioRad plastic comb was placed immediately into the gel to create the wells 
and to isolate the gel from the air. After the stacking gel solidified, it was 
transferred to a Protean II (BioRad) protein gel-running tank and submerged in 
1x SDS PAGE reservoir buffer. The comb was removed and 5-20 µl of samples 
were loaded. 5 µl of 0.2 mg/ml ColorPlus Prestained Protein Ladder, Broad 
Range (New England Biolabs), Color Prestained Protein Standard, Broad 
Range (New England Biolabs) or Unstained Protein Ladder, Broad Range (New 
England Biolabs) protein size markers were also loaded. The proteins were 
separated by electrophoresis at 100V until the blue dye front of the sample 
buffer was at the base of the gel plate. 
 
2.21.3 Native polyacrylamide gel electrophoresis 
The samples were prepared by mixing them with Native Loading Buffer. The 
samples were stored at -20ºC between uses. 
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The resolving gels were prepared as follows. Ammonium persulfate (APS) and 
tetramethylethilenediamine (TEMED) were added immediately before pouring 
the gels. 
 
8% (w/v) resolving gel 
30% (w/v) acrylamide/2.6% (w/v) bis (BioRad)   2.6 ml 
0.375 M Tris-HCl pH 8.8      7.29 ml 
10% (w/v) APS       100 µl 
TEMED        10 µl 
 
10% (w/v) resolving gel 
30% (w/v) acrylamide/2.6% (w/v) bis (BioRad)   3.4 ml 
0.375 M Tris-HCl pH 8.8      6.49 ml 
10% (w/v) APS       100 µl 
TEMED        10 µl 
 
The components were gently mixed in a Falcon tube and loaded into the 
BioRad Mini-Protean II gel casting apparatus, selecting a 1mm spacer plate. No 
stacking gel was used in these gels, so the BioRad plastic comb was placed 
immediately into the resolving gel to create the wells and to isolate the gel from 
the air. After the gel solidified, it was transferred to a Protean II (BioRad) protein 
gel-running tank and submerged in 1x Native PAGE Running buffer. The comb 
was removed and 10 µl of samples were loaded. The proteins were separated 
by electrophoresis at 100V for 5 hours and the Protean II (BioRad) protein gel-
running tank was placed on ice for the duration of the electrophoresis. 
 
2.21.4 Coomassie Blue staining 
After the electrophoresis the SDS gels were placed in Coomassie Blue stain for 
60 minutes with light shaking in order to visualise the proteins. The gels were 
then destained using 25 ml of destain solution overnight and at least three 
washes with 25 ml of destain solution after that until the background was clear. 
The gels were then stored in distilled water before being scanned and dried. 
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The molecular masses of the proteins present were estimated by comparison to 
protein standards of known molecular mass.  
 
2.21.5 Silver Staining 
The procedure from Thermo Scientific Pierce Silver Staining Kit (Life 
Technologies) for silver staining of proteins in polyacrylamide gels was followed. 
After the electrophoresis, the gels were washed twice with MilliQ water before 
starting the staining process. The gels were washed twice for 15 minutes with 
Fixing Solution, twice with Ethanol Solution for 5 minutes and then with MilliQ 
water twice for 5 minutes. The gels were then incubated for exactly one minute 
with Sensitizer Working Solution and then washed twice with MilliQ water for 1 
minute. The gels were incubated for 30 minutes at room temperature and light 
shaking with Stain Working Solution. After this incubation the gels were washed 
twice with MilliQ water for 30 seconds, and immediately after Developer 
Working Solution was added. The gels were incubated between 30 seconds 
and 3 minutes in this solution, until the protein bands appeared. Once the 
desired band intensity was reached, the Developer Working Solution was 
replaced with Stop Solution. After a 2 minutes incubation, the gels were 
incubated in fresh Stop Solution until they were dried. 
 
2.21.6 Gel Drying 
The SDS gels stained with Coomassie Blue or Silver were dried between two 
sheets of DryEase® Mini Cellophane (Novex by Life Technologies) that had 
been pre-soaked in Gel-DryTM Drying Solution (Invitrogen). A gel-drying frame 
was used to hold the gel and the drying sheets at room temperature for 24 
hours or until completely dry, after which the gels were scanned. 
 
2.21.7 Western Blot 
The protein samples were separated by SDS-PAGE or Native PAGE as 
described in Chapter 2.21.2 and 2.21.3, respectively. The gel was equilibrated 
in blotting buffer for 15 minutes before the transfer began. AmershamTM 
Hybond-ECL nitrocellulose blotting membrane (GE Healthcare) was cut to the 
same size as the gel and equilibrated in blotting buffer for 15 minutes before 
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use. The proteins were transferred from the gel to the membrane by wet 
transfer using the BioRad Mini-PROTEAN® Tetra System for 90 minutes at 
100V with ice-cold ethanol blotting buffer. 
 
After the transfer the membrane was washed twice with TBST for 5 minutes and 
once for 15 minutes. The membrane was then incubated with blocking buffer for 
1 hour at room temperature with shaking, after which it was washed with TBST 
twice for 5 minutes and once for 15 minutes. The membrane was incubated 
overnight at 4ºC with blocking buffer containing the primary antibody at an 
appropriate dilution (Table 2.6). After the incubation the membrane was 
thoroughly rinsed at least 3 times with TBST, and then incubated for 60 minutes 
at room temperature and shaking with blocking buffer containing horseradish 
peroxidase conjugated secondary antibody (Table 2.7) at 1:10,000 dilution. The 
unbound secondary antibody was then removed by washing the membrane with 
TBST once for 15 minutes and twice for 5 minutes.  
 
For the development of the membrane, the following steps were carried out in a 
dark room. Equal volumes of SuperSignal® West Pico (Thermo Scientific) 
Enhanced Chemiluminescent (ECL) substrate reagent 1 and ECL reagent 2 
were mixed and poured over the entire surface of the air-dried membrane and 
incubated for 5 minutes at room temperature. The membrane was dried and 
placed between two sheets of plastic that were inside of a film cassette. 
AmershamTM Hyperfilm-ECL (GE Healthcare) was placed on top of the 
nitrocellulose membrane and exposed for different times, depending on optimal 
detection of the proteins. After exposure, the film was washed in developer 
solution until the bands appeared, then the film was submerged immediately in 
fixer solution and rinsed in distilled water twice. The developed films were then 
air-dried before scanning. 
 
2.21.8 Bradford estimation of protein concentration 
Different concentrations of bovine serum albumin (BSA) were used to prepare 
the standard curve. 0, 2, 5, 10 and 20 µg of BSA were added to distilled water 
to a final volume of 800 µl in a Semi-micro PS spectrophotometer cuvette 
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(Fisherbrand). 200 µl of BioRad Protean Assay Dye was added and mixed. The 
absorbance at 595 nm (A595) was immediately measured using a WPA Biowave 
DNA Spectrophotometer. The spectrophotometer was calibrated to zero using 
the sample containing 0 µg of BSA. 
 
To determine the concentration of the protein samples, the samples were 
diluted in distilled water to a final volume of 800 µl in a spectrophotometer 
cuvette. Then 200 µl of BioRad Protean Assay Dye were added to the cuvette 
and mixed by inversion. The A595 was measured and the protein concentration 
was calculated from the standard curve equation. 
 
2.22 Effect of purified Phospholipase A2 (PLA2) on S. aureus 
Aliquots of 100 µl of PLA2 Buffer (Chapter 2.4.7) were inoculated with different 
concentrations of recombinant human PLA2 (Sigma-Aldrich), spitting cobra 
(Naja mossambica mossambica) PLA2 (Sigma Aldrich) and honey bee (Apis 
mellifera) PLA2 (Sigma-Aldrich) before the addition of 105 cells/ml of an 
exponential phase culture of S. aureus. Killing assays were carried out as 
explained in Chapter 2.9. Aliquots of rabbit serum, heated rabbit serum and 
adult human serum were also used following the protocol just described. 
 
2.23 Fluorescence microplate assay for PLA2 activity 
Stock solutions of assay buffer (50mM Tris-HCl, 100mM NaCl, 1mM CaCl2, 
pH8.9), DOPC, DOPG and Red/Green BODIPY PC-A2 were prepared as 
explained in Chapter 2.4.8 and Table 2.4, respectively. 30 µl of 10 mM DOPC, 
30 µl of 10 mM DOPG and 30 µl of Red/Green BODIPY PC-A2 were mixed in a 
conical microcentrifuge tube, and 77 µl of this ethanolic lipic mix was slowly and 
steadly injected over a minute into 5 ml of assay buffer that was being stirred. 
This results in 5 ml of liposomally-incorporated substrate. This mixture was 
aliquoted in amber Eppendorf tubes and kept at -20ºC until used. 
 
The VictorTM X3 2030 Multilabel Reader (Perkin Elmer) fluorescence reader 
was used and set up according to the specifications of the BODIPY PC-A2 
substrate (excitation: 485nm; emission: 535 nm, instructions from manufacturer) 
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before starting the reaction. 50 µl of the PLA2-containing samples to test were 
pipetted into a well from a Nunc® 96-well Microwell Plate, flat (Thermo 
Scientific), as well as the appropriate controls. This was mixed with 50 µl of the 
liposomally-incorporated substrate, which marked the time point zero for the 
reaction. The plate was incubated at 37ºC and measurements of the 
fluorescence were taken at appropriate times. Each sample was prepared in 
triplicate. 
 
For the standard curve samples containing known enzyme concentrations in 
assay buffer were prepared, and 50 µl of these samples were mixed with 50 µl 
of the BODIPY/DOPC/DOPG mixture per well. The time points recorded were 
the same as with the phospholipase A2 containing samples.  
 
2.24 Inactivation of purified PLA2 by purified cell wall material 
10mg/ml stocks of the different purified wall material (Chapter 2.16 and 2.17) 
were used for the inactivation of purified cobra (Naja mossambica mossambica) 
and purified honey bee (Apis mellifera) phospholipase A2. Aliquots of the 
purified phospholipase A2 were mixed with purified cell wall material (1 mg/ml 
final concentration) and incubated for 30 minutes at 4ºC with rotation. The tubes 
were then centrifuged (10000 rpm, 3 minutes, room temperature) and the 
supernatant was used to inoculate NRS at the same concentration as untreated 
phospholipase. 
 
This rabbit serum was then used in killing assays as described in the Chapter 
2.9, inoculating with 105 cell/ml of an exponential phase culture of S. aureus 
SH1000. 
 
2.25 Effect of annexin A1 on the activity of PLA2 
To test the bactericidal activity of annexin A1 on its own, aliquots of 40 µl of 
PLA2 Buffer (Chapter 2.4.7) were inoculated with 1.5 µl of human annexin A1 at 
a final concentration 50 µg/ml (Abcam) before the addition of 105 cells/ml of an 
exponential phase culture of S. aureus (Chapter 2.9) 
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To test the effect of the annexin A1 on the activity of purified cobra 
phospholipase A2, aliquots of 40 µl of PLA2 buffer were inoculated with 1.5 µl of 
human annexin A1 (final concentration 50 µg/ml) and then different 
concentrations of purified cobra phospholipase A2 were added to the solution. 
Killing assays were carried out as explained in Chapter 2.9. 
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3 CHAPTER 3: 
Identification of the bacterial elements involved in the killing 
mechanism of naive rabbit serum 
 
3.1 Introduction 
 
Evolutionary evidence suggests that mechanisms of immune defence existed 
by the time the ancestors of plants and animals diverged (Wilson et al, 1997; 
O’Neil and Greene, 1998). Whilst invertebrates and plants survive with innate 
immunity mechanisms only (O’Neil and Greene, 1998; Leulier et al, 2003; 
Beutler, 2004), in vertebrates the innate immunity acts as the first line of 
defence and evolution led to the development of the highly specific adaptive 
immunity (Beutler, 2004; Guan and Mariuzza, 2007; Chaplin, 2010). 
 
The innate immune system is able to recognize self-cells from microbial 
pathogens through the recognition of evolutionary conserved molecules that are 
specific to microorganisms and are not produced by the host (Medzhitov and 
Janeway, 2002; Vivier and Malissen, 2005). These conserved molecules are 
called ‘pathogen-associated molecular patterns’ (PAMPs) and are perceived as 
molecular markers of infection by the immune system (Medzhitov and Janeway, 
2002). These PAMPs are ‘molecular signatures’ of different types of pathogen, 
allowing the immune system to choose the most efficient mechanism against 
this particular class (Medzhitov and Janeway, 2000). Examples of these 
microbial components that are recognized include lipopolysaccharides of Gram-
negative bacteria and lipoteichoic acid of Gram-positive bacteria, along with 
peptidoglycan, mannan, flagellin and non-methylated CpG sequences present 
in both types of bacteria, as well as double-stranded RNA for viruses 
(Medzhitov and Janeway, 2002; Beutler, 2004; Guan and Mariuzza, 2007) 
 
These molecules can be recognized by a set of defined receptors called 
pathogen- or pattern-recognition receptors (PRRs) (Ausubel, 2005; Akira et al, 
2006). PRRs are germ-line encoded receptors and soluble molecules, and even 
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though their expression may be restricted to some cell types, they are not 
clonally distributed (Vivier and Malissen, 2005; Dziarski and Gupta, 2006). On 
Chapter 1.4.1.2 several molecules responsible for sensing the pathogens such 
as mannose-binding protein and collectins were discussed, but they are not the 
only ones.  
 
Peptidoglycan is an essential component of the bacterial cell wall responsible 
for the maintenance of cell integrity (Mengin-Lecreulx and Lemaitre, 2005; 
Vollmer et al, 2008) and interactions with the host (Mengin-Lecreulx and 
Lemaitre, 2005). This polymer that can be found on the outside of the 
cytoplasmic membrane (Mengin-Lecreulx and Lemaitre, 2005; Vollmer et al, 
2008), and whilst the length of the glycan strands can vary considerably its 
composition is highly conserved (Hayhurst et al, 2008; Vollmer et al, 2008; 
Vollmer and Seligman, 2010). Due to the conservation of its composition and its 
essential role in bacteria, peptidoglycan is a good target for recognition by the 
innate immune system (Dziarski and Gupta, 2005). 
 
Several pathogen-recognition molecules can detect peptidoglycan. It has been 
shown that peptidoglycan can activate macrophages in a CD14-dependent 
manner (Gupta et al, 1996; Dziarski et al, 1998). Toll-like receptor 2 (Yoshimura 
et al, 1999) and nucleotide-binding-oligomerization domain-containing proteins 
(NODs) (Franchi et al, 2002; Fournier and Philpott, 2005) also detect 
peptidoglycan, along with peptidoglycan recognition proteins (PGRPs) (Michel 
et al, 2001; Guan and Mariuzza, 2007). 
 
Teichoic acids are anionic polymers that are associated with the cell wall of 
Gram-positive organisms (Silhavy et al, 2010; Hanson and Neely, 2011). Wall 
teichoic and lipoteichoic acids are the two major types (Swoboda et al, 2010; 
Hanson and Neely, 2011). Whilst lipoteichoic acids can be recognized by the 
CD14 receptor, leading to the activation of macrophages (Cleveland et al, 
1996), wall teichoic acids limit the access of the pathogen-recognition 
molecules to peptidoglycan (Atilano et al, 2011).  
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Protein A is one of S. aureus surface proteins that can interact with pathogen-
recognition molecules. Protein A can interact directly with tumour necrosis 
factor-receptor 1 (TNFR1) in airway epithelium, reproducing the effects of TNF-
α, the ligand of TNFR1 (Gomez et al, 2004; Fournier and Philpott, 2005). 
 
These recognition molecules are able to sense the pathogen, but they are not 
able to eliminate them from the host. Other extracellular molecules produced by 
the immune system of the host take care of that, such as cationic antimicrobial 
peptides and skin fatty acids, complex protein systems like the complement 
cascade and enzymes as lysozyme and phospholipase A2. These molecules 
can be found through out the host, specially in the skin (Miller et al, 1988; Wille 
and Kydonieus, 2003; Georgel et al, 2005), tears (Qu and Lehrer, 1998; Girgis 
et al, 2003; Fluckinger et al, 2004; McDermott, 2013), serum (Taylor, 1983; 
Crokaert et al, 1988; Grönroos et al, 2002; Gasque, 2004; Menschikowski et al, 
2006; Ricklin et al, 2010) and seminal plasma (Kunze and Bohn, 1978; 
Nevalainen et al, 1993). 
 
The interaction between the bacterial cell wall components and the elements of 
the immune system is necessary for the recognition and elimination of the 
pathogens. This led us to suggest that the bacterial receptor for the antibacterial 
activity of naive rabbit serum (NRS) against Staphylococcus aureus had to be a 
surface component. 
 
 
3.1.1 Aims of this chapter 
 
Ø Study the role of wall teichoic acids in the bactericidal mechanism of NRS. 
Ø Study the role of other cell wall components through the use of mutant 
strains and purified cell wall material. 
Ø Analysis of the role of modifications of the cell wall, such as D-alanylation 
and glycosylation, on the interaction of S. aureus with NRS. 
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3.2 Results 
3.2.1 Effect of mammalian serum on S. aureus SH1000 
 
Previous studies carried out in our laboratory showed that naive rabbit serum 
(NRS) has the ability to kill S. aureus SH1000 (Bozakouk, 2011). To verify this, 
the bactericidal properties of rabbit and six other types of mammalian sera 
(mouse, calf, cow, pig, sheep, horse and rat, Table 2.5) against S. aureus were 
tested. 
 
To test their bactericidal activity, killing assays using the mammalian sera were 
carried out as explained in Chapter 2.9. An aliquot of the mammalian serum 
was inoculated with 105-106 cells/ml of an exponential phase culture of S. 
aureus SH1000 and incubated at 37ºC. Samples were taken at specific times, 
10-fold serial dilutions were made and aliquots of each dilution were spotted on 
BHI plates. Naive rabbit serum was the only serum that showed bactericidal 
activity against the bacteria (Figure 3.1). A 10-fold decrease of the bacterial 
numbers was observed after just 30 minutes of incubation in NRS, with bacterial 
count lower than the detection limit (103 cfu/ml) after 2 hours of incubation. 
 
3.2.2 Effect of adult human serum on S. aureus SH1000 
 
It has been well documented that human serum has bactericidal and 
bacteriolytic activity against Gram-negative (Waisbren and Brown, 1961; Oling, 
1977; Taylor, 1983) and Gram-positive (Lehrer and Ganz, 1996; Steinberg et al, 
1997; Noore et al, 2013) bacteria due to the action of several soluble 
components, such as complement, phospholipase, lysozyme and cationic 
antimicrobial peptides. 
 
The blood of four healthy adult volunteers was collected and prepared as 
explained in Chapter 2.13.1. To test the bactericidal activity of each serum 
against S. aureus, killing assays using 105 cell/ml of an exponential phase 
growth culture of S. aureus SH1000 were carried out as described (Chapter 
2.13.2).  
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Figure 3.1 Effect of mammalian serum on S. aureus SH1000 
The bactericidal activity of serum from different domestic mammals (Table 2.5) was 
tested against S. aureus SH1000. The colours represent different samples and these 
experiments were carried out in triplicate (biological triplicates), apart from the mouse 
serum where only 0 and 4 hr were analysed in duplicate due to the availability of the 
sample. Error bars represent the standard deviation of the means. 
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No bactericidal activity against the S. aureus was observed and a significant 
difference can be seen when compared to the effect of NRS on the bacteria 
(Figure 3.2, p<0.001). 
 
 
3.2.3 Effect of infant human serum on S. aureus SH1000 
 
The use of the S. aureus ΔtagO mutant showed that wall teichoic acid (WTA) is 
involved in the activity of NRS on the bacteria, and complement component 
C4b and mannose-binding lectin (MBL) were able to bind to purified WTA 
(Bozakouk, 2011).  
 
It has been reported that the S. aureus cell wall components are able to activate 
complement pathways (Neth et al, 2000; Lynch et al, 2004; Shi et al, 2004). 
Also that whilst serum mannose-binding lectin from adults is not able to 
recognize WTA on the cell surface due to the presence of anti-WTA antibodies, 
serum MBL from infants is able to do so (Park et al, 2010). This binding also 
serves as an antigen in the development of anti-WTA IgGs (Park et al, 2010). 
As a result it was hypothesized that infant serum might be able to carry out 
complement-mediated lysis of S. aureus due to the low levels of antibodies 
present in infants during the first 18 months of life. 
 
To confirm this hypothesis the bactericidal activity of baby serum was studied. 
Blood was obtained from four healthy infants at the Royal Hallamshire Hospital 
and the serum was purified according to the protocol in Chapter 2.14.1. Aliquots 
of the serum were incubated with an exponential phase culture of S. aureus 
SH1000, samples were taken at certain times, diluted on sterile PBS and 
spotted on BHI plates.  
 
As shown in Figure 3.3, while naive rabbit serum was able to reduce the 
bacterial count lower than the detection limit, the incubation of S. aureus in 
infant human serum led to bacterial growth. Therefore, just as seen with adult   
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Figure 3.2 Effect of adult human serum on S. aureus SH1000 
The bactericidal activity of serum from four different adult healthy volunteers was 
tested against S. aureus SH1000 and compared to naive rabbit serum (black bars). 
Samples were taken at appropriate times, 10-fold dilutions were made using PBS and 
spotted on BHI plates. After an overnight incubation at 37ºC the colony forming units/ml 
for each serum was determined. Only the results obtained after the inoculation with S. 
aureus (T= 0 hr) and at the end of the experiments (T= 4 hr) are shown to facilitate the 
comparison. The colours represent different samples and these experiments were 
carried out in triplicate (i.e. biological triplicates), error bars represent the standard 
deviation of the means. Student’s t-tests were used and significant differences are 
marked with an asterisk. 
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Figure 3.3 Effect of infant human serum on S. aureus SH1000 
The bactericidal activity against S. aureus SH1000 of serum from four infant (younger 
than 18 months old) human healthy volunteers was tested and compared to the activity 
of rabbit serum. Each sample was inoculated with between 105 and 107 cell/ml of the 
bacteria and aliquots were taken at the moment of the inoculation (T= 0 hr) and after 4 
hours of incubation at 37ºC (t= 4 hr). The colours represent the different samples and 
these experiments were carried out in triplicate (i.e. biological triplicates), with error 
bars as the standard deviation of the means. Student’s t-tests were used and 
significant differences are marked with an asterisk. 
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human serum, infant human serum has no bactericidal activity against S. 
aureus. 
 
 
3.2.4 Effect of NRS on different laboratory strains of S. aureus 
 
Previous experiments carried out in the laboratory showed differences in the 
effect of NRS on several clinical isolates of S. aureus (Bozakouk, 2011). To test 
the possible strain specificity of the effect of NRS several laboratory strains 
were used. Killing assays were carried out as described before using serum 
from the same rabbit in all cases. The rabbit serum had the ability to kill all the 
tested strains in a similar manner, with fewer colonies than the detection limit 
after 2 hours of incubation (Figure 3.4), suggesting that the receptor for the 
bactericidal activity of NRS is present in all of these strains. 
 
Even though the rabbit aliquots were inoculated with the same initial 
concentration of cells, a 10-fold difference was observed between the RN4220 
and the rest of the strains suggesting that that an enhanced bactericidal activity 
of NRS for this strain. 
 
 
3.2.5 Effect of heat treatment in bactericidal activity of NRS 
 
It has been reported that heating the serum for 30 minutes at 56ºC can 
inactivate the bactericidal activity of mammalian serum (Beckerdite-Quagliata et 
al, 1975; Redelman and Russell, 1980; Taylor, 1983). This led us to test if this 
treatment was able to inactivate the bactericidal activity of NRS against S. 
aureus SH1000. 
 
An aliquot of rabbit serum was incubated in a water bath at 56ºC for 30 minutes 
before inoculating this heated serum with 1 an exponential growth phase culture 
of S. aureus SH1000, just as described in Chapter 2.10.1. This treatment was 
repeated every time fresh rabbit serum was prepared. Just as expected   
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Figure 3.4 Comparison of the effect of NRS on S. aureus laboratory strains 
The bactericidal activity of NRS against several strains of S. aureus (Table 2.2) was 
tested, inoculating an aliquot of rabbit serum with 105-106 cells/ml of each strain. 
Cultures were incubated at 37ºC and aliquots were taken at determined times, diluted 
in PBS and spotted onto BHI plates. After an overnight incubation at 37ºC the colony 
forming units/ml on each case was determined. The colours represent the different 
strains. These experiments were carried out on triplicate (i.e. biological triplicates) and 
the error bands represent the standard deviation of the means. 
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Figure 3.5 Inactivation of the bactericidal activity of NRS using heat treatment 
Serum from four different rabbits (panel A, B, C and D) was prepared as described in 
Chapter 2.8 and aliquots were heated in a water bath for 30 minutes at 56ºC before the 
inoculation with 105-106 cells/ml of the bacteria for killing assays as described before. 
All the experiments were carried out using exponential growth phase cultures of S. 
aureus SH1000. The black line corresponds to untreated NRS, while the red line 
shows the heat-treated serum. These experiments were done in triplicate (i.e. 
biological triplicates), Student’s t-tests were used and significant differences are 
marked with an asterisk (p<0.05). The error bars represent the standard deviation of 
the means. 
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from the literature, the heat treatment of the serum before the addition of the 
bacteria inactivates its bactericidal activity (Figure 3.5, all panels). This was 
observed with all the rabbit sera that have been used during this project, 
suggesting that the bactericidal activity of NRS is temperature sensitive. 
 
 
3.2.6 Role of wall teichoic acid (WTA) in the bactericidal activity of NRS 
 
Wall teichoic acids play an important role on the colonization of the host by S. 
aureus (Weidenmaier et al, 2004; Weidenmaier et al, 2005b; Bera et al, 2007; 
Weidenmaier et al, 2008), and they are involved in the resistance of the 
bacteria to the host immune system (Kohler et al, 2009; Carvalho et al, 2015). 
Previous results obtained in the laboratory showed that wall teichoic acids were 
involved on the bactericidal activity of NRS (Bozakouk, 2011), suggesting that 
this component may have a role as the receptor for this activity. 
 
In order to verify the role of the wall teichoic acids, killing assays were carried 
out using the ΔtagO strain, mutant with a deletion of the first gene in the 
biosynthesis pathway of wall teichoic acids (Figure 1.6; Vergara-Irigaray et al, 
2008; Swoboda et al, 2010). Killing assays using NRS were carried out using 
this mutant and the parent as a control, following the protocol described 
previously (Chapter 2.9). Whilst the parental strain was killed during the course 
of the experiment, the mutant was resistant to the bactericidal activity of the 
serum (Figure 3.6). These results suggest that due to the lack of wall teichoic 
acids in the cell wall of the mutant strain the ‘killing factor’ present in rabbit 
serum was not able to interact with the bacteria, confirming the role of WTA as 
a receptor for the killing activity of the rabbit serum. 
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Figure 3.6 Role of wall teichoic acids in the bactericidal activity of NRS 
The 15981 parental (black line) and ΔtagO (red line) strains were grown to exponential 
phase before inoculating an aliquot of NRS with 105 cells/ml. These experiments were 
carried out in triplicate (i.e. biological triplicates). Student’s t-tests were used and 
significant differences are marked with an asterisk (p<0.05). Error bars correspond to 
the standard deviation of the means. 
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3.2.7 Role of lipoteichoic acid (LTA) in the bactericidal activity of NRS 
 
After confirming the role of wall teichoic acids as a potential receptor for the 
bactericidal activity of NRS, lipoteichoic acid appeared as another possible 
candidate. This molecule is the other class of teichoic acid that can be found in 
S. aureus (Neuhaus and Baddiley, 2003; Hanson and Neely, 2011) and is 
involved in virulence (Weidenmaier et al, 2004), amongst other functions. 
 
This molecule is essential for cell viability (Weidenmaier and Peschel, 2008), 
making it impossible to generate an LTA-deficient mutant in an unsupressed 
background. A mutant strain that has only 13% of LTA content when compared 
to the parental strain has been created by deletion of the ypfP gene (Fedtke et 
al, 2007). The YpfP protein mediates the synthesis of diglucosyl-diacylglycerol 
(DGlcDAG), the anchor to which the poly- [glycerophosphate] repeating unit is 
attached in B.subtilis and S. aureus (Figure 1.5; Jorasch et al, 2000). 
 
The ΔypfP mutant showed a different phenotype than the parental strain, with 
slower growth in liquid medium and smaller colonies on BHI plates (data not 
shown). When killing assays were carried out using this mutant strain no 
colonies were obtained in any of the time points, suggesting that the 
bactericidal elements of the serum kill the bacteria faster than the parental 
strain (Figure 3.7A). To test if this death was caused by the element studied in 
this project and not by another problem in the cell wall of this mutant killing 
assays were carried out using heat-treated NRS. The ΔypfP mutant behaved in 
the inactivated serum in the same way as in the active NRS while the parental 
strain was able to grow in it (Figure 3.7B), suggesting that the extremely fast 
death of this mutant strain on rabbit serum was caused by other elements of the 
serum that are not affected by the heat treatment. Therefore, it was not possible 
to grant LTA any function in this killing mechanism of the serum using this 
partial mutant strain. 
 
To test that the bacterial death observed for this mutant was not caused by 
other properties of the mammalian serum that could affect this LTA-deficient 
mutant, such as the osmolarity of the serum (Percy and Gründling, 2014), the   
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Figure 3.7 Role of lipoteichoic acids in the bactericidal activity of NRS 
The Sa113 parent (black line) and the Sa113 ΔypfP mutant (blue line) strains were 
used in killing assays using A) rabbit serum, B) heat inactivated rabbit serum, and C) 
human serum as previously described in Chapter 2.9. The same initial inoculum of both 
strains (106 cells/ml) was used in each experiment. These experiments were carried 
out in triplicate (i.e. biological triplicates). Student’s t-tests were used and significant 
differences are marked with an asterisk (p<0.05). Error bars represent the standard 
deviation of the means. 
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parent and the ΔypfP mutant strain were incubated in human serum. Both 
strains were able to survive in the human serum (Figure 3.7C), suggesting that 
the human not only differs from the rabbit serum in the mechanisms that is 
being studied in this project, but also in other elements that may change its 
properties (Waymouth, 1970). However, even though the initial inoculum was 
the same for both strains the LTA-deficient strain showed a 10-fold difference in 
the colony forming units when compared to the parent, suggesting that the 
mutant is still sensitive to some of the elements of this otherwise non-
bactericidal human serum. 
 
 
3.2.8 Role of D-alanylation of teichoic acids on the bactericidal activity of 
rabbit serum 
 
Both lipoteichoic and wall teichoic acids from S. aureus can be modified by D-
alanylation once their synthesis is complete (Perego et al, 1995; Clemans et al, 
1999; May et al, 2005). The proteins encoded by the dltABCD operon are 
responsible for the translocation and incorporation of the D-alanine into the 
teichoic acids as it was explained in Chapter 1 (Chapter 1.3.5.3) (Perego et al, 
1995; Peschel et al, 1999). 
 
After obtaining evidence showing the role of wall teichoic acid as the receptor of 
the bactericidal activity of NRS, the function of the modification of the teichoic 
acids was studied. A dltA mutant where the spectinomycin resistance gene 
replaces the dltA gene was used in these experiments (Peschel et al, 1999; 
Table 2.2). 
 
The dltA strain exhibited similar growth in liquid culture when compared to its 
parent strain, as well as when plated on BHI agar plates. The dltA strain was 
also used in killing assays as previously described (Chapter 2.9). An enhanced 
bactericidal rate of the rabbit serum on the mutant was observed when 
compared to the parental strain (Figure 3.8). While the reduction of colony 
forming units under the detection limit was observed after two hours in the 
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parental strain, this only took 30 minutes for the dltA strain. This suggests that 
the absence of the D-alanylation in the teichoic acids of S. aureus makes the 
bacteria more susceptible to the bactericidal elements of the rabbit serum. 
 
Even though the aliquots of rabbit serum were inoculated with the same amount 
of cells initially, a 10-fold difference in the colony forming units (CFU) count was 
seen between the parental and the mutant strain at the beginning of the 
experiment. This suggested that the bactericidal elements of the rabbit serum 
had higher affinity for the cell wall of the mutant strain, allowing the rabbit serum 
to start killing the bacteria immediately. 
 
To be able examine this difference between the mutant and the parental strain, 
killing assays were carried out using diluted rabbit serum. It has been shown in 
this laboratory that NRS can be diluted up to four times without losing its 
bactericidal activity (Bozakouk, 2011). Different dilutions of the rabbit serum 
were made using sterile PBS and the protocol to test the bactericidal activity of 
this solution was carried out as explained in Chapter 2.9. No survival was 
observed for the ΔdltA mutant in any of the dilutions used, whilst the rabbit 
serum diluted 2 times led to a 100-fold decrease in the parental strain (Figure 
3.9). This supports the suggestion that the elements of the serum that are 
responsible for the bacterial killing have a higher affinity for the cell wall of the 
D-alanylation mutant than the parental strain. 
 
 
3.2.9 Role of glycosylation of teichoic acids in the bactericidal activity of 
NRS 
 
After obtaining results suggesting that the D-alanylation of the teichoic acids 
plays a role in the survival of S. aureus in NRS, other modifications of the 
bacterial cell wall were studied. 
 
Once the biosynthesis of wall teichoic acids is completed, they can be modified 
by D-alanylation or glycosylation (Neuhaus and Baddiley, 2003; Weidenmaier   
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Figure 3.8 Role of the D-alanylation of teichoic acids in the bactericidal activity of 
NRS against S. aureus 
The Sa113 ΔdltA mutant was used for killing assays using NRS as described in 
Chapter 2.9. The parent (black line) and the ΔdltA (red line) were grown until 
exponential phase before inoculation into rabbit serum by 105 cells/ml. These 
experiments were carried out in triplicate (i.e. biological triplicates) and Student’s t-tests 
were used. The significant differences are marked with an asterisk (p<0.05) and error 
bars represent standard deviations of the means. 
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Figure 3.9 Effect of the dilution of rabbit serum in the bactericidal activity against 
ΔdltA strain 
NRS was diluted 2- and 3-fold using sterile PBS before inoculation with 105 cells/ml of 
the Sa113 parent or ΔdltA mutant strain. Killing assays were carried out as described 
(Chapter 2.9). For an easier comparison of the dilutions for different dilutions and 
strains, only the starting and ending time points are shown. These experiments were 
carried out in triplicate (i.e. biological triplicates). Significant differences are shown with 
asterisks (p<0.05, Student’s t-test). Error bars correspond to standard deviation of the 
means. 
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and Peschel, 2008; Xia et al, 2010b). As explained previously, the dltABCD 
operon is responsible for the modification of the wall teichoic acids via the 
addition of D-alanine esters into the C2 hydroxyl position (Neuhaus and 
Baddiley, 2003). On the other hand, the glycosylation adds an N-
acetylglucosamine residue into the C4 hydroxyl of the poly-ribitolphosphate unit 
(Sobhanifar et al, 2015). This monosaccharide can be added through a α- or a 
β- linkage via the TarM or TarS proteins, respectively (Xia et al, 2010b; Brown 
et al, 2012). Whilst the tarS gene co-localize with wall teichoic acid biosynthesis 
gene clusters (Brown et al, 2012), tarM does not co-localizes with wall teichoic 
acid gene clusters and is not present in every S. aureus genome (Winstel et al, 
2014). 
 
The configuration of this glycosidic linkage varies and it has been possible to 
identify strains of S. aureus solely with α - or β-O linked monosaccharide, whilst 
others display a mixture of linkages with variable abundance between individual 
strains (Torii et al, 1964; Xia et al, 2010b; Sobhanifar et al, 2015). 
 
It has been suggested that these sugar modifications are involved in the host 
antibody response to wall teichoic acids (Juergens et al, 1963; Xia et al, 2010b) 
and in the binding of bacteriophages to S. aureus (Chaterjee, 1969; Winstel et 
al, 2014). It has been shown that the lack of β-O-GlcNac renders MRSA strains 
susceptible to β-lactam antibiotics, suggesting that this sugar might work as a 
scaffold for proteins that are involved in PBP2a activity (Brown et al, 2012). 
 
Mutant strains with deletions for the α-O-glycosyltransferase (ΔtarM) and β –O-
glycosyltransferase (ΔtarS) genes, along with ΔtarMΔtarS and ΔtarMΔtarS 
complemented with tarS (ΔtarMΔtarS pRB-tarS) were used to test the role of 
the glycosylation of the wall teichoic acids on the survival of S. aureus against 
rabbit serum. No significant differences between the mutant strains, or between 
the mutants and the parental strain, were found when growth curves of all the 
strains were made in BHI. When the killing assays were carried out it was found 
that all the mutant strains were susceptible to the bactericidal elements present 
in the serum, without significant differences compared to the parental strain 
(Figure 3.10, panels A, B, D). However, while all the strains reached bacterial   
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Figure 3.10 Role of the glycosylation of teichoic acids in the bactericidal activity 
of NRS 
An initial inoculum of 106 cells/ml of the S. aureus RN4220 mutant strains A) ΔtarM, B) 
ΔtarS, C) ΔtarMΔtarS and D) ΔtarMΔtarS pRB-tarS, as well as the parental strain 
(black line) were used for killing assays to test the bactericidal activity of NRS. These 
assays were carried out as described in Chapter 2.9. These experiments were carried 
out in triplicate (i.e. biological triplicates) and Student’s t-tests were carried out. 
Significant differences are shown with asterisks (p<0.05). Error bars correspond to the 
standard deviation of the means. 
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numbers lower than the detection limit after 4 hours of incubation, significant 
differences were found for the double mutant only after 30 and 120 minutes of 
incubation, suggesting that this strain is slightly less sensitive than the other 
strains to the NRS killing (Figure 3.10C). 
 
In order to examine more closely the effect of the serum on the different mutant 
strains, diluted serum was used to carry out killing assays. As in Chapter 3.2.8, 
2- and 3-fold dilutions were made using sterile PBS and the strains were grown 
until they reached exponential growth phase before inoculating the serum. The 
undiluted and the 2-fold diluted serum was able reduce the bacterial count 
under the detection limit (103 cfu/ml) in all the strains used, confirming that 
diluting the serum 2 times does not affect its bactericidal activity (Figure 3.11). 
The 3-fold diluted serum was not able to kill all the ΔtarM or the ΔtarS mutants, 
but a significant reduction of 1000-fold in the bacterial count was found for the 
parent, the double mutant and the double mutant complemented with the β–O-
glycosyltransferase (Figure 3.11, p<0.05). Even though the differences between 
the single mutants and the double mutant strains were not significant (p<0.05), 
they indicate that the role of this modification of the wall teichoic acids in the 
activity of the bactericidal elements of the rabbit serum against S. aureus 
remains unclear.  
 
 
3.2.10 Role of L-lysine modification of phospholipids in the bactericidal 
activity of NRS 
 
The D-alanylation modification of the bacterial cell wall protects S. aureus from 
cationic antimicrobial peptides and other soluble components of the host 
immune system because the incorporation of the positively charged residues 
are capable of neutralizing the negative charge of the cell wall. Other 
modifications of the cell surface help in this protection by the introduction of 
positive charges (Kovacs et al, 2006), such as the deacetylation of N-
acetylglucosamine in peptidoglycan by the PgdA protein in S. pneumoniae  
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Figure 3.11 Effect of diluted NRS on its bactericidal activity against S. aureus 
glycosylation mutants 
The S. aureus RN4220 mutant strains for the genes responsible for the glycosylation, 
ΔtarM, ΔtarS, ΔtarMΔtarS and ΔtarMΔtarS pRB-tarS, as well as the parental strain, 
were used for killing assays to test their survival in naive rabbit serum diluted 2- and 3-
fold on sterile PBS. The undiluted and diluted serum were inoculated with 105-106 
cells/ml of the different strains and the cultures were incubated at 37ºC. Only the 
results for the beginning and end of the experiment are shown in order to make the 
comparison easier. The experiments were carried out in triplicate (i.e. biological 
triplicates). Student’s t-tests were carried out and the asterisk show significant 
differences to the parental strain (p<0.05). Error bars represent the standard deviation 
of the means. 
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(Vollmer and Tomasz, 2000; Kovacs et al, 2006) and the lysinylation of 
membrane lipids by the MrpF protein in S. aureus (Peschel et al, 2001).  
 
MprF (multiple peptide resistance factor) is a S. aureus virulence factor that is 
involved in the escape from the innate host defences (Peschel et al, 2001). This 
protein is able to add a L-lysine residue to the anionic phosphatidylglycerol, 
synthesizing lysyl-phosphatidylglycerol (Weidenmaier et al, 2005a). This 
modification neutralizes the negative charge and enhances the positive charge 
of the bacterial surface, facilitating the repulsion of the cationic antimicrobial 
peptides (Weidenmaier et al, 2005a), defensins (Peschel et al, 2001) and other 
molecules such as Group IIA phospholipase A2 (Koprivnjak et al, 2002). 
 
In order to test if this modification was involved in the bactericidal mechanism of 
the NRS, a ΔmprF mutant and the complemented strain were tested. The mprF 
gene was replaced by the erythromycin resistance gene (ermB) via homologous 
recombination in this mutant strain (Weidenmaier et al, 2005a). The parent and 
mutant strains showed similar growth curves in liquid culture and colonies when 
plated in BHI agar plates. When compared to the parental strain, the rabbit 
serum has similar bactericidal activity against the deletion mutant and the 
complemented strain (Figure 3.12A and B).  
 
When the killing assays were carried out using 2- and 3- fold diluted rabbit 
serum (as explained in Chapter 3.2.9), differences were observed between the 
strains when the rabbit serum was diluted 3-fold (Figure 3.13). Whilst a 
reduction in the bacterial count of the mutant strain lower than the detection 
limit (103 cfu/ml) was observed in all the assays, the parent showed some 
survival in the diluted serum and the complemented strain was completely 
resistant to the bactericidal activity of the serum when it was diluted 3-fold. The 
differences between the parent and the complemented strain might be caused 
by the multiple copies of the mprF gene present in the plasmid-complemented 
strain (Yang et al, 2013). However, while the differences between strains with 
and without this modification in 3-fold diluted NRS showed a trend they were 
not significant (p<0.05), suggesting that the role of L-lysine in the resistance of 
S. aureus to NRS was not as important as the D-alanylation.   
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Figure 3.12 Role of the L-lysine modification of phospholipids in the bactericidal 
activity of NRS against S. aureus 
An initial inoculum of 105 cells.ml of the S. aureus Sa113 mutant strains A) ΔmprF and 
B) ΔmprF pRB474-mprF were used for killing assays to test the bactericidal activity of 
rabbit serum. The black line represents the parent strain in both graphs. These 
experiments were carried out in triplicate (i.e. biological triplicates). Student’s t-tests 
were carried out and no significant differences were found (p>0.05). Error bars 
correspond to the standard deviation of the means. 
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Figure 3.13 Effect of dilution of rabbit serum in its bactericidal activity against S. 
aureus ΔmprF mutant strain 
An initial inoculum of 104-105 cells/ml of the Sa113 ΔmprF and ΔmprF pRB474-mprF 
strains, as well as the parent, were used for killing assays to test their survival in NRS 
diluted 2- and 3-fold in sterile PBS. These assays were carried out as described in 
Chapter 2.9 and the experiments were carried out in triplicate (i.e. biological triplicates). 
Student’s t-tests were carried out and no significant differences were found (p>0.05). 
Error bars correspond to the standard deviation of the means. 
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3.2.11 Effect of rabbit serum on rabbit and human evolved strains of S. 
aureus 
 
The ability of a microbial pathogen to colonize a host is defined as host 
specificity (Pan et al, 2014). This host specificity is determined by interactions 
between the pathogen and the host (Pan et al, 2014). S. aureus is a major 
resident and transient colonizer of the skin and mucosa of humans and 
primates and can occasionally live on domestic animals (McCarthy et al, 2012; 
Pantosti, 2012). It has been shown that S. aureus uses the haemoglobin-
binding protein IsdB to capture haemoglobin for heme-iron acquisition, and that 
the bacteria has a preferential binding to human haemoglobin when compared 
to murine haemoglobin (Torres et al, 2006; Pishchany et al, 2010; Pan et al, 
2012). This suggests that the iron availability in human contributes to the host 
specificity of S. aureus (Pishchany et al, 2010). However, this pathogen has 
also been associated with infections in economically important livestock such as 
cows, sheep and rabbits (Viana et al, 2015) 
 
Bacterial pathogens can switch and adapt to different host species, but the 
molecular mechanisms involved are not well understood (Herron-Olson et al, 
2007; Guinane et al, 2010). It has been shown that while some specific genetic 
backgrounds, known as lineages, are associated with specific mammalian hosts 
(Sung et al, 2008), others can cause infections in a broad number of animal 
species (Pantosti, 2012).  
 
S. aureus clonal complex CC121, also known as clone ST121, can cause skin 
infections and necrotizing pneumonia in humans (Viana et al, 2015). A highly 
virulent epidemic ST121 clone associated with skin abscesses and mastitis in 
rabbits has recently emerged (Vancraeynest et al, 2006). This colonization of 
humans and rabbits can be explained by the existence of host-specific subtypes 
of the ST121 clone (Viana et al, 2015). This host adaptation was not caused by 
the acquisition of mobile genetic elements, but by a single mutation in the dltB 
gene. This mutation was sufficient and required to turn the human strain, which 
is incapable of infecting rabbits, into a strain that can cause epidemics in rabbit 
farms (Viana et al, 2015). In addition to this mutation, the rabbit isolates require 
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a mutation in rot (repressor of toxins) gene regulator to infect the skin. Two 
additional mutations in the dltB gene enhanced the infectivity and bacterial 
proliferation within rabbit skin lesions (Viana et al, 2015). 
 
As stated above, the rabbit dltB gene shows three single nucleotide 
polymorphisms (SNPs) when compared to the human evolved strain. Two of 
these SNPs change amino acids (T113K and Y250H), while the third one 
changes the stop codon of the protein to a tyrosine, after which a new stop 
codon appears (*405Y). In other words, the rabbit DltB protein has two 
substitutions and is one residue longer that the human protein. The rabbit 
isolates also present a nonsense mutation in the global virulence regulator rot 
(K103*). The role of these mutations in the rabbit infectivity was tested by their 
introduction into the human ST121 strain F (Viana et al, 2015). 
 
Rabbit infectivity was not the only parameter tested using these rabbit and 
human ST121 strains. Their cell wall composition was studied and the 
peptidoglycan structure was not affected, and neither was the protein profile of 
the proteins bound to the bacterial cell wall (Viana et al, 2015). The mutations 
present in the DltB might have an effect on the interaction of the bacteria with 
the host immune system, and this was tested by killing assays using naive 
rabbit serum. 
 
These experiments were also carried out to confirm the importance of the D-
alanine esters present in the bacterial cell wall on the survival of the bacteria 
against rabbit serum. This role was confirmed in Chapter 3.2.8 using a ΔdltA 
mutant strain. Those results suggested that the absence of these residues 
make the bacteria more susceptible to the bactericidal elements of the rabbit 
serum because they have a higher affinity for this bacterial cell wall when 
compared to the parental strain. 
 
As previously stated, the function of the DltB protein in the D-alanylation 
pathway is not completely clear. It has been suggested that this protein is 
involved in the movement of either the D-alanine residue across the 
cytoplasmic membrane (Perego et al, 1995; Reichman et al, 2013), or the Dcp  
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Table 3.1 Rabbit and human evolved S. aureus strains 
All of the strains were constructed and their sequence was analysed in Viana et al 
(2015). Data on infectivity were taken from Viana et al (2015): I: highly pathogenic; NI: 
not highly pathogenic; NA: no data available.  
 
Strain Genotype 
Rabbit 
infectivity 
Survival in 
rabbit serum 
CH 3934 Parental J strain, rabbit origin I Yes 
CH9982 J strain, ΔdltB NA No 
CH 8348 
J strain with human version of DltB 
protein due to reversion of the 3SNPs 
present in the rabbit protein (DltBH) 
NI Yes 
CH 9548 
J strain with human version of Rot 
regulator due to reversion of the SNP 
present in the rabbit protein (RotH) 
NI Yes 
CH 7705 Parental F strain, human origin NI No 
CH 8569 F strain with mutation in rot present in the rabbit isolates (rot K103*) NI No 
CH 9602 F strain with mutation in dltB present in the rabbit isolates (dltB *405Y) I No 
CH 9700 
F strain with mutations in rot (rot 
K103*) and dltB (dltB *405Y) present 
in rabbit isolates 
I Yes 
CH 9897 
F strain with mutations in rot (rot 
K103*) and dltB (dltB *405Y) present 
in rabbit isolates, also cured from the 
prophage inserted in the β-toxin gene 
I Yes 
CH 10310 
F strain with mutations in dltB present 
in the rabbit isolates (dltB T113K, 
Y250H, *405Y) 
I No 
CH 10311 
F strain with mutations in dltB (dltB 
T113K, Y250H, *405Y) and rot (rot 
K103*) present in the rabbit isolates 
I No 
CH 10320 
F strain with mutations in dltB present 
in the rabbit isolates (dltB T113K, 
Y250H) 
NA No 
DL 9 
Parental ST96 clone, rabbit origin 
with 2 SNPs in dltB when compared 
to the human clone (dltB K402R, 
*405Y) 
I Yes 
BK 4337 Parental ST96 clone, human origin NI No 
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complex through the cytoplasmic membrane and in the incorporation of the D-
alanine into the teichoic acids (Koprivnjak et al, 2006; Reichman et al, 2013).  
 
To study the effect of the different mutations on the survival of S. aureus 
against rabbit serum, killing assays were carried out using these strains (Table 
3.1). The bactericidal effect of rabbit serum was tested first on the ST121 clone 
parent or J strain (CH 3934), and compared to the ΔdltB mutant (CH 9982), the 
strain with the Rot regulator from human isolates (RotH; CH 8348) and the strain 
with DltB protein from human isolates (DltBH; CH 9548). Killing assays were 
carried out as explained in Chapter 2.9, inoculating aliquots of rabbit serum with 
106 cell/ml of cultures of each strain in exponential growth phase. 
 
Even though the rabbit serum had the ability to kill the J parental strain, this 
bactericidal effect was not as strong as with the other laboratory strains tested 
in this project (as shown in Chapter 3.2.4). After four hours of incubation in 
rabbit serum only a 100-fold decrease in the bacterial numbers was observed. 
When compared to the J mutant strains, no significant difference was found for 
the strain with the Rot from human isolates (Figure 3.14B) or with the DltB 
protein from human isolates (Figure 3.14C). The ΔdltB mutant, on the contrary, 
was strongly affected by the bactericidal elements of the rabbit serum, reaching 
numbers lower than the detection limit by 30 minutes of incubation in the NRS 
(Figure 3.14A). This behaviour was similar to that of the ΔdltA mutant, 
confirming the important role of this modification of the teichoic acids in the 
survival of the bacteria in rabbit serum.  
 
For the ST121 human clone or F strains, the bacterial count of the parental 
strain was lower than the detection limit after 2 hours of incubation. When the 
effect of NRS on the parent was compared to the effect on the different human 
mutant strains significant differences were found for two strains: CH 9700 and 
CH 9897 (Figure 3.15C and D, respectively). Both of these strains have a 
mutation in rot (resulting in K103*) and in dltB (resulting in *405Y), and the CH 
9897 strain also was cured from the prophage inserted in the β-toxin gene. As 
explained in table 3.1, these mutations in the dltB and rot human genes allowed   
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Figure 3.14 Effect of NRS on the survival of ST121 clone rabbit strains 
The bactericidal effect of NRS was tested on the J strain, the ST121 clone rabbit origin 
strain (CH 3934, black line) and compared with A) J ΔdltB (CH 9982), B) J RotH (CH 
8384), and C) J DltBH (CH 9548). All the strains were grown until they reached 
exponential growth phase before inoculating a rabbit serum aliquot with 106 cell/ml. 
Killing assays were carried out as explained in Chapter 2.9. These experiments were 
carried out in triplicate (i.e. biological triplicates). Student’s t-tests were carried out and 
asterisks show significant differences (p<0.05). Error bars represent the standard 
deviation of the means. 
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Figure 3.15 Bactericidal effect of NRS on ST121 clone human strains 
The bactericidal activity of rabbit serum was tested against the F strains, ST121 human 
clone. The F parental strain (CH 7705, black line in all panels) was compared to A) CH 
8569 (rot K103*), B) CH 9692 (dltB *405Y), C) CH 9700 (rot K103*; dltB *405Y), D) CH 
9897 (rot K103*; dltB *405Y; cured from the prophage inserted in the β-toxin gene), E) 
CH 10310 (dltB T113K, Y250H, *405Y), F) CH 10311 (rot K103*; dltB T113K, Y250H, 
*405Y), G) CH 10320 (dltB T113K, Y250H). 
 
106 cells/ml of each strain were inoculated into aliquots of rabbit serum and killing 
assays were carried out in triplicate (i.e. biological triplicates, Chapter 2.9). Student’s t-
tests were carried out and significant differences are marked with asterisks (p<0.05). 
Error bars represent the standard deviation of the means. 
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the bacteria to infect rabbits (Viana et al, 2015). This suggests that the 
mutations not only have an effect in the infectivity of the strains but also in the 
interactions with the host immune system. 
 
Another S. aureus rabbit isolate, ST96, was also tested against rabbit serum. 
This clone has two SNPs when compared to the human clone (Table 3.1), and 
dltB one of them is different than the SNPs present in the ST121 rabbit clone. 
Just as with the ST121 isolates, the ST96 human strain is killed faster by the 
NRS when compared to the rabbit strain (Figure 3.16). This supports the idea of 
host adaptation by the rabbit isolates. 
 
 
3.2.12 Pre-incubation of NRS with different types of purified cell wall 
material and its effect on the killing activity 
 
In order to further analyze the role of the WTA as receptor for NRS and to test 
the importance of the interaction between WTA and peptidoglycan for the 
bactericidal activity, different types of fragmented cell wall material were purified 
from S. aureus SH1000 as explained in Chapter 2.16. Aliquots of rabbit serum 
were mixed with 1 mg/ml of unstripped (PG+WTA) or hydrofluoric acid stripped 
(just PG) peptidoglycan. This mixture was incubated for 30 minutes at 4ºC with 
rotation and then centrifuged. The supernatant was collected and placed in a 
new tube to be used for killing assays with S. aureus SH1000, while the 
insoluble material was washed with sterile MilliQ water at least three times, after 
which was resuspended in 30 µl of MilliQ and stored at -20ºC for further use.  
 
As expected, whilst the pre-incubation with pure peptidoglycan (stripped PG) 
was able to partially inactivate the killing activity (Figure 3.17A), the cell wall 
sample that contained wall teichoic acid (unstripped) was able to completely 
inactivate the bactericidal activity of the rabbit serum (Figure 3.17B). 
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Figure 3.16 Effect of NRS on rabbit and human S. aureus isolates 
Aliquots of rabbit serum were inoculated with A) 106 cell/ml of ST121 clones and B) 105 
cells/ml of ST96 clones and killing assays were carried out. Rabbit isolates are shown 
as black lines and human isolates red lines. These experiments were carried out in 
triplicate (i.e. biological triplicates) and significant differences are shown with asterisks 
(p<0.05). Error bars represent the standard deviation of the means. 
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Figure 3.17 Effect of pre-incubation of NRS with cell wall material on its 
bactericidal activity 
Aliquots of NRS were incubated for 30 minutes at 4ºC with 1mg/ml of stripped 
peptidoglycan [Pure PG] and unstripped peptidoglycan [PG+WTA] after which they 
were centrifuged. The insoluble material was washed and stored at -20ºC, whilst the 
supernatant was used for killing assays as described before (Chapter 2.9). A) Pure PG 
and B) PG+WTA pre-treated serum was inoculated with 106 cells/ml of an exponential 
growth phase culture of SH1000 and killing assays were carried out as explained 
previously. The experiments were carried out in triplicate (i.e. biological triplicates) and 
the error bars correspond to the standard deviation of the means. Significant 
differences are shown with asterisks (p<0.05). 
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3.2.13 Effect of pre-incubation of rabbit serum with purified wall teichoic 
acid in its bactericidal activity against S. aureus 
 
The previous results gave more evidence in the role of wall teichoic acids as the 
receptor for the killing activity of the rabbit serum. To confirm this role, the ability 
of pure wall teichoic acids to deplete the antibacterial activity of the rabbit serum 
was tested. In order to do this wall teichoic acid from the SH1000 wild type 
strain of S. aureus was purified as described in Chapter 2.17. The purity of the 
WTA was tested for lack of proteins and exopolysaccaride by protein gel 
stained by silver stain and Alcian blue, respectively. 
 
To test the effect of this purified cell wall material, aliquots of rabbit serum were 
mixed with 1 mg/ml of purified wall teichoic acid. The samples were incubated 
for 30 minutes at 4ºC and the tubes were then centrifuged. The purified wall 
teichoic acid is soluble so there was no ‘pellet’ after the centrifugation step. The 
supernatant was collected very carefully and used for killing assays as 
described before (Chapter 2.9). 
 
When the bactericidal activity against S. aureus of this pre-treated serum was 
compared to the activity of untreated naive rabbit serum, a partial inactivation of 
this activity could be observed (Figure 3.18). This partial inactivation can be 
compared to the inactivation obtained by using pure peptidoglycan on the rabbit 
serum (Figure 3.17A), while the total inactivation of the antibacterial activity of 
the serum obtained after the treatment of peptidoglycan with wall teichoic acid 
(PG+WTA) suggests that the WTA needs to be bound to peptidoglycan in order 
to work as the receptor for the killing elements present in the rabbit serum.  
 
 
3.2.14 Purification of cell wall material from different S. aureus mutant 
strains and its effect on the antibacterial activity of NRS 
 
After establishing the role of the wall teichoic acids as the receptor for the killing 
elements present in the rabbit serum, the effect of other types of purified cell   
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Figure 3.18 Effect of purified WTA in rabbit serum bactericidal activity 
An aliquot of rabbit serum was pre-incubated with 1 mg/ml of purified wall teichoic acid 
for 30 minutes at 4ºC, after which the mixture was centrifuged and the supernatant was 
used for killing assays as previously described using an initial inoculum of 106 cells/ml 
of S. aureus SH1000. The antibacterial activity of untreated rabbit serum (black line) 
and treated rabbit serum (red line) were compared. These experiments were carried 
out in triplicate (i.e. biological triplicates). Student’s t-tests were carried out and no 
significant differences were found (p>0.05). Error bars correspond to the standard 
deviation of the means. 
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wall material was tested. By purifying peptidoglycan from the different mutant 
strains the role of cell wall components could be studied.  
 
As shown in Figure 3.6 of this chapter the ΔtagO strain, which lacks wall 
teichoic acids, is resistant to the killing activity of the rabbit serum. This 
suggests that the killing element present in the serum cannot bind to these 
bacteria without wall teichoic acid in their cell wall. The peptidoglycan from the 
ΔtagO strain was purified following the protocol explained in Chapter 2.16. 
 
As shown in Figure 3.8, the ΔdltA strain, which lacks the D-alanylation 
modification in the teichoic acids, was highly sensitive to the bactericidal activity 
of the rabbit serum. This suggests that the lack of the D- alanylation 
modification in the teichoic acid increases the affinity of the ‘killing factor’ from 
the rabbit serum for the bacteria, allowing the serum to kill the bacterial cells 
faster. Hence, a complete inactivation of the bactericidal activity of the rabbit 
serum would expected after the pre-incubation of the serum with this type of 
purified cell wall material.  
 
Cell wall material from the ΔtagO and ΔdltA mutant strains was purified and it 
was used for the inactivation of the rabbit serum killing activity (Chapter 2.16.2). 
Rabbit serum was incubated for 30 minutes with 1 mg/ml of the cell wall 
material, after which the mixture was centrifuged. The insoluble material was 
washed with sterile MilliQ water and stored at -20ºC until used, while the 
supernatant was used for killing assays.  
 
The pre-incubation of rabbit serum with cell wall from the ΔtagO mutant had no 
effect on the bactericidal activity of the serum when compared to untreated 
rabbit serum (Figure 3.19A), showing that the killing factor present in the rabbit 
serum is not able to effectively bind to this peptidoglycan. Pre-incubation with 
cell wall material from the ΔdltA mutant leads to the complete loss of the killing 
activity of the rabbit serum (Figure 3.19B). The level of inactivation of the 
antibacterial activity is higher in this case than when using cell wall with wall 
teichoic acid from the parental strain (Figure 3.17B), confirming that the lack of  
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Figure 3.19 Pairwise comparison of the effect of pre-incubation of NRS with 
purified cell wall fragments from different S. aureus strains 
NRS was incubated with purified peptidoglycan from the ΔtagO and ΔdltA mutants for 
30 minutes at 4ºC before being centrifuged. The insoluble material was washed and 
stored at -20ºC for further use, while the supernatant was used for killing assays with 
an initial inoculum 106 cells/ml of an exponential growth phase culture of SH1000. The 
experiments with A) ΔtagO and B) ΔdltA purified cell wall material were carried out in 
triplicate (i.e. biological triplicates), showing significant differences with asterisks 
(p<0.05). The error bars correspond to the standard deviation of the means. 
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Figure 3.20 Role of WTA glycosylation on the effect of pre-incubation of NRS 
with purified cell wall material 
Killing assays were carried out using the supernatant of rabbit serum incubated with 
purified A) peptidoglycan with wall teichoic acid from the parental strain and B) 
peptidoglycan with wall teichoic acid from the ΔtarM ΔtarS strain as explained 
previously. The insoluble material was washed and stored until further use at -20ºC. 
These experiments were carried out in triplicate (i.e. biological triplicates) and error 
bars represent the standard deviation of the means. Significant differences are shown 
with asterisks (Student’s t-test, p<0.05). 
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D-alanylation leads to an increased affinity for the killing factor(s) present in the 
rabbit serum. A 100-fold increase in one hour in the bacterial numbers was 
observed for the bacteria incubated in NRS treated with this purified cell wall 
material. This could be due to a mistake during the dilution process, as the cell 
doubling time cannot explain this. 
 
Cell wall from RN4220 ΔtarM ΔtarS was also purified following this protocol, as 
well as cell wall material from RN4220. Purified cell wall material from both 
strains was able to completely inactivate the serum when compared to 
untreated rabbit serum (Figure 3.20A and B, respectively). This suggests that 
glycosylation of the teichoic acids has no effect on the bactericidal activity of the 
rabbit serum (Figure 3.10). 
 
3.2.15 Effect of pre-incubation of naive rabbit serum with purified 
lipoteichoic acid on its antibacterial activity against S. aureus 
 
To confirm that lipoteichoic acids had no effect over the bactericidal activity of 
the rabbit serum, LTA was purified from S. aureus using 1-butanol extraction 
followed by hydrophobic interaction chromatography as explained in Chapter 
2.18. The presence of lipoteichoic acids after the purification was verified using 
specific monoclonal antibodies against LTA (Figure 3.21). 
 
Just as expected from the results obtained using the LTA- deficient mutant 
strain (Figure 3.7A), the pre-incubation of rabbit serum with purified lipoteichoic 
acids had no significant effect on the bactericidal activity of rabbit serum against 
S. aureus when compared to untreated rabbit serum (Figure 3.22). 
 
 
3.2.16 Comparison of the wall teichoic and lipoteichoic acid D-alanine 
content 
 
The D-alanine content of different types of purified cell wall was measured in 
order to verify the importance of this modification in the bactericidal activity of   
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Figure 3.21 Reactivity of purified LTA with specific antibodies  
Lipoteichoic acid was purified as explained previously (Chapter 2.18), diluted 10-fold 
using sterile PBS and 200 µl of each sample was loaded into each well. The number 
on top of the figure shows the dilution loaded in each well. The membrane was 
incubated with blocking buffer for 60 minutes, washed and then incubated for 60 
minutes with blocking buffer containing the primary antibody at 1:1,000 dilution (mouse 
monoclonal anti-LTA antibody). The membrane was then incubated with the secondary 
antibody (1:10,000 dilution) for 60 minutes, washed and developed using the 
SuperSignal® West Pico Enhanced Chemilunminescent Kit. The membrane was 
developed for 30 minutes. 
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Figure 3.22 Effect of purified LTA on rabbit serum bactericidal activity 
Lipoteichoic acids were purified from S. aureus SH1000 using 1-butanol extraction 
followed by hydrophobic interaction chromatography (Grundling and Schneewind, 
2007a). Aliquots of rabbit serum were incubated with 1mg/ml of this purified material 
and killing assays were carried out using the supernatant after centrifugation and 105 
cells/ml of an exponential growth phase culture of SH1000. These experiments were 
carried out in triplicate (i.e. biological triplicates). The error bars represent the standard 
deviation of the means. No significant differences were found (p>0.05). 
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the rabbit serum. These experiments were carried out using purified wall 
teichoic and lipoteichoic acid from different S. aureus strains, which were 
purified as explained in Chapter 2.17 and 2.18, respectively. 
 
First, the D-alanine content of different components of the cell wall of SH1000 
was determined. As expected, the D-alanine content detected for 1 mg/ml of 
peptidoglycan with wall teichoic acids and for 1 mg/ml of pure wall teichoic acid 
was similar, while no D-alanine esters were detected in the sample where WTA 
has been removed. No significant difference was found between the D-alanine 
content of the purified lipoteichoic acid when compared to the content of purified 
wall teichoic acid (Table 3.2). These values match previously reported data 
(Jenni and Berger-Bächi, 1998; Giaouris et al, 2008). D-alanine in 
peptidoglycan did not contribute to this assay as it was removed by 
centrifugation after trichloroacetic acid extraction. 
 
Next, the D-alanine content was measured for different strains of the rabbit and 
human isolates studied in Chapter 3.2.11. Mutant strains for the dltB gene were 
chosen for both isolates. For the rabbit isolates, CH 3934 (parent strain), CH 
9982 (ΔdltB strain) and CH 9548 (ΔdltB strain with human DltB protein) were 
studied, while CH 7705 (parent strain), CH 9692 (dltB *405Y) and CH 10310 
(dltB T113K, Y250H, *405Y) were studied for the human ST121 isolate. Wall 
teichoic and lipoteichoic acids were purified as explained previously (Chapter 
2.17.1 and 2.18.1, respectively) for each of these six strains and the D-alanine 
content was determined using the same protocol as with the SH1000 strain. 
 
Significant differences (p<0.05) were found in the D-alanine content of the 
purified wall teichoic acid from the wild type and mutant strains for both the 
rabbit and human isolates (Table 3.3A), with 88% decrease in the D-alanine 
content between CH 3934 and CH 9982 (34±9.4 µg/ml and 4.1±0.2 µg/ml, 
respectively) and 78% decrease between CH 7705 and CH 10310 (24±0.1 
µg/ml and 7.6±1.0 µg/ml, respectively). However, no significant differences 
were found in the D-alanine levels of the lipoteichoic acid between the parental 
and mutant strains (Table 3.3B). 
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Table 3.2 D-alanine content of cell wall material from S. aureus SH1000  
The D-alanine content of different purified cell wall fractions from SH1000 was 
measured using a modified protocol from Peschel et al, 1999. These experiments were 
carried out in duplicate and the values shown here were obtained using the equation 
from the calibration curve (Figure 2.1). (-): No significant values. 
 
Cell wall purification D-alanine content (µg/ml) 
PG+WTA 34  
Pure PG 0.0 
Pure WTA 50 
Pure LTA 47 
 
  
 136 
Table 3.3 D-alanine content of teichoic acids from rabbit and human strains of S. 
aureus. 
D-alanine content of A) purified wall teichoic acid and B) purified lipoteichoic acid. The 
experiments were carried out on triplicate and these values were obtained using the 
equation from the calibration curve (Figure 2.1). ANOVA tests were carried out using 
Bonferroni adjustment as shown in (Viana et al, 2015) 
 
A 
Strain Genotype 
D-alanine 
(µg/ml) 
% compared to 
parent 
CH 3934 ST121 rabbit, parent strain 34 ± 9.4 - 
CH 9982 ST121 rabbit, ΔdltB 4.1 ± 0.02 12.05  
CH 9548 ST121 rabbit, human DltB 21 ± 0.8 61.70 
CH 7705 ST121 human, parent strain 24 ± 0.1 - 
CH 9692 ST121 human, DltB *405Y 9.0 ± 0.6 42.80  
CH 10310 ST121 human, DltB 3 SNPs 7.6 ± 1.0 22.35 
 
B 
Strain Genotype 
D-alanine 
(µg/ml) 
% compared to 
parent 
CH 3934 ST121 rabbit, parent strain 52 ± 1.3 - 
CH 9982 ST121 rabbit, ΔdltB 42 ± 2.6 80.82 
CH 9548 ST121 rabbit, human DltB 55 ± 5.4 105.31 
CH 7705 ST121 human, parent strain 44 ± 3.2 - 
CH 9692 ST121 human, DltB *405Y 29 ± 8.3 66.01 
CH 10310 ST121 human, DltB 3 SNPs 52 ± 2.3 118.91 
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3.3 Discussion 
 
Previous work carried out in the laboratory showed that naive rabbit serum 
(NRS) has antibacterial activity against S. aureus (Bozakouk, 2011), however 
the mechanism involved in this bacterial killing remained unknown. The aim of 
this project is to identify not only the element(s) of the rabbit serum that are 
responsible for this bactericidal activity against S. aureus, but also the bacterial 
components that play a role as receptors for this killing mechanism.  
 
The innate immune system of vertebrates is able to identify pathogens from 
self-cells through the recognition of evolutionary conserved molecules produced 
only by pathogens, called ‘pathogen-associated molecular patterns’ (PAMPs) 
(Medzhitov and Janeway, 2002; Vivier and Malissen, 2005). The host immune 
system is able to identify these PAMPs not only as signs of infection but also as 
‘molecular markers’ specific for different types of pathogens, allowing the 
immune system to choose the most efficient defence mechanism (Medzhitov 
and Janeway, 2000). 
 
Due to the conservation of its composition and the essential role that plays in 
the bacteria (Dziarski and Gupta, 2005), several pathogen-recognition 
molecules can detect peptidoglycan, including a specific group of proteins 
called peptidoglycan-recognition proteins (PGRPs) (Michel et al, 2001; Guan 
and Mariuzza, 2007). The teichoic acids found in the cell wall of Gram-positive 
bacteria can also be recognized by the immune system of the host (Cleveland 
et al, 1996; Atilano et al, 2011).  
 
It is known that the interaction between elements of the bacterial cell wall and 
the immune system of the host is essential for the recognition and clearance of 
pathogens (Cleveland et al, 1996; Janeway and Medzhitov, 2002). Therefore, 
the bacterial component that acts as a receptor for the antibacterial activity of 
the naive rabbit serum is likely to be a surface component present in the S. 
aureus cell wall. 
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Previous work carried out in the laboratory identified wall teichoic acid (WTA) as 
a candidate for this role as the bactericidal activity receptor (Bozakouk, 2011). 
Wall teichoic acids play a role in the resistance of the bacteria to the host 
immune system (Kohler et al, 2009; Carvalho et al, 2015) and also in 
colonization (Weidenmaier et al, 2004; Weidenmaier et al, 2005b; Bera et al, 
2007; Weidenmaier et al, 2008). TagO is the first protein involved in the 
biosynthesis of wall teichoic acids in S. aureus (Figure 1.6) (Neuhaus and 
Baddiley, 2003; Brown et al, 2008; Pereira et al, 2008; Xia et al, 2010a) and a 
deletion in the corresponding gene results in the complete absence of wall 
teichoic acids from the bacterial cell wall (Weidenmaier et al, 2005b; Vergara-
Irigaray et al, 2008). A ΔtagO strain was resistant to the bactericidal activity of 
the NRS, whilst a decrese in the bacterial count under the detection limit was 
found for the parent (Figure 3.6). This suggested that the lack of wall teichoic 
acids in the bacterial cell wall allowed the bacteria to survive in the serum 
because the ‘killing factor’ present in the rabbit serum was not able to interact 
with the bacteria or it was not able to reach its final target. Cell wall material 
purified from ΔtagO had no effect on the bactericidal activity of the NRS (Figure 
3.19A). As no WTA is present in this material the killing component(s) present in 
the rabbit serum was not able to bind to this affinity matrix. This confirmed the 
role of WTA as receptor for the killing activity of the rabbit serum. 
 
This essential role of WTA was verified by the complete inactivation of the 
bactericidal activity caused by peptidoglycan with wall teichoic acids, whilst 
peptidoglycan stripped of WTA was able to only partially inactivate NRS (Figure 
3.17). Overall this strogly suggested that WTA is the receptor for the ‘killing 
factor’ in the NRS. 
 
The role of lipoteichoic acid (LTA), the other teichoic acid present in S. aureus, 
as a potential receptor for the NRS bactericidal activity was studied. As LTA is 
essential for the bacteria it was impossible to create an LTA-deficient mutant in 
an unsuppressed background. However, the deletion of the ypfP gene allowed 
the creation of a mutant strain with only 13% of LTA content when compared to 
the parental strain (Fedtke et al, 2007). The YpfP protein mediates the 
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synthesis the anchor to which the poly-[glycerophosphate] repeating unit is 
attached during the synthesis of LTA in S. aureus (Jorasch et al, 2000). 
 
The ΔypfP strain was affected by the NRS immediately after inoculation as no 
colonies were obtained in any of the time points studied, while decrease of 
colony forming units under the detection limit for the parent strain was observed 
only after two hours of incubation (Figure 3.7A). This suggests that the mutant 
was strongly affected by the bactericidal elements of the rabbit serum from the 
beginning of the experiment. Immediate bacterial death after inoculation was 
also observed when the mutant was incubated with heat-inactivated rabbit 
serum (Figure 3.7B), suggesting that the LTA-deficient mutant is sensitive to 
other elements of the rabbit serum that are not affected by the heat-inactivation. 
Consequently, it was not possible to determine if the LTA had a function in this 
heat sensitive NRS. The ΔypfP mutant was also partially susceptible to human 
serum compared to the parent (Figure 3.7C), demonstrating its overall 
sensitivity. Also pre-incubation of purified LTA with NRS had no effect on the 
antibacterial activity (Figure 3.22). Thus it is unlikely that LTA is a major 
requirement for the bactericidal mechanism of NRS. 
 
After determination of the role of wall teichoic acid as the component of the 
bacterial cell wall that interacts with the ‘killing factor’ present in the rabbit 
serum, the different modifications of this molecule were studied. Once the 
biosynthesis of this polymer is complete, wall teichoic acids can be modified by 
D-alanylation or glycosylation (Perego et al, 1995; Clemans et al, 1999; May et 
al, 2005; Xia et al, 2010a; Sobhanifar et al, 2015). Killing assays to test the 
bactericidal effect of the rabbit serum on different mutant strains for the D-
alanylation (ΔdltA) and glycosylation (ΔtarM, ΔtarS and ΔtarM ΔtarS) were 
carried out, and peptidoglycan from the ΔdltA strain and the ΔtarM ΔtarS double 
mutant was purified to test its effect on the bactericidal activity of the NRS. 
 
The ΔdltA strain was more sensitive to the bactericidal effect of the rabbit serum 
than the parent strain from the beginning of the experiment and its bacterial 
counts was lower than de detection limit after 30 minutes of incubation (Figure 
3.8). As the addition of the D-alanine esters to the teichoic acids changes the 
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net charge of the cell surface, the stronger effect of the bactericidal activity of 
the rabbit serum on the ΔdltA strain could be explained as a higher affinity of 
the ‘killing factor’ for the cell wall of the mutant. This higher affinity of the ‘killing 
factor’ was confirmed by the complete inactivation of all the bactericidal activity 
of the rabbit serum after 30 minutes of pre-incubation with purified cell wall from 
the ΔdltA strain (Figure 3.19B). This suggested that the interaction between the 
‘killing factor’ and S. aureus might be electrostatic and that the D-alanylation of 
the teichoic acids is important for the survival of the bacteria in NRS.  
 
Conversely, deletion of the α- and β-glycosylation had no effect on the 
bactericidal activity of NRS (Figure 3.11). However, some differences were 
observed between the single and the double mutant strain in diluted serum 
(Figure 3.11), suggesting that its role in the bactericidal activity of NRS is not 
completely understood. Also pre-incubation of NRS with cell wall material from 
the ΔtarM ΔtarS strain had the same effect as that from the parent (Figure 
3.20). All of this suggests that glycosylation of WTA has no impact on the NRS 
killing mechanism. 
 
The MprF protein is a virulence factor of S. aureus that is able to add a L-lysine 
residue to membrane lipids (Peschel et al, 2001; Weidenmaier et al, 2005a), 
introducing positive charges. Whilst no differences in the effect of undiluted 
NRS on a ΔmprF mutant, its complemented strain and the parental strain were 
found (Figure 3.12), the differences observed in the effect of 3-fold diluted 
serum between the strains with and without the modification showed a trend 
(Figure 3.13). This might indicate that whilst it has been reported that this 
modification affects the response of the bacteria to some elements of the 
immune system of the host, the addition of this amino acid is not as important 
as the addition of D-alanines to the teichoic acids in this killing mechanism of 
the NRS.  
 
The adaptation of S. aureus to humans as hosts is demonstrated by many the 
different strategies including facilitation of the adherence to host tissue 
(Tompkins et al, 1990; van Belkum et al, 2009), evasion of the host immune 
system and nutrient acquisition (Torres et al, 2006; Pishchany et al, 2010; Pan 
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et al, 2012). However, S. aureus is also associated with infections in 
economically important livestock such as cows, sheep and rabbits (Viana et al, 
2015). 
 
S. aureus clonal complex CC121 (clone ST121) can cause skin infections and 
necrotizing pneumonia in humans and recently a highly virulent ST121 capable 
to infect rabbits has emerged (Vancraeynest et al, 2006; Viana et al, 2015). 
This host adaptation is caused by a single mutation in the dltB gene that is 
sufficient and required to turn this human strain (which is unable to infect 
rabbits) into a strain that causes epidemics in rabbit farms (Viana et al, 2015). 
Three other single mutations are necessary to infect the skin and to enhance 
the infectivity, two of which are in the dltB gene. It was hypothesized that the 
mutations present in the dltB gene might have an effect on the interaction of the 
bacteria with the host immune system. This hypothesis led us to study these 
rabbit and human strains by in vitro killing assays using rabbit serum.  
 
Whilst the human isolates were susceptible to the bactericidal activity of the 
NRS, the rabbit isolates were able to survive in the rabbit serum (Figure 3.16), 
confirming that the adaptation of the rabbit strains to the host involves 
resistance to the killing mechanism that is being studied in this project. 
 
Although the rabbit serum had bactericidal activity against the different mutant 
rabbit strains (Figure 3.14), this effect was observed as a 100-fold decrease in 
the bacterial numbers instead of complete bacterial death. The ΔdltB rabbit 
strain, however, was extremely sensitive to the rabbit serum and was 
completely killed after just 30 minutes of incubation (Figure 3.14A), just as the 
ΔdltA strain, confirming the importance of this modification in the survival of the 
bacteria. 
 
On the other hand, most of the human isolates were completely killed by the 
rabbit serum (Figure 3.15). Only two human strains, both with mutations in the 
rot (K103*) and dltB (*405Y), were able to survive in the rabbit serum (Figure 
3.15C [CH 9700] and D [CH 9897]). These mutations allow human isolates to 
infect as the rabbit isolates do (Viana et al, 2015), suggesting that the mutations 
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are not only involved in the infectivity of the bacteria but in survival in the rabbit 
serum, where they are in contact with all the components of the immune system 
the host.  
 
The D-alanine content was measured for WTA and LTA purified from rabbit and 
human isolates with different mutations in the dltB gene. No significant 
difference was found for the D-alanine content in LTA (Table 3.3B), while 
significant differences between the mutant and parental strains were found for 
D-alanine content of WTA (Table 3.3A). From these results we can propose that 
whilst the lipoteichoic acids are not involved in the bactericidal mechanism of 
the rabbit serum, the wall teichoic acids seem to be involved in the bactericidal 
mechanism as both the receptor that interacts with the ‘killing factor’ and 
through the presence of the D-alanine esters. 
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4 CHAPTER 4: 
Identification of naive rabbit serum components responsible 
for antibacterial activity 
 
4.1 Introduction 
 
In Chapter 3 wall teichoic acid was identified as the likely bacterial component 
that acts as the receptor for the bactericidal activity of the rabbit serum. The 
importance of the D-alanylation of teichoic acids was also shown, suggesting 
that the first interaction between the bacteria and the elements of the serum 
responsible for this killing might be of an electrostatic nature.  
 
In order to understand the bactericidal mechanism, the serum elements 
responsible for it must to be identified. This mechanism is independent of the 
cellular components of the immune system due to the use of 0.2µm pore size 
filters during the purification process of the rabbit serum. All of the cells present 
in the mammalian blood are bigger than the pore size of the filters used, 
resulting in sterilized serum without cellular components. This suggests that 
killing mechanism of the NRS is not cell mediated. 
 
Immunoglobulins are proteins produced and secreted by differentiated B cells 
(Parkin and Cohen, 2001). Immunoglobulins are able to recognize specific parts 
of an antigen, allowing binding. This antigen-antibody binding is known as 
opsonisation and targets the antigen containing structure for phagocytosis 
(Chaplin, 2010; Kumar and Sharma, 2010). The immunoglobulins are also 
involved in the activation of the complement system through the classical 
pathway. This pathway is activated by soluble antigen-antibody complexes or 
by antibodies bound to bacterial cells (Gasque, 2004). The complement 
component C1q recognizes these antigen-antibody complexes, which leads to 
the formation of the C1 complex and further activation of the classical pathway 
(Ricklin et al, 2010). It has been reported that immunoglobulins also participate 
in activation of the lectin pathway (Roos et al, 2010). However, previous results 
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obtained in our laboratory established that the NRS bactericidal mechanism is 
immunoglobulin-independent (Bozakouk, 2011). 
 
‘Pathogen-associated molecular pattern’ (PAMPs) molecules, such as 
lipopolysaccharide and peptidoglycan, are molecules conserved and shared by 
many infectious agents that the host is able to recognize by using specific 
pattern recognition receptors (Beutler, 2004; Ausubel, 2005; Akira et al, 2006). 
Some of these pattern recognition receptors are soluble proteins, such as C-
reactive protein, collectins and mannose-binding lectin (Matsushita and Fujita, 
1992; Beutler, 2004).  
 
Mammalian cells also produce soluble components that are able to kill 
pathogens. For example, antimicrobial peptides, cationic peptides that can 
interact with the bacterial membrane (Zasloff, 2002; Beutler, 2004; Hancock 
and Sahl, 2006), cause bacterial death by inhibition of extracellular polymer 
synthesis or intracellular functions, or by disruption of the integrity of the cell 
membrane (Ong et al, 2002; Yeaman and Yount, 2003; Hancock and Sahl, 
2006).  
 
The complement system, formed by serum and cell membrane proteins, is 
essential for the innate immune response against bacterial infecions. It is able 
to recognize and kill pathogens (Gasque, 2004) and enhances the B and T 
responses (Barrington et al, 2001; Carroll et al, 2004; Gál et al, 2007; Ansari 
and Sayegh, 2008). While it is known that the membrane attack complex is able 
to kill Gram-negative bacteria through the formation of pores on the bacterial 
membrane, which leads to lysis (Taylor, 1983; Frank et al, 1987), Gram-positive 
bacteria is not affected by the membrane attack complex due to the presence of 
the thick layer of peptidoglycan of the cell wall (Joiner et al, 1984). 
 
However, recent papers show that several components of the complement 
system can interact with Gram-positive bacteria. It has been reported that 
mannose-binding lectin can bind to the surface of S. aureus and lead to the 
activation of the lectin pathway (Ma et al, 2004; Park et al, 2010). Lipoteichoic 
acids are able to activate the lectin pathway through binding with L-ficolin 
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(Lynch et al, 2004), and the C5b-9 complex can be found on the surface of 
several Gram-positive bacteria including S. aureus (Berends et al, 2013). 
 
Up to this point, results have shown that the bactericidal activity of the NRS 
against the bacteria must be caused by a soluble component of the immune 
system that is able to interact with the wall teichoic acids present in the cell wall. 
Taking into consideration the results obtained previously in the laboratory, 
which showed that complement components, mannose-binding lectin and C4b, 
bound to purified cell wall from S. aureus, it was decided to start the 
identification of the rabbit serum elements by determining the role of the 
complement system in the bactericidal activity against S. aureus.  
 
 
4.1.1 Aims of this chapter 
Ø Analysis of the role of the complement system, especially of the lectin 
pathway, in the bactericidal mechanism of the rabbit serum. 
Ø Identification of elements of the NRS that are able to interact with S. aureus 
purified cell wall material by mass spectrometry. 
Ø Study of the role of the identified components in the antibacterial mechanism 
of the NRS against S. aureus.  
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4.2 Results 
4.2.1 Inactivation of the bactericidal activity of NRS by 
ethyleneglycoltetraacetic acid (EGTA) treatment 
 
Previous experiments carried out in the laboratory suggested that mannose-
binding lectin and the complement component C4b might be involved in the 
killing mechanism of the rabbit serum against S. aureus (Bozakouk, 2011). As 
demonstrated in Chapter 3, heating the serum at 56ºC for 30 minutes 
inactivates the antibacterial activity. It is known that the complement 
components C2 and Factor B are affected by heat (Ecker et al, 1943a; Kerr and 
Porter, 1978; Servais et al, 1991; Morgan, 2000). These results suggested that 
the lectin pathway of complement activation might be involved in the 
bactericidal mechanism. 
 
To confirm this involvement of the lectin pathway, several inactivation protocols 
were used. Ethyleneglycoltetraacetic acid (EGTA) is a chelating agent that has 
a 105-times higher affinity for calcium than for magnesium (Bryan, 1974), and it 
has been reported that pre-incubation of serum with this chelating agent 
inactivates its bactericidal activity by blocking the classical (Des Prez et al, 
1975; Fine, 1978; Morgan, 2000) and the lectin (Schwaeble et al, 2002; Roos et 
al, 2003; Takahashi et al, 2006) pathways of complement activation. 
 
To test if this chelating agent was able to inactivate the rabbit serum, aliquots of 
NRS were incubated with 10 mM of sterile EGTA for 60 minutes at 37ºC before 
the inoculation of 105 cell/ml of an exponential phase culture of S. aureus 
SH1000. After the inoculation of the bacteria into the serum killing assays were 
carried out (Chapter 2.10.2). E. coli MC1061 was used as a control for the 
inactivation of the complement system in the serum. Only 50µM EGTA was 
used instead as a higher concentration was found to be intrinsically inhibitory 
for E. coli (data not shown).  
 
Even though the addition of EGTA reduced the bactericidal activity of the rabbit 
serum against both S. aureus and E. coli (Figures 4.1A and B), the inactivation 
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was not total when tested against the E. coli strain. This suggests that calcium 
is necessary for the activity of the rabbit serum components that are capable of 
killing S. aureus, whilst E. coli is affected by other calcium-independent 
elements also present in the rabbit serum. 
 
 
4.2.2 Effect of EGTA-magnesium chloride and EGTA-magnesium 
chloride/calcium chloride on NRS antibacterial activity 
 
After confirming that the components of NRS responsible for the bactericidal 
activity against S. aureus need calcium in order to be active, the reactivation of 
the killing activity was tested by adding magnesium and calcium ions into the 
solutions.  
 
As explained previously, whilst the alternative pathway only needs magnesium 
to be active (for the assembly of the C3bFb complex) (Des Pres et al, 1975; 
Morgan, 2000), the classical and lectin pathways need magnesium (for the 
assembly of C4b2a complex) (Des Pres et al, 1975; Morgan, 2000) and calcium 
(for the C1 complex assembly and for MBL activity, respectively) (Platts-Mills 
and Ishizaka, 1974; Morgan, 2000; Schwaeble et al, 2002; Takahashi et al, 
2006; Gál et al, 2009). Therefore, only the alternative pathway of complement 
activation is active when the rabbit serum is pre-incubated with equimolar 
concentrations of EGTA and magnesium chloride. The addition of calcium 
chloride to this mixture reactivates the classical and the lectin pathways. 
 
In order to identify the complement pathway involved in the bactericidal activity 
of NRS, magnesium and magnesium with calcium were added to aliquots of 
EGTA-inactivated NRS as explained previously (Chapter 2.11). Magnesium 
chloride was added to test the effect of the alternative pathway, while 
magnesium chloride and calcium chloride was added to recover the activity of 
the classical and the lectin pathways of complement activation. 
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Figure 4.1 Effect of EGTA pre-incubation in the bactericidal activity of NRS 
Aliquots of NRS were preincubated with EGTA for 60 minutes at 37ºC, and then 
inoculated with A) 107 cells/ml of S. aureus SH1000, or B) 105 cells/ml of E. coli 
MC1061. Samples were taken at appropriate time points, diluted on sterile PBS and 
spotted onto agar plates. The bactericidal activity of rabbit serum (black line) was 
compared with the activity of the serum treated with the chelating agent (red line). 
These experiments were carried out in triplicate (i.e. biological triplicates) and 
significant differences are shown with asterisks (Students t test, p<0.05). The error 
bars represent the standard deviation of the means. 
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As the three complement pathways can kill E. coli, this bacterium was used as a 
positive control to test if the addition of the divalent cations to the EGTA-
inactivated NRS reactivated the killing activity. Just as expected, the addition of 
magnesium chloride is enough to reactivate the rabbit serum (Figure 4.2A) and 
similar results were obtained when magnesium and calcium ions were added 
into the serum in presence of EGTA (Figure 4.2B). The bactericidal activity of 
the serum reactivated by the addition of magnesium and of magnesium along 
with calcium has no significant difference compared to the bactericidal activity of 
the untreated serum (Figure 4.2C), confirming than the addition of these 
divalent cations counteract the chelating action of the EGTA. 
 
After confirming the reactivation of bactericidal activity of the serum by the 
addition of the divalent cations by the use of E. coli, this killing activity was 
tested for S. aureus. Neither the addition of magnesium chloride or magnesium 
chloride along with calcium chloride resulted in a reactivation of the bactericidal 
activity of the NRS (Figure 4.3A and B, respectively). The addition of 
magnesium and calcium even caused bacterial growth. A significant difference 
in the bactericidal activity was observed between untreated and treated serum 
(Figure 4.3C). No reactivation of the bactericidal activity was observed when the 
concentration of divalent cations was doubled (data not shown), suggesting that 
the effect of EGTA on the mechanism involved in the killing of S. aureus is 
different than for E. coli. 
 
 
4.2.3 Effect of zymosan A on the bactericidal activity of naive rabbit 
serum 
 
The complement component C3 plays an important role in the complement 
system. The three complement pathways are activated by different signals 
(Beutler, 2004) but come together through the generation of the C3 convertases 
(C4b2a for the classical and lectin pathways, and C3bFb for the alternative 
pathway), which are able to cleave C3, generating C3a and C3b (Rooijakkers   
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Figure 4.2 Effect of pre-incubation of NRS with EGTA-magnesium chloride and 
EGTA-magnesium chloride/calcium chloride on its bactericidal activity against E. 
coli 
Aliquots of rabbit serum were pre-incubated with equimolar concentrations of A) EGTA 
and magnesium chloride or B) EGTA, magnesium chloride and calcium chloride for 60 
minutes before inoculating this solution with an exponential growth phase culture of E. 
coli MC1061. C) Comparison of the bactericidal activities of untreated and treated 
rabbit serum against the bacteria. These experiments were carried out in triplicate (i.e. 
biological triplicates) and significant results are shown with asterisks (Students t test, 
p<0.05). Error bars correspond to the standard deviation of the means. 
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Figure 4.3 Effect of pre-incubation of NRS with EGTA-magnesium chloride and 
EGTA-magnesium chloride/calcium chloride on its bactericidal activity against S. 
aureus 
Aliquots of rabbit serum were pre-incubated with 10 mM of A) EGTA and magnesium 
chloride or B) EGTA, magnesium chloride and calcium chloride for 60 minutes at 37ºC 
before inoculating this solution with 106 cell/ml of an exponential growth phase culture 
of S. aureus SH1000. C) Comparison of the bactericidal activities of untreated and 
treated rabbit serum against the bacteria. These experiments were carried out in 
triplicate (i.e. biological triplicates) and the error bars correspond to the standard 
deviation of the means. Significant results are shown with asterisks (Students t test, 
p<0.05). 
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and van Strijp, 2007; Ricklin et al, 2010; Laarman et al, 2011; Shishido et al, 
2012). 
 
The C3a fragment is a small cationic pro-inflammatory peptide (Klos et al, 2009) 
that also has potent antimicrobial activity by itself (Nordahl et al, 2004). The 
C3b fragment deposits on the bacterial surface and acts as a signal for 
phagocyte uptake by neutrophils and macrophages (Rooijakkers and van Strijp, 
2007; Shishido et al, 2012). The opsonisation of the bacteria also leads to the 
amplification of cleavage of C3 via the activation of the alternative pathway 
(Rooijakkers et al, 2005c; Laarman et al, 2011) and the formation of the C5 
convertase (Petersen et al, 2000; Ricklin et al, 2010).  
 
Due to the important role of the complement component C3, it has been shown 
that its depletion leads to the complete inactivation of the alternative pathway 
and also affects the rest of the complement system (Des Prez et al, 1975; Smith 
et al, 1982; Rooijakkers et al, 2005c; Fritzinger et al 2009). It has been reported 
that the use of zymosan A, a polysaccharide from the cell wall of S. cerevisiae 
composed by glucan and mannan residues, can be used to efficiently deplete 
C3, partially C5 and other terminal complement components from the serum 
(Smith et al, 1982; Morgan, 2000; Zhang et al, 2003).  
 
Thus, the effect of zymosan A on the bactericidal activity of rabbit serum 
against S. aureus was tested. As explained in Chapter 2.10.3, the zymosan A 
was activated before being used in the rabbit serum following instructions from 
the manufacturer. Once it was activated, an aliquot of rabbit serum was 
incubated with 1 mg/ml of zymosan A and incubated for 60 minutes at 37ºC. 
After the incubation this mixture was centrifuged and the supernatant was used 
for killing assays as explained previously (Chapter 2.9). As expected, the serum 
treated with zymosan A had no bactericidal activity against S. aureus SH1000 
when compared to untreated serum (Figure 4.4).  
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Figure 4.4 Effect of Zymosan A from S. cerevisiae pre-incubation on the 
antibacterial activity of rabbit serum 
Activated zymosan A from S. cerevisiae was used to inactivate the killing activity of 
rabbit serum. Aliquots of NRS were treated with 1 mg/ml activated zymosan A and 
preincubated for 60 minutes, after which the mixture was centrifuged and the 
supernatant was used for killing assays. The bactericidal activity was tested on 106 
cells/ml of S. aureus SH1000 and compared against the activity of untreated rabbit 
serum. The experiments were carried out in triplicate (i.e. biological triplicates). The 
error bars represent the standard deviation of the means and significant differences are 
shown with asterisks (Students T-test, p<0.05). 
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4.2.4 Effect of ammonium salts and ammonium hydroxide on the 
bactericidal activity of rabbit serum 
 
The complement components C3 and C4 posses an intramolecular thioster 
group that is essential for their activity (Law et al, 1980; Law and Dodds, 1997; 
Wouter et al, 2005). When these components are cleaved they become active, 
leaving the reactive thioster group available to bind covalently to elements 
found on bacterial surfaces, such as carbohydrates (Law and Dodds, 1997; 
Wouters et al, 2005; Rooijakkers and van Strijp, 2007).  
 
It has been known for many years that the addition of ammonia and other 
strong nucleophiles are able to inactivate the activity of these components 
(Gordon et al, 1926; Ecker et al, 1943a; Ecker et al, 1943b; Law et al, 1980; von 
Zabern et al, 1981; Morgan, 2000). The inactivation occurs because the 
ammonia is able to interact with the proteins, breaking the thioester group and 
causing a conformational change (Isenman et al, 1981; Pangburn, 1992; Law 
and Dodds, 1997). Even though this change can be reversed and the thioester 
reformed, the inactive form of C3 (C3b-like) can be cleaved by the complement 
components factor H and factor I (Pangburn, 1992).  
 
Due to the important role of C3 and C4 in the formation of the C3 convertases 
(Beutler, 2004; Ricklin et al, 2010), the effect of incubation with ammonium 
solutions on the bactericidal activity of the NRS was tested. Aliquots of rabbit 
serum were mixed with 150 mM of the different solutions used and incubated at 
37ºC, before adjusting the pH back to 7.4. The mixtures were then inoculated 
with S. aureus and killing assays were carried out as explained previously 
(Chapter 2.9). The effect of the ammonium solutions on bacterial growth was 
also tested and no significant effect was observed (data not shown). 
 
As expected from literature, the preincubation of the rabbit serum with ammonia 
led to an inactivation of the bactericidal activity against S. aureus (Figure 4.5, all 
the panels). These results, along with the results from the experiments using 
heat, EGTA and zymosan A, suggested that the complement system might be  
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Figure 4.5 Effect of pre-incubation with ammonium compounds in the 
bactericidal activity of rabbit serum 
The solutions used were prepared as explained in Chapter 2.10.4 of Materials and 
Methods. Aliquots of NRS were preincubated for 45 minutes at 37ºC with 150 mM of A) 
Ammonium acetate, B) Ammonium carbonate, C) Ammonium chloride, and D) 
Ammonium hydroxide, after which the pH was adjusted at 7.4. 105-106 cells/ml of S. 
aureus were then added. The experiments were carried out in triplicate (i.e. biological 
triplicates) and significant differences between the untreated (black line in all panels) 
and treated (red line) serum are shown with asterisks (Student’s t-test, p<0.05). The 
error bars represent the standard deviation of the means. 
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involved in the killing mechanism of naive rabbit serum against S. aureus and 
that further experiments were needed in order to confirm this hypothesis. The 
100-fold increase in the bacterial numbers observed between 3 and 4 hours in 
figure 4.5C could be due to an error in the dilution process. This explanation 
could be used for other experiments that showed this increased growth. 
 
 
4.2.5 Inactivation of the naive rabbit serum antibacterial activity using 
antibodies against complement components 
 
The results obtained from the complement inactivation protocols and evidence 
from work previously carried out in the laboratory (Bozakouk, 2011) led to the 
hypothesis that the complement system was involved in the bactericidal activity 
of the NRS against S. aureus. However these inactivation protocols were not 
specific against the complement and they could be affecting another serum 
component that was involved in the antibacterial activity of the rabbit serum.  
 
To gather more evidence to confirm the role of the complement in the bacterial 
death caused by the rabbit serum, more specific protocols were needed. It has 
been reported that the use of antibodies against complement components leads 
to the inactivation of the complement system (Whitehead et al, 1981; Gupta-
Bansal et al, 2000; Mastellos et al, 2004; DiLillo et al, 2006). Thus, antibodies 
against specific components of the rabbit complement system were used to 
inactivate the killing activity of the naive rabbit serum.  
 
Four complement components were chosen for this inactivation: mannose-
binding lectin, component C4b, C5b and C9. The first two components were 
identified by mass spectrometry as components of the rabbit serum bound to 
purified cell wall (Bozakouk, 2011). All the activation pathways lead to the 
formation of the membrane attack complex and components C5b and C9 are 
essential for its deposition and formation, which led us to also pick them for the 
inactivation. 
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As explained previously, the mannose-binding lectin (MBL) is a recognition 
molecule that binds to carbohydrates present in the bacterial cell wall and leads 
to the activation of the lectin pathway through the activation of the MBL-
associated serine proteases (MASPs) (Matsushita et al, 2000b; Gasque, 2004; 
Ricklin et al, 2010). This MBL-MASPs complex cleaves the complement 
components C2 and C4, leading to the formation of the C3 convertase C4bC2a 
(Matsushita et al, 2000a; Petersen et al, 2000; Schwaeble et al, 2002; Ricklin et 
al, 2010). The C4bC2a complex is also the C3 convertase of the classical 
pathway of complement (Petersen et al, 2001; Ricklin et al, 2010). This complex 
not only cleaves C3 but is also used for the formation of C4bC2aC3b, the C5 
convertase of the classical and lectin pathways (Petersen et al, 2001; Seelen et 
al, 2005; Ricklin et al, 2010) 
 
4.2.5.1 Design and synthesis of antibodies against rabbit complement 
components 
 
Whilst antibodies against all the human complement components have been 
developed and are currently available via many companies, the antibodies, 
however, show no cross-reactivity with rabbit proteins. Another problem was 
that the anti-human protein antibodies were developed using rabbit as a host, 
which could lead to serious cross-reactivity between the secondary antibody in 
the Western blots used to confirm the identity of the complement components 
and the endogenous immunoglobulins present in the rabbit serum. This led to 
the design of our own anti-rabbit complement antibodies and synthesize them 
using chicken as the host organism.  
 
The first step was to identify the sequences of the proteins chosen for the 
antibody production. The predicted sequences were obtained from the protein 
database from the National Center for Biotechnology Information (NCBI) and 
their identity was confirmed using the Basic Local Alignment Search Tool 
(BLAST) from Uniprot.org (http://www.uniprot.org/blast/). Conserved domains 
within the proteins were identified using the Conserved Domains Database from 
NCBI, further confirming both their identity and function. 
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Once the proteins and sequences were chosen, companies are able to produce 
the antibodies were identified. Most companies produce antibodies using 
purified proteins. While most human complement components can be 
purchased purified from several companies, the rabbit versions are not 
available. The purification protocols that can be found in the literature used 
large volumes of human blood to obtain these components. When compared to 
the amount of blood obtained from one rabbit (70 ml of blood maximum), the 
number of rabbits needed to purify each component was too large and very 
expensive. This meant that only the sequences of the proteins were available. 
 
GenScript was the only company that offered custom polyclonal antibody 
production from protein sequences using a variety of animal hosts. Due to the 
interest in avoiding any cross-reaction between the antibodies and the 
immunoglobulins present in the rabbit serum in the inactivation experiments and 
in the western blots, chicken was chosen as the animal host for the antibody 
production due to its distant phylogenetic relationship with rabbit. Chicken was 
also chosen as the host because high concentration of immunoglobulins can be 
found in the egg yolk. As they lay multiple eggs a high yield of purified 
polyclonal antibody by the end of the production was obtained. 
 
From the protein sequences, GenScript was able to design several peptides for 
each protein using their GenScript OptimumAntigenTM design tool. All of the 
peptides were considered easy to synthesize and purify, and had an extra 
cysteine added to the C- or N- terminus to facilitate conjugation to carrier 
proteins. Several characteristics of the peptides were analysed and reported, 
including hydrophobicity, flexible regions, signal peptides, homology, helix, 
sheet and transmembrane regions. If more than one peptide met the criteria, 
the company also reported about the expected antigenicity, hydrophilicity and 
surface probability. These parameters were taken into consideration at the 
moment of choosing the peptides that were synthesized.  
 
From the list of peptides provided by Genscript, one peptide was chosen for 
each complement component. The sequences of the peptides are shown in 
Table 4.1. Alignment of the peptides and the rabbit (Oryctolagus cuniculus) 
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genome showed not only 100% of identity between these sequences and the 
predicted complement components, but also their location within the protein 
(Figure 4.6). 
 
Once GenScript synthesized the desired peptides, they were used to produce 
the antibodies using chickens as host organisms. The whole process took four 
months, from preparation of the antigen to the purification and quality control of 
the antibody. The chickens were immunized four times with the antigen, with 
two weeks between the fist and second immunization and three weeks for the 
third and fourth. By the end of the process GenScript sent not only the affinity-
purified antibodies, but also the synthesized antigen, serum from pre-
immmunized chickens and antiserum obtained after the fourth immunization. As 
two chickens were used for each protein, GenScript sent two vials of affinity-
purified antibodies. 
 
 
4.2.5.2 Effect of anti-rabbit complement components antibodies in the 
bactericidal activity of NRS 
 
One of the many immune evasion strategies of S. aureus involves the secretion 
of molecules that are able to inactivate different components of the complement 
cascade. These include the staphylococcal complement inhibitor (SCIN), which 
binds to the membrane-bound C3 convertases blocking all the complement 
pathways (Foster, 2005; Rooijakkers et al, 2005c; Rooijakkers et al, 2006; 
Rooijakkers and van Strijp, 2007); the extracellular fibrinogen binding protein 
(Efb), able to bind to C3, blocking its deposition on the bacterial surface and its 
activation beyond C3b (Lee et al 2004a; Lee et al, 2004b; Jongerius et al, 
2007); and staphylococcal syperantigen-like protein 7 (SSL-7), molecule that is 
able to bind to C5, inhibiting the formation of the membrane attack complex and 
the production of C5a (Langley et al, 2005; Bestebroer et al, 2010; Langley et 
al, 2010). 
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Table 4.1 Sequence of peptides used for antibody production 
GenScript designed different peptides for each of the rabbit proteins. The peptides 
used for antibody production are shown here. The extra cysteine residue added for 
conjugation to carrier proteins is bolded. 
 
 
Protein Peptide sequence 
MBL CTSVADSERGALRAE 
C4 IQEKGVEWSDPLPKC 
C5 CSETLTREAREERLL 
C9 CKEKLLTKAKMVDVT 
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Figure 4.6 Location of synthesized peptides within rabbit complement 
components sequences 
The location of the peptides used for the production of anti-complement components 
antibodies is shown in red, whilst blue shows the location of the active domain of each 
protein. Green shows the transmembrane region. A. Mannose-binding lectin 
(Accession number XP_002718411.1), B. complement component C4 
(XP_002714341.1), C. complement component C5 (XP_002722895.1), D. complement 
component C9 (NP_001075815.1). 
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These molecules synthesized by bacterias are not the only way to block the 
complement system. It has been reported that the use of monoclonal antibodies 
blocks the complement system. As the component C5 is common for all the 
complement pathways and is essential for the formation of the membrane 
attack complex, several antibodies against this component have been 
developed and showed results that suggest they may be used to prevent 
collagen-induced arthritis (Wang et al, 1995) and complement-mediated 
damage of xenogeneic organs (Rollins et al, 1995). Eculizumab, a humanized 
monoclonal antibody against C5 developed by Solaris, blocks both the pro-
inflammatory and the cytolytic effects of the C5 activation and is used to treat 
paroxysmal nocturnal hemoglobinuria disease (Rother et al, 2007).  
 
For the inactivation experiments using the anti-rabbit complement components 
antibodies, stock solutions of the antibodies developed by GenScript were 
prepared and aliquots of rabbit serum were mixed with different concentrations 
of the antibodies. These mixtures were incubated for 60 minutes and then 
inoculated with 105-106 cells/ml of an S. aureus culture in exponential phase, 
after which killing assays were carried out (Chapter 2.9). 
 
No inactivation was observed when the control antibody was added to the rabbit 
serum (Figure 4.7E). The pre-incubation of rabbit serum with 300 µg/ml and 400 
µg/ml of antibodies against mannose-binding lectin, complement components 
C4, C5 and C9 led to a significant inactivation of the antibacterial activity when 
compared to the activity of untreated serum (Figure 4.7A, B, C and D, green 
and orange bars respectively). These results suggested the role of the lectin 
pathway of complement in the bactericidal activity of the serum and the 
importance of the membrane attack complex in bacterial death. 
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Figure 4.7 Effect of anti-complement antibodies on the bactericidal activity of 
rabbit serum 
Aliquots of rabbit serum were incubated with different concentrations (100-400µg/ml) of 
antibodies against A. MBL, B. C4, C. C5, D. C9, E. control chicken antibody. The 
bactericidal activity after 60 minutes pre-incubation was tested against an exponential 
phase culture of S. aureus SH1000. Results for the start and final time point (0 and 4 
hr, respectively) are shown in order to make comparisons easier. These experiments 
were carried out in triplicate (i.e. biological triplicates) and the error bars correspond to 
standard deviation of the mean. Significant differences between the untreated serum 
(black bars in all panels) and the treated serum are shown with asterisks (Students t-
test, p<0.05). n.s. : non significant. 
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4.2.5.3 Study of the specificity of the anti-rabbit complement components 
antibodies 
 
Not only the ability of these antibodies to inactivate the bactericidal activity of 
the rabbit serum was tested, but also their capacity to recognize the proteins 
they were raised against through Western blot. As explained before, these 
antibodies were raised using peptides from the rabbit proteins and they are not 
expected to crossreact with the human proteins. Comparison of the protein 
sequences shows that while some residues are fully conserved, most of the 
peptides only have a weak conservation with the human protein sequences 
(Figure 4.8). 
 
The affinity of the antibodies against the peptides they were raised against was 
tested through immunoblots using nitrocellulose membranes and 
chemiluminescence kits for visualization of the signal. While a strong signal was 
obtained in each case, this signal was weaker when using the C4 
peptide/antibody pair (Figure 4.9). This weaker interaction with the antibody 
could explain the level of inactivation of the bactericidal activity of the serum 
when it was pre-incubated with this antibody in comparison to the other 
antibodies.  
 
To verify the presence of the complement proteins in the rabbit serum and their 
interaction with the antibodies Western blots were carried out. Each of the 
antibodies was tested against samples prepared using serum from four different 
rabbits and from four different human volunteers. The synthesized peptides 
were used as positive controls for the antibodies. The samples were prepared 
and resolved as explained in Chapter 2.21.6, and the membranes were 
developed using a chemiluminescence kit. 
 
No reactive proteins against any of the antibodies were observed in rabbit or 
human serum (Figure 4.10, all panels). The antibodies against the complement 
components MBL, C5 and C9 were only able to interact with the sample 
containing the synthesized peptide (Lane 2 in Fig. 4.10 A, C and D,   
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Figure 4.8 Sequence alignments between complement components from human 
(Homo sapiens) and rabbit (Oryctolagus cuniculus) 
Alignment of the sequences of rabbit, human and peptide sequences of A.MBL, B. C4, 
C. C5 and D. C9. The alignments were made using ClustalW, with the EBLOSUM62 
matrix. The residues that are marked with an asterisk (*) are fully conserved; colon (:) 
indicates strongly conserved substitutions and full stop (.) indicates weakly conserved 
residue substitutions. The extra cysteine added to the peptide sequence is not shown. 
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Figure 4.9 Enhanced chemiluminescence signal from immunoblots using 
synthesized peptides and chicken antibodies 
A 10 µl aliquot (5µg) of each synthesized peptide MBL was placed directly into a 
nitrocellulose membrane, then air dried before following the slot blot system protocol 
from Chapter 2.21.1. The membranes were incubated with 1. Specific antibody and 2. 
Chicken control antibody. The signal was obtained after 5 minutes of incubation for 
development.  
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Figure 4.10 Reactivity of the anti-rabbit complement component antibodies 
Aliquots of 10 µg of each synthesized peptide (lane 2), serum from four different rabbits 
(lanes 3, 4, 5 and 6) and serum from four different human volunteers (lanes 7, 8, 9 and 
10), along with 5 µl of Color Prestained Protein Standard, Broad Range from New 
England Biolabs (lane 1), were analysed in 10% (w/v) SDS-PAGE and Western blot. 
The blots were incubated with the chicken produced antibodies against rabbit A. MBL, 
B. C4, C. C5 and D. C9 at a 1: 5,000 dilution. The arrows show the expected size for 
each protein: 96kDa for MBL, 210kDa for C4, 180kDa for C5 and 69kDa for C9. The 
signal was obtained after 20 minutes of incubation for development. 
 
  
 169 
respectively). No signal was obtained using the antibody against C4 (Figure 
4.10B). 
 
As three of the chicken antibodies against the rabbit complement components 
(MBL, C5 and C9) were only able to react with the synthesized peptide they 
were raised against but not with any protein present in the samples prepared 
with sera from different rabbits, a problem could be the concentration of the 
proteins in the samples loaded into the gel and thus a 24-wells slot blot system 
(CORE Life Sciences) was used. 
 
To test the reactivity of the antibodies for proteins in the serum, a 10-1- to 10-4- 
fold dilution of rabbit and human serum were used. 50 µl of each sample was 
loaded into the wells, the membranes were incubated with each of the 
antibodies according to the protocol explained in Chapter 2.21.1 and signals 
were obtained only after 30 minutes of development using chemiluminescence.  
No signal was obtained for rabbit serum, confirming that these antibodies are 
not able to react with proteins in this serum. On the contrary, all of the 
antibodies were even able to interact with human proteins present in the sera 
diluted 10-3-fold (Figure 4.11, all panels). Similar results were obtained when 
anti-human complement antibodies were used (data not shown). 
 
These experiments indicated that the antibodies produced in chicken by 
GenScript were not able to interact with the complement proteins present in the 
rabbit serum. They only showed reactivity with the peptides they were raised 
against. This suggests that the linear peptides do not contain epitopes held by 
the full length protein. This could be due to modifications or other structural 
features. Without a clear signal identifying the rabbit complement proteins it 
cannot be said that the inactivation that was obtained is due to a specific 
interaction between that antibody and its target protein. 
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Figure 4.11 Study of reactivity of anti-rabbit complement components antibodies 
with rabbit and human sera using a 24-well slot blot system 
Rabbit (NRS) and human (HS) serum was diluted 10-fold using sterile PBS and 50 µl 
of each sample was loaded into each well: A. undiluted sera, B. 10-1 dilution, C. 10-2 
dilution, D. 10-3 dilution, E. 10-4 dilution. The membrane was incubated with blocking 
buffer for 60 minutes, after which was washed and then incubated for 60 minutes with 
blocking buffer containing the primary antibody at 1:10,000 dilution (MBL, C4, C5 and 
C9, as indicated in the figure). The membranes were then incubated with the 
secondary antibody (1:10,000 dilution) for 60 minutes, washed and developed using 
the SuperSignal® West Pico Enhanced Chemilunminescent kit. The membranes were 
developed for 30 minutes. 
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4.2.6 Purification of human and rabbit serum components by centrifugal 
filters and study of their bactericidal activity 
 
To characterize the elements of the NRS that were responsible for its 
bactericidal activity against S. aureus, the rabbit serum was separated into 
different fractions according to molecular mass and the fractions were tested on 
their ability to affect the growth of the bacteria.  
 
In order to obtain the different fractions, the sera were separated using Amicon 
Ultra 0.5ml centrifugal filters, Ultracel (Millipore) with different molecular mass 
cut-off: 10, 30 and 50 kDa. Rabbit serum was placed into the sample reservoir 
and centrifuged following the instructions of the manufacturer (Chapter 2.15.1) 
By the end of this separation, eight different fractions of rabbit serum were 
collected: smaller and larger than 10 kDa, smaller and larger than 30 kDa, 
smaller and larger than 50 kDa, between 10 and 30 kDa, and between 30 and 
50 kDa. All the fractions were stored at -80ºC until further use. The same 
protocol was used with human serum. 
 
To confirm that the filtration process itself had no negative effect on the overall 
bactericidal activity of the fractions, all the fractions obtained using each of the 
filters were mixed together. Before mixing the fractions it was taken into 
consideration that this separation process also concentrated the fraction 
containing the component with larger molecular mass than the cut-off of each 
filter. No significant difference between the killing activity of untreated rabbit 
serum and the reconstituted serum was observed (Figure 4.12), suggesting that 
this separation process did not have an effect on the bactericidal activity of the 
serum components. The same experiments were carried out with the human 
serum fractions and no difference between the activity of the untreated and 
reconstituted serum was found (data not shown).  
 
After confirming that filtration had no effect on the bactericidal activity of the 
rabbit serum, the bactericidal activity of the different fractions was tested. As 
explained previously, it was necessary to take into consideration the 
concentration of the fraction containing components with larger molecular mass   
 172 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 Pairwise comparison of the reconstitution of the bactericidal activity 
of the fractioned NRS against S. aureus 
Aliquots of the rabbit serum fractions were mixed to reconstitute the serum before 
being inoculated with 5x105 to 106 cells/ml of an exponential phase culture of S. aureus 
SH1000. Killing assays were carried out as explained previously (Chapter 2.9). 
Experiments were carried out in triplicate (i.e. biological triplicates). Student’s t-tests 
were carried out and no significant differences were found (p>0.05). Error bars 
correspond to the standard deviation of the means. 
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than the cut-off of each filter. Therefore, the fraction containing the components 
smaller than the cut-off of each filter was used directly in the experiments, while 
the fraction containing the components bigger than the cut-off were diluted 
accordingly using sterile PBS. 
 
The experiments showed that none of the serum fractions had a bactericidal 
activity comparable to the antibacterial activity of the untreated serum (Figure 
4.13). Two of the rabbit serum fractions, containing components smaller than 30 
kDa and components smaller than 50 kDa (Figure 4.13C and E, respectively), 
showed an effect on the bacteria similar to bacteriostatic effect, while all the 
other fractions allowed bacterial growth. The fractions containing components 
between 10-30 kDa and between 30-50 kDa also allowed bacterial growth 
(Figure 4.14). These results suggested that the elements of the rabbit serum 
responsible for the killing activity might be found in the fractions containing 
components smaller than 30 kDa and smaller than 50 kDa in a concentration 
that affects the bacteria but not high enough to kill them completely. These 
antibacterial elements might be also present in other fractions but they are not 
able to kill the bacteria due to a concentration issue, or because they need 
another element in order to be able to kill the bacteria and this element was not 
present in the fractions. 
 
No bactericidal activity against S. aureus was observed when killing assays 
were carried out using the fractions obtained from the human serum. Previous 
work carried out in the laboratory showed that the combination of fractions from 
human and rabbit serum resulted in a ‘reconstituted serum’ capable of killing 
the bacteria (Bozakouk, unpublished). Here a finer separation took place and 
the human serum used was obtained directly from healthy human volunteers. 
When these experiments were repeated no bactericidal activity was observed 
for any of the combinations studied (Figure 4.15), suggesting that the rabbit 
serum fractions cannot augment the human serum.  
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Figure 4.13 Pairwise comparison of the effect of fractionated rabbit serum on S. 
aureus 
Aliquots of the fractionated rabbit serum were inoculated with 105 cells/ml of S. aureus 
SH1000 and killing assays were carried out to test the bactericidal activity of each 
fraction. A. Smaller than 10 kDa, B. Larger than 10 kDa, C. Smaller than 30 kDa, D. 
Larger than 30 kDa, E. Smaller than 50 kDa, F. Larger than 50 kDa. These 
experiments were carried out in triplicate (i.e. biological triplicates) and significant 
differences are shown with asterisks (Student’s t-test, p<0.05). The error bars 
represent the standard deviation of the means. 
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Figure 4.14 Comparison of the bactericidal activity of fractionated and untreated 
rabbit serum  
Aliquots of the fractionated and untreated rabbit serum were inoculated with 105 
cells/ml of an exponential phase culture of S. aureus SH1000 and killing assays were 
carried out to test the bactericidal activity of each fraction. A. Components between 10-
30 kDa, B. Components between 30-50 kDa. These experiments were carried out in 
triplicate (i.e. biological triplicates), the error bars correspond to the standard deviation 
of the means and the asterisks show significant differences (Student’s t-test, p<0.05). 
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Figure 4.15 Bactericidal activity of the mixed human and rabbit serum fractions 
Aliquots of smaller (SR) and larger (LR) fractions of rabbit serum were mixed with 
smaller (SH) and larger (LH) fractions of human serum according to the filters used, 
obtaining ‘reconstituted’ serum. The bactericidal activity of this ‘reconstituted’ serum 
was tested through killing assays using 5x105 cells/ml of S. aureus SH1000. Fractions 
were obtained using A. 10 kDa, B. 30 kDa, or C. 50 kDa filters as explained previously. 
The activity of untreated human (black bars) serum is present in every graph for 
comparison. These experiments were carried out in duplicate. 
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4.2.7 Identification of rabbit serum components that bind to S. aureus 
purified cell wall 
 
To continue with the identification of the rabbit serum components responsible 
for its bactericidal activity against S. aureus, purified cell wall material was used. 
In the previous Chapter it was shown that the NRS lost its antibacterial activity 
when it was pre-incubated with different types of purified cell wall material. 
These results suggested that the binding of the serum elements responsible for 
the killing to the purified cell wall caused the inactivation of the bactericidal 
activity of the serum. 
 
 
4.2.7.1 Visualization of protein profiles of affinity matrices pre-incubated 
with NRS 
 
In Chapter 3 the NRS pre-incubated with cell wall material was used for killing 
assays and the experiments highlighted the role of the wall teichoic acids in this 
process, along with the importance of D-alanylation. The insoluble material 
obtained after the incubations was washed with sterile MilliQ water and stored 
at -20ºC.  
 
Due to the ability of the purified material to inactivate the NRS, this material was 
used as an affinity matrix for the serum components that are able to kill S. 
aureus. To check if there was a difference between the bound elements, the 
cell wall bound material was studied and protein patterns were compared 
through SDS-PAGE and silver staining of the resulting gel.  
 
As shown in Figure 4.16, the protein patterns of the individual samples are 
different from each other. The cell wall material from the incubations that were 
able to completely inactivate the bactericidal activity of NRS showed more 
protein bands (lanes 3 and 6) than the material from serum that was only 
partially inactivated (lanes 2 and 4). These results supported the hypothesis  
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Figure 4.16 Silver staining of 10% (w/v) SDS-PAGE of pre-incubated cell wall 
material samples 
1mg/ml of each cell wall purification was pre-incubated with 1ml of NRS for 30 minutes 
at 4ºC before being centrifuged. The insoluble material was washed three times with 
sterile MilliQ. Samples were prepared as explained previously (Chapter 2.21.2), diluting 
the samples 10-fold beforehand in order to facilitate the loading of the sample into the 
gel. Lane 1: Protein ladder (molecular weight (MW): 10-230 kDa range); 2: stripped PG 
[hydrofluoric acid treated PG, no WTA]; 3: unstripped PG [PG+WTA]; 4: purified WTA; 
5: cell wall material from ΔtagO; 6: cell wall material from ΔdltA; 7: cell wall material 
from RN4220; 8: cell wall material from RN4220 ΔtarM ΔtarS.  
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that the elements of the serum that are responsible fot the killing of the bacteria 
were absorbed out of the rabbit serum by the purified cell wall material.  
 
 
4.2.7.2 Mass spectrometry analysis of rabbit serum proteins bound to 
purified cell wall material 
 
The different protein profiles observed by silver staining of the gels led to the 
next step: the identification of the different proteins. This identification was 
carried out by mass spectrometry analysis of the proteins bound to the cell wall 
material obtained after the pre-incubation with NRS. For this analysis three 
types of affinity matrices were used: stripped (peptidoglycan without WTA) and 
unstripped (peptidoglycan with WTA) peptidoglycan from S. aureus SH1000 cell 
wall material from the ΔdltA strain. These samples were chosen as they showed 
differential absorptive capacity for the NRS killing activity (Figures 3.17 and 
3.19). 
 
Mass spectrometry (MS) is a technique used for qualitative and quatitative 
analysis of proteins. This method provides information about the identity, 
structure, molecular mass, amount and purity of a sample (Ardrey, 2003; 
Becker and Bern, 2011; Cappadona et al, 2012). It has been widely reported 
that different types of mass spectrometry can be used to analyse proteins 
present in blood. This technique has been used to characterize the full 
proteome of human blood (Adkins et al, 2002; Shen et al, 2005), but also to 
identify low-molecular mass and low-abundance proteins that would go 
unnoticed using other methods (Merrel et al, 2002; Jaros et al, 2013). For 
example, MS analysis is currently used to identify biomarkers for different types 
of cancer (Zhang et al, 2004; De Bock et al, 2010; Mook et al, 2010; Timms et 
al, 2011; Tessitore et al, 2013). 
 
A mass spectrometer has three main components: the ionization source, the 
mass analyser and the ion detector. The sample to be analysed is ionized and 
broken into charged fragments, which are separated in a mass analyser 
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according to their mass to charge ratio (m/z). This separation typically occurs by 
accelerating the charged fragments by application of a magnetic or an electric 
field. Different types of mass analysers can be used, each with different 
resolutions and useful for the analysis of different types of sample. The ion 
detector recognizes the charged fragments and the results are shown as a 
spectrum of the abundance of these ions as a function of the mass-to-charge 
ratio. It is possible then to identify the molecules by comparing the results 
obtained to known masses and characteristic or theoretical fragmentation 
patterns (Trauger et al, 2002; Glish and Vachet, 2003; Wysocki et al, 2005).  
 
In order to obtain the samples that were analysed, aliquots of 1 ml of rabbit 
serum were incubated with 1 mg/ml of each of the cell wall purifications that 
were used as affinity matrices. After the incubation, the samples were 
centrifuged and the supernatant was used in killing assays to test that the 
bactericidal activity of these samples was affected by the treatment. The 
recovered insoluble material was washed several times with MilliQ, resolved by 
10% (w/v) SDS-PAGE and stained using silver to demonstrate the different 
profile of proteins bound to each matrix. The insoluble material was then 
prepared for MS as explained in Chapter 2.20.1 using 16 hours of digestion with 
1mg/ml of trypsin to completely digest the proteins. 
 
Liquid Chromatography Mass Spectrometry (LC-MS) analysis of the three 
samples was carried out (Chapter 2.20.2) and the resulting spectra was 
searched with Mascot against the Swissprot Database using ‘Rodentia’ as 
taxonomic filter. Proteins with at least two peptides identified and with a 
confidence interval of 95% or higher were reported. 
 
Between 245 and 317 proteins were identified through LC-MS in each 
preparation. Eleven proteins showed differential presence in the samples and 
only three proteins were present in the samples capable of completely 
inactivating the serum (unstripped peptidoglycan from SH1000 and unstripped 
peptidoglycan from ΔdltA) and not in the sample that only caused partial 
inactivation (stripped peptidoglycan) (Table 4.2). These proteins were 
immunoglobulin kappa chain V- region AH80, immunoglobulin lambda chain C   
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Table 4.2 Comparison of protein profiles from LC-MS analysis 
The eleven proteins that were not present in all of the samples are shown here.  
 (+): present; (-): not present  
 
Protein 
Stripped cell 
wall material  
Unstripped cell 
wall material  
Unstripped ΔdltA 
cell wall material  
Alpha-1-antiproteinase F + - - 
Hemoglobin subunit beta-
1/2 
- + - 
Cholisteryl ester transfer 
protein (fragment) 
- + - 
Complement component 
C9 
- + - 
Ig kappa chain V region 
AH80-5 
- + + 
Ig lambda chain C region - + + 
Cystatin-C - + - 
Lysozyme C - + - 
Phospholipase A2 
(fragment) 
- + + 
Ig kappa chain V region 
BS-1 
- - + 
Annexin A1 - - + 
Metalloproteinase inhibitor 
3 (fragments) 
- - + 
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region, and phospholipase A2. These immunoglobulin fragments belong to the 
light chains of mammalian antibodies and they were considered unlikely to be 
part of the bactericidal mechanism. 
 
Phospholipase A2 (PLA2) is part of a superfamily of enzymes capable of 
hydrolysing phospholipids in the sn-2 position, leading to the generation of 
arachidonic acid and lysophospholipid (Balsinde et al, 2002; Wu et al, 2010). 
Arachidonic acid can be converted into eicosanoid, a signalling molecule that 
plays a role in immune responses, inflammation and pain perception. The 
lysophospholipids can serve as a precursor for lipid mediators such as 
lysophosphatidic acid and platelet activating factor (Schaloske and Dennis, 
2006). 
 
These proteins can be divided into five kinds of enzymes based on their 
catalytic mechanism as well as functional and structural features (Schaloske 
and Dennis, 2006; Dennis et al, 2011). One of these groups is the secreted 
PLA2 (sPLA2), small secreted proteins (14-16 kDa) that usually contains 6 to 8 
sulphide bonds (Schaloske and Dennis, 2006) and require of µM levels of 
calcium for catalysis due to their His/Asp catalytic dyad (Dennis et al, 2011; 
Murakami and Lambeau, 2013). It is known that the secreted PLA2 (sPLA2) has 
antibacterial activity against Gram-positives, including S. aureus. Its activity is 
affected by heat and zymosan, and the initial binding of PLA2 to S. aureus is 
based upon electrostatic interactions between the protein and the cell surface 
(Weinrauch et al, 1996; Qu and Lehrer, 1998; Santagelo et al, 1999; Buckland 
and Wilton, 2000; Koduri et al, 2002; Dennis et al, 2011). This led to the new 
hypothesis that sPLA2 might be the element responsible for the bactericidal 
activity of the NRS against S. aureus.  
 
 
4.2.8 Effect of the inactivation of phospholipase A2 (PLA2) on the 
bactericidal activity of NRS against S. aureus 
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Thus far it has been shown that the antibacterial activity of the rabbit serum is 
affected by temperature, calcium concentration and by pre-incubation with 
zymosan A, ammonium salts and ammonium hydroxide. All of these treatments 
resulted in the complete inactivation of the bactericidal activity of the serum 
against S. aureus but they are non-specific and can affect several elements of 
the serum. Some of the elements that could be affected by these protocols 
were part of the complement system, which led us to study the role of this 
system in the bactericidal activity of the rabbit serum. However, in Chapter 4.3.5 
it was confirmed that the complement system was likely not involved. 
 
After identifying PLA2 as a candidate for the rabbit serum component 
responsible for the killing activity of the NRS, the effect of its inactivation on the 
antibacterial activity was studied. It has been reported that the activity of PLA2 
is affected by heat treatment (Paliyath et al, 1999; Santangelo et al, 1999; 
Merchant et al, 2011), zymosan A from S. cerevisiae (Daum et al, 1998; Harboe 
et al, 2012) and by pre-incubation with a chelating agent (Harwig et al, 1995; 
Qu and Lehrer, 1998; Dennis et al, 2011), concurring with the NRS results 
obtained previously. 
 
It has been reported that the activity of the PLA2 can be affected by the use of 
arachinodyl trifluoromethyl ketone (AACOCF3) and 4-bromophenacyl bromide 
(BPB) (Balsinde et al, 1999; Ouyang and Kamisnki, 1999; Dennis et al, 2011). 
These compounds interact with specific types of phospholipases, which could 
help elucidate if the secreted phospholipase A2 (sPLA2) is really the 
bactericidal element of the rabbit serum.  
 
The arachinodyl trifluoromethyl ketone is an analogue of arachidonic acid that 
interacts directly with the phospholipase and acts as a tight-binding inhibitor of 
the cytoplasmic (cPLA2) and the calcium-independent phospholipase (iPLA2) 
(Street et al, 1993; Ackerman et al, 1995; Loweth et al, 1996, Dennis et al, 
2011). 4-bromophenacyl bromide is able to covalently bind to an exposed 
histidine residue present on the sPLA2, inhibiting the catalytic activity of the 
protein (Roberst et al, 1977; Mayer et al, 1993, Kim and Bonventre, 1993). This 
compound does not affect cPLA2 or iPLA2 (Balsinde et al, 1999). 
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In order to test the effect of AACOCF3 and BPB on the bactericidal activity of 
the rabbit serum, these compounds were added to aliquots of NRS mixed with 
S. aureus. To determine possible effects of the inhibitors on S. aureus directly 
growth curves were carried out. The inhibitors had a significant negative effect 
on bacterial growth in each case (data not shown). This negative effect on the 
survival of S. aureus SH1000 was also observed when these inhibitors were 
added to heat inactivated rabbit serum (data not shown). This precluded the 
use of AACOCF3 and BPB to confirm the role of PLA2 in the bactericidal activity 
of NRS. 
 
Another molecule that is able to inhibit the activity of PLA2 is dithiothreitol 
(DTT). DTT is a strong reducing agent used to differentiate sPLA2 from the 
other types of phospholipase (Lambeau and Gelb, 2008). sPLA2 has a high 
number of disulphide linkages (between 6 and 8) that DTT is able to reduce, 
destabilizing the protein structure and affecting its activity (Castle and Castle, 
1981; Mizushima et al, 1989; Singer et al, 2002; Lambeau and Gelb, 2008).  
 
After confirming that DTT had no negative effect on S. aureus growth (data not 
shown), phospholipase A2 inactivation experiments were carried out. Aliquots 
of rabbit serum were mixed with DTT and pre-incubated for 30 minutes at 37ºC 
before the addition of the bacteria. This treatment was capable to inactivate the 
bactericidal activity of NRS against S. aureus, suggesting that sPLA2 was 
involved in this killing mechanism (Figure 4.17). A 100-fold increase in the 
bacterial numbers was observed between 3 and 4 hours of incubation in the 
NRS treated with this reducing agent. This increase could be due to a mistake 
in the dilution process prior to the plating, as the cell doubling time cannot 
explain this. 
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Figure 4.17 Effect of dithiothreitol pre-incubation on the bactericidal activity of 
NRS 
Aliquots of rabbit serum were treated with 10 mM DTT and pre-incubated for 30 
minutes at 30ºC, and then inoculated with 5x104 cell/ml of an exponential phase culture 
of S. aureus SH1000. The activity of the treated serum (red line) was compared with 
the activity of untreated rabbit serum (black line). This experiment was carried out in 
triplicate (i.e. biological triplicates) and significant differences are shown with asterisks 
(Students t-test, p<0.05). The error bands correspond to the standard deviation of the 
means. 
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4.2.9 Effect of anti-phospholipase A2 antibodies in the bactericidal 
activity of rabbit serum 
 
All the serum inactivation protocols used so far were non-specific and could 
affect other components of the serum as well as sPLA2. It has been reported 
that antibodies can be used not only to identify sPLA2, but also to inactivate its 
phospholipase activity (Murakami et al, 1988; Mizushima et al, 1989; Koduri et 
al, 1998). This approach was used to analyse the role of sPLA2 in the bacterial 
killing caused by the NRS. Rat monoclonal antibodies able to recognize the low 
molecular PLA2 were selected and purchased, as this low molecular protein 
corresponds to the secreted PLA2. 
 
Rabbit serum was pre-incubated with different concentrations of monoclonal 
antibodies (10-100 µg/ml) before inoculating the mixtures with S. aureus 
SH1000 to test if there was any effect on the bactericidal activity. No significant 
difference between the bactericidal activity of untreated and treated serum was 
observed using the rat control antibody for any of the concentrations studied 
(Figure 4.18A). Whilst some effect on the antibacterial activity was observed 
when the serum was pre-incubated with 50 µg/ml of anti-PLA2 antibody, 
significant inactivation of the rabbit serum was observed when the rabbit serum 
was pre-incubated with 75 µg/ml or higher concentrations of the anti-PLA2 
antibodies (p< 0.05; Figure 4.18B). 
 
As a significant inactivation of the bactericidal activity was observed when the 
serum was pre-incubated with 75 µg/ml of the anti-PLA2 antibodies, complete 
killing assays were carried out using this concentration. Just as expected, the 
bactericidal activity was inactivated when the NRS was treated with the 
monoclonal anti-PLA2 antibodies, while treatment with the control antibody had 
no effect (Figure 4.19). This confirms the role of the secreted phospholipase A2 
in the bactericidal activity of naive rabbit serum against S. aureus. 
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Figure 4.18 Effect of anti-PLA2 antibodies on the bactericidal activity of NRS 
Aliquots of rabbit serum were pre-incubated with 10-100 µg/ml of A. rat control 
antibody, B. rat monoclonal anti-PLA2 antibodies before inoculating with 105 cells/ml of 
an exponential phase culture of S. aureus SH1000 to test their effect on the 
bactericidal activity of NRS. Treated serum was compared with untreated rabbit serum 
(black bars) and significant differences are marked with asterisks (Student t-test, 
p<0.05). These experiments were carried out in triplicate (i.e. biological triplicates). 
Error bars represent the standard deviation of the means. 
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Figure 4.19 Pairwise comparison of the effect of anti-PLA2 antibodies on the 
antibacterial activity of rabbit serum 
Aliquots of rabbit serum were incubated for 30 minutes with 75µg/ml of A. rat control 
antibody, B. rat monoclonal anti-phospholipase A2 antibody, before inoculating with 
104-105 cells/ml of S. aureus SH1000. These experiments were carried out on triplicate 
(i.e. biological triplicates) and significant differences between the bactericidal activity of 
untreated serum (black line) and the treated serum are shown with asterisks (Students 
t-test, p<0.05). Error bars correspond to the standard deviation of the means. 
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4.2.10 Study of the specificity of anti-phospholipase A2 antibodies  
 
To verify the reactivity of the antibodies against the secreted phospholipase A2 
present in the rabbit serum, 10-fold dilutions up to 10-10 of rabbit and human 
serum were prepared using sterile PBS. 200 μl of each sample was loaded into 
the wells of the 24-wells slot blot system. The membrane was incubated with 
the monoclonal anti-PLA2 antibodies and signals were obtained after 10 
seconds of development using the chemiluminescence kit. As expected, the 
antibodies were able to interact with proteins present in the rabbit serum but not 
in the human serum confirming the specificity for the rabbit PLA2 (Figure 4.20). 
 
To verify that the anti-PLA2 antibodies were interacting with the desired protein, 
samples using human and rabbit and human serum were prepared and 
Western blots were carried out as explained in Chapter 2.21.6, developing the 
membrane using a chemiluminescence kit.  
 
None of the proteins present in the human serum were able to interact with the 
anti-PLA2 antibody (Figure 4.21, lanes 2-5), while a 16kDa band was observed 
in all the samples prepared with serum from different rabbits (Figure 4.21, lanes 
7-10). The band has the expected molecular weight of the sPLA2, 
demonstrating that the antibody interacts in a specific manner. The other bands 
that are present in this Western blot might correspond to dimers and other 
polymeric forms of the protein, which can also be exist in the serum in the 
presence of calcium (Castle and Castle, 1981). 
 
4.2.11 Reactivity of anti-PLA2 antibodies to proteins bound to purified cell 
wall material after incubation with NRS 
 
Previously (Chapter 4.2.7), differential binding of the NRS killing factor to 
purified cell wall fractions revealed sPLA2 as the potential active component. To 
determine if this correlates with specific sPLA2 levels the monoclonal antibody 
was used. The 24-well slot blot system was used and serial dilutions of stripped 
peptidoglycan (PG without WTA), unstripped cell wall material (PG+WTA) from   
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Figure 4.20 Reactivity of anti-phospholipase A2 antibodies with rabbit and 
human sera 
Rabbit (NRS) and human (HS) serum was diluted 10-fold using sterile PBS and 200 µl 
of each sample was loaded into each well: A. undiluted sera, B. 10-1 dilution, C. 10-2 
dilution, D. 10-3 dilution, E. 10-4 dilution, F. 10-5 dilution, G. 10-6 dilution, H. 10-7 dilution, 
I. 10-8 dilution, J. 10-9 dilution, K. 10-10 dilution. The membrane was incubated with 
blocking buffer for 60 minutes, washed and incubated for 60 minutes with blocking 
buffer containing the primary antibody at 1:10,000 dilution. The membrane was then 
incubated with the secondary antibody (1:10,000 dilution) for 60 minutes, washed and 
developed using the SuperSignal® West Pico Enhanced Chemilunminescent kit. The 
membranes were developed for 10 seconds. 
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Figure 4.21 Specificity of the anti-phospholipase A2 antibody for rabbit serum 
proteins 
Serum from four healthy human volunteers (lanes 2, 3, 4 and 5) and from four different 
rabbits (lanes 7, 8, 9 and 10), along with the Color Prestained Protein Standard, Broad 
Range from New England Biolabs (lane 1) were analysed by 10% (w/v) SDS-PAGE 
and Western blot. The membrane was incubated with the anti-PLA2 antibodies at a 
1:5,000 dilution. The signal was obtained after 30 seconds of incubation for 
development.  
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SH1000 and unstripped material purified from ΔdltA pre-incubated with NRS 
were loaded into each well. 
 
PLA2 was present in all the samples but at different concentrations (Figure 
4.22). The signal obtained using stripped peptidoglycan was weaker than the 
signal for the unstripped cell wall material from SH1000 and for material purified 
from ΔdltA. This qualitatively supports the hypothesis that the differences in the 
degree of inactivation of the rabbit serum are caused by the variation in the 
affinity of the bactericidal component for different types of cell wall components. 
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Figure 4.22 Identification of phospholipase A2 bound to affinity matrices after 
pre-incubation with rabbit serum 
Bound material obtained from the incubation of rabbit serum with 1 mg/ml of A. Pure 
peptidoglycan, B. Unstripped cell wall material from parental strain, C. Cell wall 
material from the ΔdltA, was diluted 10-fold using sterile PBS and 200 µl of each 
sample was loaded into each well. The number on top of the figure shows the dilution 
present in each well, from undiluted (10-0) to 10-10-fold diluted (10-10). 
The membranes were incubated with blocking buffer, then washed and incubated for 
60 minutes with blocking buffer containing the monoclonal anti-phospholipase A2 
antibodies at 1:10,000 dilution. The membrane was then incubated with the secondary 
antibody (1:10,000 dilution) for 60 minutes, washed and developed using the 
SuperSignal® West Pico Enhanced Chemilunminescent kit. All the membranes were 
developed for 10 seconds, except the membrane with lipoteichoic acid (C) that was 
developed for 5 minutes. 
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4.3 Discussion 
 
Components of the complement system were initially identified as possible 
candidates for the bactericidal element of the rabbit serum as previous work 
carried out in the laboratory identified mannose-binding lectin (MBL) and 
complement component C4b as proteins bound to purified cell wall material 
(Bozakouk, 2011). This hypothesis was supported by the inactivation of the 
antibacterial activity of the rabbit serum by several complement inactivation 
protocols such as the use of calcium chelating agents (Des Prez et al, 1975; 
Morgan, 2000; Schwaeble et al, 2002; Roos et al, 2003; Takahashi et al, 2006), 
heat treatment (Ecker et al, 1943a; Kerr and Porter, 1978; Servais et al, 1991; 
Morgan, 2000) and pre-incubation with zymosan A from S. cerevisiae (Smith et 
al, 1982; Morgan, 2000; Zhang et al, 2003). 
 
However, these protocols were non-specific for the complement system and 
can also affect other elements present in the rabbit serum. Dr. Suzan 
Roiijakkers from University Medical Centre Utrecht (The Netherlands) 
performed experiments using specific inhibitors against the central complement 
components C3 and C5, and found that the bactericidal activity of the serum 
against S. aureus was not affected, suggesting that the killing activity was not 
mediated by complement (Personal Communication). 
 
To clarify the role of complement, antibodies against the rabbit proteins were 
synthesized and used for inactivation experiments and to identify the 
components in the NRS. MBL and C4 were chosen due to the results observed 
previously in the laboratory (Bozakouk, 2011), and C5 and C9 were chosen due 
to their role in the formation of the membrane attack complex.  
 
During the project the annotation of the predicted C5 sequence was altered to 
C3 (NCBI accession number XP_002722895.1). As explained previously the 
complement component C3 is as essential as C5, so this change in the protein 
that the antibody targets should not affect the experiments that were carried out 
to analyse the role of the complement system. 
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Anti-MBL, C4, C5 and C9 antibodies affected the bactericidal activity of the 
NRS. These results suggested that the lectin pathway of the complement was 
involved in the bacterial killing observed in rabbit serum. However, no 
interaction was found between the antibodies and the proteins present in the 
NRS as shown by the lack of signal when the rabbit samples were resolved by 
Western blot or when the 24-well slot blot system was used. 
 
This lack of reactivity with rabbit proteins suggested that the peptides used to 
produce these antibodies were not the ones that were chosen. This means that 
the inactivation of the bactericidal activity observed in killing assays could be 
caused by interaction of the antibodies with proteins or other elements of the 
rabbit serum that were not identified because the real target for these 
antibodies is unknown.  
 
The mass spectrometry analysis of the proteins bound to the different types of 
purified cell wall showed the absence of complement components bound to the 
affinity matrices capable of inactivating the NRS, proving that the complement 
system is likely not involved in the antibacterial activity of the NRS.  
 
Once the complement system was discarded as responsible for the bactericidal 
effect of NRS, other methods such as fractionation by centrifugal filters were 
used to try to identify the ‘killing factor’. The antibacterial activity of each fraction 
of NRS was studied in order to distinguish which of them contained the 
bactericidal element, and also to clarify if the bactericidal activity was caused by 
one or more elements of the serum. 
 
None of the fractions studied had bactericidal activity against the bacteria and 
only the fractions containing components ‘smaller than 30 kDa’ and ‘smaller 
than 50 kDa’ showed a bacteriostatic effect, suggesting that these fractions 
contain elements of the rabbit serum capable of affecting the bacterial growth 
but not concentrated enough to kill the bacteria as the whole serum does. This 
‘killing element’ might be also present in other fractions but at a low 
concentration. The concentration of other elements necessary for the 
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bactericidal activity, such as small molecules like calcium or other proteins that 
may form a complex with the killing element, might also be affected. 
 
To confirm the species specificity of the killing mechanism, human serum was 
also separated using these centrifugal filters. Bacterial growth was observed in 
all the fractions, and when rabbit and human fractions were mixed to 
reconstitute a ‘chimeric’ serum no bactericidal effect against S. aureus was 
observed in any case. This suggests that the phenomenon is NRS specific.  
 
In the previous chapter it was shown that purified cell wall material from S. 
aureus acts as an affinity matrix that binds the component(s) present in NRS 
responsible for its bactericidal activity. When the protein profiles of NRS 
elements bound to the affinity matrices were studied, more proteins were found 
bound to the matrices capable of completely inactivating the serum than to the 
ones that caused only partial inactivation.  
 
The mass spectrometry analysis of the proteins bound to stripped 
peptidoglycan, to peptidoglycan with WTA and to peptidoglycan from the mutant 
with WTA but lacking D-alanylation (ΔdltA strain) identified different proteins 
attached to each affinity matrix. Due to the ability of the unstripped 
peptidoglycan and the unstripped peptidoglycan from ΔdltA to completely 
inactivate the NRS, proteins present in both of these samples were examined in 
order identify the ‘killing factor’.  
 
One of the identified proteins was phospholipase A2 (PLA2), part of a 
superfamily of enzymes that can bind to membrane surfaces and hydrolyze 
membrane phospholipids at the sn-2 position (Berg et al, 2001; Koduri et al, 
2002). They are present in several bodily fluids including tears and serum 
(Weinrauch et al, 1996; Qu and Lehrer, 1998). These enzymes play a role in 
inflammation and immune response (Nevalainen et al, 2008). It has been 
reported that these proteins have a bactericidal effect against Gram-negative 
(Harwig et al, 1995) and Gram-positive (Qu and Lehrer, 1998) bacteria, and that 
secreted phospholipase A2 (sPLA2) has a potent antibacterial activity against 
S. aureus (Weinrauch et al, 1996; Qu and Lehrer, 1998; Dominiecki and Weiss, 
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1999; Laine et al, 1999; Koprivnjak et al, 2002). It has also been reported that 
the activity of sPLA2 is affected by calcium concentration, heat and zymosan A 
(Daum et al, 1998; Paliyath et al, 1999; Santangelo et al, 1999; Merchant et al, 
2011; Harboe et al, 2012), making sPLA2 a good candidate for the ‘killing 
factor’ present in NRS. 
 
In order to have an effect on the phospholipids present in the cell membrane of 
Gram-positive bacteria, PLA2 needs to be able to recognize and bind to the 
bacterial cell wall and move through it in order to gain access to these 
phospholipids (Foreman-Wykert et al, 1999; Koprivnjak et al, 2008). This 
process can be separated into four steps: PLA2 binds to the bacterial surface, 
penetrates through the peptidoglycan, degrades the phospholipids present in 
the membrane and activates bacterial autolysins (Foreman-Wykert et al, 1999). 
 
It has been reported that the initial binding of the phospholipase A2 to the cell 
surface of S. aureus is based upon electrostatic interactions between the 
protein and the bacterial cell surface (Foreman-Wykert et al, 1999; Koprivnjak et 
al, 2002). This protein is highly cationic, which allows it to interact and penetrate 
the anionic bacterial cell wall (Buckland et al, 2000; Beers et al, 2002; 
Koprivnjak et al, 2002). Lipoteichoic and wall teichoic acids are anionic 
molecules present in the bacterial cell wall that are capable of interact with this 
enzyme, helping PLA2 to reach the phospholipids in the membrane (Koprivnjak 
et al, 2002). This interaction between the teichoic acids and PLA2 might cause 
the inactivation of the bactericidal activity of the rabbit serum when pre-
incubated with this purified components. 
 
As the D-alanylation modification of the teichoic acids results in the addition of 
positive charges into the cell wall (Peschel et al, 1999; Koprivnjak et al, 2002; 
Fedtke et al, 2004), this modification also may affect the interaction of PLA2 
with the cell surface of S. aureus. This could explain the important role of this 
modification in the survival of the bacteria in rabbit serum shown in the previous 
chapter (Chapter 3.2.8). It has been reported that the presence of D-alanylation 
increases 100-fold the bacterial resistance to sPLA2 (Koprivnjak et al, 2002; 
Hunt et al, 2006). The lack of this modification in the ΔdltA mutant might also 
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explain the total inactivation of the bactericidal activity observed when the rabbit 
serum was pre-incubated with purified cell wall from this strain: the positive 
PLA2 was able to interact more with this bacterial cell wall with negative net 
charge. 
 
Cations such as magnesium and calcium are able to bind to the bacterial cell 
wall, with half of the binding sites in the polyphosphate groups of the teichoic 
acids and the other half in the carboxyl units of the peptidoglycan (Thomas and 
Rice, 2014). It seems plausible that the strain without WTA (ΔtagO mutant) 
binds less calcium ions on the bacterial surface than the parental strain, 
affecting the availability of this cation for the calcium-dependent secreted 
phospholipase A2 (Qu and Lehrer, 1998; Balsinde et al, 1999). The level of 
calcium available can also be affected by the D-alanylation modification of the 
teichoic acids (Koprivnjak et al, 2002). The absence of D-alanylation in the 
ΔdltA strain might increase the binding of calcium to the cell surface, increasing 
the availability for PLA2. 
 
Once the PLA2 is bound to the bacterial surface, it needs to penetrate the 
peptidoglycan in order to reach the phospholipids present in the bacterial 
membrane. It has been previously shown that mutant strains of S. aureus 
lacking wall teichoic acids show resistance against the action of PLA2 due to 
the inability of the bound PLA2 to access and act on the phospholipids present 
in the bacteria (Koprivnjak et al, 2008). These results could explain why wall 
teichoic acid deficient mutants (ΔtagO strain) are resistant to the bactericidal 
activity of the NRS.  
 
It has also been reported that the D-alanylation might have a role in the ability 
of PLA2 to reach the bacterial membrane (Koprivnjak et al, 2002; Hunt et al, 
2006). The teichoic acids inserted into the peptidoglycan form a negatively 
charged network that connects the bacterial cell wall and the membrane 
(Neuhaus and Baddiley, 2003). In the ΔdltA mutant strain both WTA and LTA 
lack the D-alanine modification, turning this network more negative. This 
change in the charge of the ‘ladder’ used by PLA2 to reach the phospholipids 
might facilitate the penetration of the enzyme. 
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The role of PLA2 was supported by the use of a specific monoclonal antibody, 
which caused a complete inactivation of the bactericidal activity of NRS. The 
antibody was also able to specifically identify the protein in the serum obtained 
from different rabbits. Additionally, it was possible to relate the differential level 
of protein binding with the degree of inactivation caused by treatment with an 
specific affinity matrix, detecting a higher amount of PLA2 bound to the cell wall 
material that was able to completely inactivate the NRS than to the purifications 
that only caused a partial inactivation of the killing activity.  
 
Together the evidence is compelling that secreted phospholipase A2 is the 
component of the rabbit serum responsible for its antibacterial activity against 
S. aureus. However, the results obtained from the fractionated serum 
experiments suggest that PLA2 is not the only element involved in this 
bactericidal activity. It is necessary to identify other possible elements in order 
to be able to explain the killing mechanism. Experiments using purified 
phospholipase A2 were carried out to confirm that this enzyme was able to kill 
S. aureus and to find the minimal system necessary for the bacterial killing. All 
of this will be explained in the next chapter. 
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5 Chapter 5:  
Bactericidal mechanism of NRS against S. aureus 
 
5.1 Introduction 
 
In the previous chapters wall teichoic acid was identified as the bacterial 
component that acts as a likely receptor for the bactericidal activity of the rabbit 
serum, and secreted phospholipase A2 (sPLA2) as the element of the NRS 
responsible for the bacterial killing. However, experiments carried out using 
fractionated rabbit serum suggested that sPLA2 was not the only component 
involved in this bactericidal activity.  
 
In order to explain the antibacterial mechanism that allows rabbit serum to kill S. 
aureus, it is necessary to identify any other components involved. These could 
affect activity of phospholipase directly or assist in interactions at the bacterial 
surface. The presence of these additional components could explain why the 
bactericidal activity against S. aureus is only observed with rabbit serum and 
not with other mammals. 
 
Due to the involvement of PLA2 in many biological processes such as 
inflammation, immune response, reproduction and skin homeostasis (Balsinde 
et al, 1999; Lambeau and Gelb, 2008; Murakami et al, 2010; Murakami et al, 
2013), and its association with several diseases including septic and allergic 
shock, rheumatoid arthritis, adult respiratory distress syndrome and pancreatitis 
(Scheuer, 1998; Murakami et al, 2010), PLA2 needs to be regulated. There 
have been reports showing that phosphorylation cascades (Lin et al, 1993; Qiu 
et al, 1993; Qiu et al, 1998), phosphatidylinositol 4,5-biphosphate levels 
(Monsior et al, 1998) and intracellular calcium elevations (Glover et al, 1995; 
Qiu et al, 1998) are able to regulate the activation of the cytosolic PLA2. It has 
also been reported that the calcium-independent PLA2 can be regulated by 
 202 
different mechanisms, including ATP binding, caspase cleavage and possible 
ankyrin repeat mediated protein aggregation (Burke and Dennis, 2009; Dennis 
et al, 2011) 
 
Calcium can affect the activity of the secreted phospholipase A2 (sPLA2) as its 
catalytic activity is dependent on this cation (Qu and Lehrer, 1998; Balsinde et 
al, 1999; Koprivnjak et al, 2002) and it has been reported that the levels of 
calcium in rabbit blood are higher than in other mammals, including humans 
(Brown, 1928; Redrobe, 2002; Rosenthal, 2006). However, as none of the NRS 
fractions studied in Chapter 4 had bactericidal activity on their own, but the 
reconstituted serum was able to kill S. aureus, there is another factor in the 
rabbit serum apart from calcium that is essential for the activity of the enzyme 
and the antibacterial activity of the NRS. 
 
Pancreatic PLA2 is also regulated by proteolysis as it is synthesized in the 
acinar cells and secreted as a zymogen, only becoming active after trypsin 
cleavage of an N-terminal heptapeptide (Volwerk et al, 1984; Lenting et al, 
1988; Scheuer, 1989; Murakami et al, 2010). However, this kind of irreversible 
activation has only been observed for pancreatic PLA2. 
 
PLA2 is not only present in mammals, but also in the venom of bees, scorpions 
and snakes (Moreira et al, 2002; Lizano et al, 2003; Lambeau and Gelb, 2008; 
Petras et al, 2010; Stábeli et al, 2012). These venomous animals have to 
regulate not only the enzymatic activity of PLA2, but also its myotoxic, cytotoxic, 
cardiotoxic, edematogenic and anticoagulating activities (Faure, 2000; Machiah 
and Gowda, 2006; Stábeli et al, 2012; Harris and Scott-Davey, 2013). It has 
also been reported that animals resistant to snake venom such as the 
mongoose (Herpestes edwardsii) and the opossum (Dedelphis marsupialis) 
showed the presence of protein factors in their blood which inhibit the activity of 
venom components (Qi et al, 1994; Neves-Ferreira et al, 2000; Lizano et al, 
2003), including metalloproteinase and PLA2 inhibitors (Perales et al, 1992; Fox 
and Bjarnason, 1998; Pérez and Sánchez, 1999; Lizano et al, 2003). 
 
 
 203 
5.1.1 Aims of this chapter 
Ø Analysis of the bactericidal activity of purified phospholipase A2 against S. 
aureus. 
Ø Identification of the other component(s) of the rabbit serum involved in the 
bactericidal activity against S. aureus. 
Ø Study of the interaction between phospholipase A2 and other NRS 
components. 
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5.2 Results 
5.2.1 Effect of purified PLA2 on S. aureus 
 
In Chapter 4 sPLA2 was identified as the component of the rabbit serum 
responsible for its bactericidal activity against S. aureus. These results were 
obtained using rabbit sPLA2 in the context of the rest of the rabbit serum. In 
order to further analyse the role of PLA2 purified material was used. 
 
Purified sPLA2 from rabbit serum is unavailable and it was not practical to purify 
it due to the lack of availability of bulk NRS and the heat sensitivity of the killing 
factor. Thus the effect of other purified PLA2, that are commercially available, 
was tested. Recombinant human PLA2 was purchased from Abcam, whilst 
honey bee (Apis mellifera) and spitting cobra (Naja mossambica mossambica) 
venom PLA2 were purchased from Sigma-Aldrich. 
 
The protein sequences of the rabbit, human and honey bee PLA2 were found in 
the NCBI Protein Database, but as no sequence for spitting cobra was available 
the sequence for PLA2 from Indian cobra (Naja naja) was used instead. 
Sequence analysis showed the domain corresponding to the PLA2 superfamily 
in all of them. All of the rabbit PLA2 catalytic residues were conserved in the 
human and cobra proteins, while only three of the five residues were conserved 
in the honey bee phospholipase (Figure 5.1). The pairwise sequence alignment 
using the EMBOSS Neddle program showed that the rabbit PLA2 shares more 
identity with the human protein (77.1%) than with the Indian cobra (48.7%) or 
the honey bee (18.6%) phospholipases. 
 
The bactericidal activity of the recombinant human PLA2 (rhPLA2) and of the 
purified spitting cobra and honey bee venom PLA2 against S. aureus was 
tested first in buffer. It has been reported that the activity of PLA2 can be tested 
when bacteria are suspended in Purified Phospholipase A2 Buffer (Pernet et al, 
2014). For these experiments a range of different concentrations of PLA2 were 
inoculated with S. aureus SH1000, after which killing assays were carried out as 
explained previously (Chapter 2.23).  
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Figure 5.1 Multiple sequence alignment between PLA2 from rabbit, human, 
Indian cobra and honey bee. 
Alignment of the sequences for phospholipase A2 from rabbit (accession number 
XP_002719839.1), human (NP_000919.1), Indian cobra (AAA66029.1) and honey bee 
(NP_001011614.1) venom was carried out using the Multiple Sequence Analysis from 
Clustal Omega (previously ClustalW) using the EBLOSUM 62 matrix. Residues marked 
with an asterisk (*) are fully conserved; colon (:) indicates strongly conserved 
substitutions and full stop (.) indicates weakly conserved residue substitutions. The red 
squares show the catalytic residues of the rabbit phospholipase A2 
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Recombinant human PLA2 (Figure 5.2A) and honey bee PLA2 (Figure 5.2B) 
had no effect on bacterial numbers. Spitting cobra PLA2 led to bacterial death 
under the detection limit after 4 hours of incubation when 65 or 100 units of the 
enzyme were added to the PLA2 Buffer (Figure 5.2C). More detailed analysis 
was carried out to study the kinetics of bacterial death, revealing that 65 units/L 
of cobra PLA2 (final concentration) caused bacterial death after 2 hours (Figure 
5.3). 
 
 
5.2.2 Effect of purified spitting cobra venom (Naja mossambica 
mossambica) PLA2 (cvPLA2) on the bactericidal activity of NRS 
 
The effect of the addition of this purified enzyme to the NRS was studied. For 
these experiments 65 units/L of cvPLA2 were added to aliquots of rabbit serum 
and the bactericidal activity of these mixtures against S. aureus was tested. 
Counterintuitively, when cvPLA2 was added to NRS, growth was observed 
rather than enhanced bacterial killing (Figure 5.4). This suggested that the 
added enzyme was interacting with the PLA2 or with another component of the 
serum, inactivating its bactericidal activity. 
 
As explained in the previous chapter, the 100-fold increase in the bacterial 
numbers observed between 3 and 4 hours in figure 5.4 could be due to an error 
in the dilution process. 
 
The same enhanced bacterial growth was observed when cvPLA2 was added 
to heat inactivated NRS when compared to the heated serum (Figure 5.5A). 
This suggests that the added cvPLA2 interacts with components of the serum 
that caused the bacteriostatic effect observed in the heated NRS. However, 
when cvPLA2 was mixed with human serum no significant differences were 
observed when compared to the effect of the human serum on S. aureus 
(Figure 5.5B).  
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Figure 5.2 Effect of purified PLA2 on S. aureus 
The effect of A) recombinant human PLA2, B) purified honey bee PLA2, or C) spitting 
cobra PLA2 (cvPLA2) on S. aureus SH1000 viability was tested (Chapter 2.9). 
Bacterial survival in buffer is also shown (black bars). The experiments were carried 
out in triplicate (i.e. biological triplicates) and the error bars represent the standard 
deviation of the means. Student’s t-tests were carried out and the significant 
differences are marked with asterisks. n.s.: non-significant differences. 
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Figure 5.3 Effect of cvPLA2 on S. aureus 
The effect of 65 units/L (final concentration) of cvPLA2 on 105 cells/ml of S. aureus 
SH1000 survival was tested and compared to PLA2 Buffer (black line). The 
experiments were carried out in triplicate (i.e. biological triplicates) and the error bars 
represent the standard deviation of the means. Student’s t-tests were carried out and 
the significant differences are marked with asterisks. 
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Figure 5.4 Effect of the addition of cvPLA2 on the bactericidal activity of NRS 
The bactericidal effect of rabbit serum (black line) on 105 cells/ml of SH1000 was 
compared to the effect of the rabbit serum with 65 units/L of cvPLA2 (final 
concentration) added. These experiments were carried out in triplicate (i.e. biological 
triplicates). The error bars represent the standard deviation of the means. Student’s t-
tests were carried out and the significant differences are marked with asterisks. 
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Figure 5.5 Effect of the addition of cvPLA2 on the bactericidal activity of heated 
NRS and human serum 
65 units/L of cvPLA2 were added to A) Heated rabbit serum (30 minutes at 56ºC), and 
B) Human serum, prior to a S. aureus killing study using an initial inoculum of 104-105 
cells/ml (Chapter 2.9). These experiments were carried out in triplicate (i.e. biological 
triplicates) and the error bars correspond to the standard deviation of the means. 
Student’s t-tests were carried out and the significant differences are marked with 
asterisks. 
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5.2.3 Analysis of the bactericidal activity of heat-treated cvPLA2 when 
added to rabbit serum 
 
In order to explain the enhanced bacterial growth observed when cvPLA2 was 
added to NRS and to heated NRS, experiments testing the activity of the 
enzyme were carried out. To test if this effect was caused by interactions 
between components of the rabbit serum and the active PLA2, the enzyme was 
inactivated before the start of the experiments. The enzyme was inactivated 
using the heat treatment protocol used to inactivate NRS: 56 ºC for 30 minutes.  
 
Heat-treated cvPLA2 loses its bactericidal activity (Figure 5.6A). However, the 
enhanced bacterial growth was still present when the heat-treated cvPLA2 was 
added to both NRS and to heated NRS (Figures 5.6B and C, respectively). 
Thus cvPLA2 does not have to be bactericidally active in buffer to inactivate 
NRS.  
 
 
5.2.4 Effect of boiled cvPLA2 on S. aureus 
 
As cvPLA2 activity does not appear to be required for its inhibitory properties on 
NRS, the role of its overall structure was determined. cvPLA2 was boiled 
(100ºC) for 30 minutes to denature it. 
 
Denaturated cvPLA2 had no bactericidal activity (Figure 5.7A). The mixture of 
NRS with the boiled enzyme was able to kill the bacteria to less than the 
detection limit (103 cfu/ml) after two hours of incubation (Figure 5.7B). No 
significant differences were observed when the boiled enzyme was added to 
heated rabbit serum or human serum compared to serum alone (Figure 5.7C 
and D, respectively). Thus the structure of the cvPLA2 is important for the 
interaction with rabbit components, not its activity. 
 
  
 212 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 Effect heat-treated cvPLA2 on S. aureus 
65 units/L of untreated (black line) or heat-treated (56ºC for 30 minutes) (red line) 
cvPLA2 was added to A) PLA2 Buffer, B) NRS, C) Heated NRS, D) Human serum. S. 
aureus SH1000 killing assays were carried out using an initial inoculum of 105 cells/ml 
(Chapter 2.9). The experiments were carried out in triplicate (i.e. biological triplicates). 
The error bars represent the standard deviation of the means. Student’s t-tests were 
carried out and significant differences are shown with asterisks. 
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Figure 5.7 Effect boiled cvPLA2 on S. aureus 
65 units/L of untreated (black line) or boiled (100ºC for 30 minutes) (blue line) cvPLA2 
were added to A) PLA2 Buffer, B) NRS, C) Heated NRS, D) Human serum. S. aureus 
SH1000 killing assays were carried out using an initial inoculum of 105 cells/ml 
(Chapter 2.9). The experiments were carried out in triplicate (i.e. biological triplicates) 
and the error bars represent the standard deviation of the means. Student’s t-tests 
were carried out and significant differences are shown with asterisks. 
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5.2.5 Effect of pre-incubation with cell wall material on the bactericidal 
activity of cvPLA2 
 
The previous chapter (Chapter 4.2.6) demonstrated that other elements present 
in the rabbit serum affected the bactericidal activity of the phospholipase A2. 
Experiments using cvPLA2 confirmed these results, as the addition of the 
purified enzyme into the rabbit serum inactivates the bactericidal activity of both 
the NRS and the cvPLA2. This interaction occurs whether the purified PLA2 is 
active or not, but the structure of the PLA2 is necessary for the inactivation of 
the NRS. This led to the study of the role of the modulating factors present in 
the rabbit serum in order to confirm the hypothesis that these components 
might be involved in the interaction between the PLA2 and the bacterial surface. 
 
Previously I have shown that purified cell wall material can be used as an 
affinity matrix to absorb PLA2 from NRS, and that cvPLA2 inhibits NRS 
bactericidal activity. In order to test if cvPLA2 interacts with cell wall it was pre-
incubated with different purified cell wall fractions (Chapter 2.24), after which 
the mixture was centrifuged and the supernatant was used for killing assays in 
PLA2 Buffer. In all cases cvPLA2 activity was lost after pre-incubation with all 
types of cell wall material (Figure 5.8). The supernatant from ΔdltA cell wall 
absorbed material showed significantly less killing activity compared to other 
cell wall preparations (p< 0.01, Figure 5.8). 
 
The effect of cvPLA2 absorbed with cell wall material on the bactericidal activity 
of NRS was also studied. The addition of the supernatant from all the pre-
incubations led to partial inactivation of the activity of the rabbit serum and to 
bacterial growth after 4 hours of incubation (Figure 5.9). This was significantly 
less (p<0.05) than the inactivation caused by the untreated cvPLA2. Thus 
purified cvPLA2 binds to the different components of the bacterial cell wall, but 
not entirely in the conditions used.  
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Figure 5.8 Effect of pre-incubation of cvPLA2 with cell wall material on its 
bactericidal activity. 
65 units/L cvPLA2 (final concentration) was pre-incubated with 1mg/ml of stripped 
peptidoglycan (PG, red bars), pure wall teichoic acid (WTA, blue bars), unstripped cell 
wall (PG WTA, green bars) from SH1000 parental strain, and with unstripped cell wall 
from ΔdltA strain (PG ΔdltA, orange bars) for 30 minutes at 4ºC. Killing assays were 
carried out on supernatants after absorption and centrifugation as explained, using an 
initial inoculum of 105 cells/ml of SH1000 (Chapter 2.9). The experiments were carried 
out in triplicate (i.e. biological triplicates) and the error bars represent the standard 
deviation of the means. Student’s t-tests were carried out and significant differences 
are marked with asterisks. 
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Figure 5.9 Effect of pre-incubation of cvPLA2 with cell wall material on killing 
activity in rabbit serum 
65 units/L (43µg/ml) of cvPLA2 was pre-incubated with stripped peptidoglycan (PG, red 
bars), pure wall teichoic acid (WTA, blue bars), unstripped cell wall (PG WTA, green 
bars) from the SH1000 parental strain, and with unstripped cell wall from a ΔdltA strain 
(PG ΔdltA, orange bars) as previously explained (Chapter 2.24). Killing assays were 
carried out on supernatants after centrifugation, using an initial inoculum of 105 cells/ml 
of SH1000 (Chapter 2.9). The experiments were carried out in triplicate (i.e. biological 
triplicates). The error bars represent the standard deviation of the means, Student’s t-
tests were carried out and significant differences are marked with asterisks. 
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5.2.6 Fluorescence microplate assay for functional characterization of 
PLA2 activity 
 
An explanation for the bactericidal activity of rabbit serum against S. aureus can 
be found in the difference in concentration and the catalytic activity of PLA2 
from rabbits when compared to other mammals. As stated previously, it has 
been reported that rabbits have higher levels of this enzyme in comparison to 
humans (Kudo et al, 1993; Weinrauch et al, 1996; Weinrauch et al, 1998; 
Nevalainen et al, 2008), and that the rabbit PLA2 is also more catalytically 
active than the human protein (Aufenanger et al, 1993; Zhang et al, 2005; 
Nevalainen et al, 2008). 
 
Results presented in Chapter 5.2.1 showed that cvPLA2 was able to kill S. 
aureus when the concentration used was similar to that found in rabbit serum 
(65 units/L), but could not when a human equivalent concentration was used (5 
units/L). Human and rabbit serum phospholipase A2 activity was measured 
using fluorogenic substrates. Colorimetric and fluorometric assays have been 
used to study phospholipase activity (Huang et al, 2006; Price, 2007), including 
the activity of PLA2 present in alligator serum using fluorometric assays and 
BODIPY incorporated into E. coli (Merchant et al, 2009). This led to the study of 
the activity of the phospholipase A2 present in rabbit and in human sera via 
fatty acid digestion using dye labelled PLA2 substrate incorporated into 
liposomes (Rahman et al, 2010; Tsao et al, 2015). 
 
For the determination of phospholipase activity, liposomes were synthesised 
using 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-Dioleoyl-sn-
glycero-3-rac-(1-glycerol) (DOPG) and glycerophosphocholines labelled in the 
sn-2 position with BODIPY (boron-dipyrromethene) (Figure 5.10) following the 
instructions explained in Chapter 2.23. These liposomes were then mixed with 
aliquots of rabbit and human serum and incubated at 37ºC. The fluorescence of 
each mixture was measured using an excitation wavelength of 485 nm and an 
emission wavelength of 535 nm in a VictorTM X3 2030 Multilabel Reader   
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Figure 5.10 Structure of the BODIPY substrate and both lipids used for liposome 
synthesis 
A. Structure of the BODIPY labelled glycerophosphocoline. The BODIPY® 558/568 
attached at the sn-1 position and the BODIPY® FL pentanoic are shown. Adapted from 
‘Fluorogenic Phospholipase A Substrates’ manual from Invitrogen (Thermo Fisher 
Scientific).  
B. 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC) 
C. 1,2-Dioleoyl-sn-glycero-3-rac-(1-glycerol) (DOPG)  
Lipid structures modified from the Avanti® Lipids webpage 
(http://www.avantilipids.com/) 
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(Perkin Elmer). The cleavage of the labelled glycerophosphocholine in sn-2 
position by PLA2 results in an increase in the BODIPY® FL fluorescence 
emission detected at 535 nm due to a decrease in the quenching by 
fluorescence resonance energy transfer (FRET) to the BODIPY ® 558/568 
present in the sn-1 position (Figure 5.10A). PLA2 specific activity was 
expressed as the change in the fluorescence intensity per minute per µl of the 
PLA2 containing sample (Cai et al, 2013). Even though the fluorescence was 
measured at 30 minutes intervals for 4 hours, the specific activity was 
calculated using the change in the fluorescence intensity in the first 60 minutes 
as this corresponds to the initial rate period.  
 
Significant differences in the fluorescence intensity were observed between the 
rabbit and human serum from 30 minutes of incubation until the end of the 
experiment (p<0.001, Figure 5.11A), and comparison of the specific activities of 
the PLA2 present in the serum also showed significant differences (p<0.001, 
Figure 5.11B). 
 
The catalytic activity of inactivated rabbit serum was also examined. Aliquots of 
rabbit serum were inactivated using heat treatment and by adding a calcium 
chelating agent (EGTA) to the heated serum as explained previously (Chapter 
2.10.1 and 2.10.2, respectively), and the fluorescence intensity was measured 
(Chapter 2.23). Inactivation of the NRS using heat led to a 66% decrease in the 
specific PLA2 activity, whereas heat followed by EGTA pre-incubation caused a 
92% decrease in the specific phospholipase activity (Figure 5.12). 
 
It has been reported that the bactericidal activity of rabbit serum is lost when 
diluted 4-fold in sterile PBS (Bozakouk, 2011). The phospholipase activity of the 
diluted serum was examined and no significant difference between the 
undiluted NRS and the diluted samples was found until the rabbit serum was 
diluted 10-2-fold (p<0.01, Figure 5.13). Thus the loss of killing activity does not 
correlate directly with PLA2 activity hinting that other dilution dependent factors 
are found in the serum. 
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Figure 5.11 Comparison of the phospholipase activity of rabbit and human serum 
A) Progress curves, and B) Specific activity for PLA2 rabbit and human serum. 50 µl of 
BODIPY® labelled liposomes were mixed with 50 µl of rabbit (black) or human (red) 
serum, and the fluorescence intensity of the mixtures was measured every 30 minutes 
at 535 nm as explained (Chapter 2.23). The curves represent the mean of three 
independent experiments. The error bars correspond to the standard deviation of the 
means and significant differences are marked with asterisks (p<0.001, Student’s t-test). 
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Figure 5.12 Specific phospholipase activity of inactivated rabbit serum 
Heat inactivated NRS (red bar) and heat inactivated NRS pre-incubated with EGTA 
(blue bar) were tested for PLA2 activity (Chapter 2.23). The fluorescence intensity 
registered was used for the specific activity calculations, and these values were 
compared to untreated NRS (black bar). Significant differences are shown with 
asterisks (p<0.05, Student’s t-test). These experiments were carried out in triplicate 
and the error bars represent the standard deviation of the means. 
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Figure 5.13 Specific phospholipase activity of diluted NRS 
Aliquots of dye labelled liposomes were mixed with 50 µl of samples containing 
different dilutions of rabbit serum. The fluorescence intensity of the mixture was 
measured every 30 minutes at 535nm as explained (Chapter 2.23). The specific 
activity of the diluted samples was compared to NRS (black bars) and significant 
differences are shown with asterisks (p<0.01 and p<0.001, Student’s t-test). These 
experiments were carried out in triplicate and the error bars represent the standard 
deviation of the means. 
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Next, the activity of the different purified PLA2s was measured. For these 
purified PLA2s, the specific activity was calculated as the fluorescence intensity 
per minute per µg of protein. Human recombinant PLA2 showed no activity, 
whereas both the honey bee and spitting cobra PLA2 had significantly higher 
activity than rabbit serum (p<0.001, Figure 5.14). By comparing the specific 
activities of NRS and cvPLA2 it was possible to determine that the NRS has 
12.04 µg/L of sPLA2. This value is within the range of sPLA2 in serum 
measured for mammals (Nevalainen et al, 1985; Dorsam et al, 1995). 
 
 
5.2.7 Role of annexin A1 in the bactericidal activity of PLA2 
 
Experiments using fractionated rabbit serum suggested that sPLA2 was not the 
only serum component involved in the bactericidal mechanism against S. 
aureus (Figures 4.13 and 4.14). This hypothesis was supported by the study of 
phospholipase activity of diluted rabbit serum. Whilst bactericidal activity of NRS 
is lost when the serum is diluted 4-fold in sterile PBS, PLA2 activity was only 
lost by >100-fold dilution.  
 
Due to the large number of proteins present in serum (Pieper et al, 2003; 
Chiaradia et al, 2012), the search for this extra factor involved in the 
antibacterial activity of NRS started with the list of proteins identified by mass 
spectrometry analysis of the serum proteins bound to affinity matrices (Chapter 
4.2.7). As PLA2 was present in the bound proteins analysed by mass 
spectrometry, it was speculated that the new factor capable of modulating PLA2 
could also be found in these fractions. Amongst these proteins identified by 
mass spectrometry was annexin A1.  
 
The annexins are a family of proteins that are capable of binding to 
phospholipids in a calcium-dependent manner (Parente and Solito, 2004; 
Rescher and Gerke, 2004). This family contains hundreds of gene products 
expressed in most species including insects, plants, protozoa and vertebrates   
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Figure 5.14 Comparison of the specific phospholipase activity of NRS and 
purified PLA2  
The fluorescence intensity for samples containing honey bee, spitting cobra and 
recombinant human PLA2 was determined (Chapter 2.23). The specific phospholipase 
activity of these samples was compared to the equivalent specific activity of NRS 
(12.04µg/L, black bar) and significant differences are shown with asterisks (p<0.001, 
Student’s t-test). These experiments were carried out in triplicate and the error bars 
correspond to the standard deviation of the means.  
 
  
NRS Bee PLA2 cvPLA2 rhPLA2
0
20
40
60
80
Fl
uo
re
sc
en
ce
 in
te
ns
ity
/m
in
/µ
g
***
***
***
 225 
(Morgan and Fernandez, 1997; Rand, 2000; Rescher and Gerke, 2004). Twelve 
different annexins have been described in humans (I-XI and XIII) (Gerke and 
Moss, 2002). 
 
These proteins have two main domains: an N-terminal region, diverse in 
sequence and length, responsible for the regulation of the interaction with other 
proteins and the membrane (Raynal and Pollard, 1994; Gerke and Moss, 2002; 
Rescher and Gerke, 2004); and the conserved C-terminal region, also called 
‘annexin core domain’, which possesses the calcium and the membrane binding 
sites (Gerke and Moss, 2002; Rescher and Gerke, 2004). The annexins are 
involved in several intracellular and extracellular processes, including cell 
division, apotosis, regulation of the activity of ion channels, vesicle trafficking, 
phagocytosis, growth regulation, calcium signalling, binding of molecules to the 
cell surface, coagulation and control of inflammatory responses (Gerke and 
Moss, 2002; Hayes and Moss, 2004; Gerke et al, 2005). 
 
Annexin A1 (Anx-A1) is capable of binding to negatively charged phospholipids 
in a pH- and calcium- dependent manner (Rosengarth et al, 2001; D’Acquisto et 
al, 2008), and it is involved in the regulation of the innate and adaptive immune 
responses. This protein inhibits phagocytosis (D’Acquisto et al, 2008), mast 
cells degranulation (Bandeira-Melo et al, 2005) and polymorphonuclear 
leukocyte trafficking and adherence (Chatterjee et al, 2005; D’Acquisto et al, 
2008). It also prevents the adhesion of monocytes to endothelial cells (Solito et 
al, 2000). Annexin A1 can promote T-cell proliferation, inflammatory responses 
and Th1 differentiation, but can also inhibit Th2 differentiation (D’Acquisto et al, 
2007; D’Acquisto et al 2008). 
 
Annexin A1 is also involved in the modulation of the inflammatory responses 
through the regulation of the activity of PLA2 (Parente and Solito, 2004; 
D’Acquisto et al, 2008). It has been reported that annexin A1 is able to inhibit 
the activity of cytosolic PLA2, but the mechanism involved in this is not clear. 
While some studies showed that the inhibition occurs through substrate 
depletion (Davidson et al, 1987), others reported that annexin A1 interacts 
directly with this phospholipase (Kim et al, 1994; Lim and Pervaiz, 2007). Due 
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to the known regulatory role of annexin A1 on cPLA2, this protein was chosen 
as the first serum element to test for a role in the bactericidal mechanism of 
sPLA2 present in NRS against S. aureus. 
 
To elucidate the role of the annexin A1 in the activity of sPLA2, experiments 
were carried out using purified human protein (Abcam). First, it was confirmed 
that annexin A1 had no bactericidal activity against S. aureus on its own as no 
significant difference was found between PLA2 Buffer alone and PLA2 Buffer 
with the protein (Figure 5.15).  
 
Next, the effect of annexin A1 on the bactericidal activity of cvPLA2 was tested. 
Aliquots of PLA2 buffer were inoculated with 65 units/L and with 32.5 units/L of 
cvPLA2 and the bactericidal activity of these solutions was tested. As shown 
previously, 65 units/L of this PLA2 was enough to decrease the bacterial count 
lower than the detection limit, whilst 32.5/L units had no bactericidal effect 
(Figure 5.16A and B, respectively). 
 
No effect was observed when the protein was added to the aliquot of PLA2 
Buffer containing 65 units/L of cvPLA2 (Figure 5.16A). However addition of 
annexin to 32.5 units/L of cvPLA2 gave a significant increase in the bactericidal 
activity against S. aureus (p<0.01, Figure 5.16B). These results, along with 
those showed in Figure 5.2C, suggested that there is a critical concentration of 
cvPLA2 that needs to be present in order to kill S. aureus. A 2-fold dilution of 
cvPLA2 allows bacterial survival, but the presence of annexin A1 increases the 
bactericidal activity by lowering the threshold needed to kill the bacteria. 
 
Native polyacrylamide gels electrophoresis was used to examine any direct 
interaction between annexin A1 with cvPLA2 using antibodies against annexin 
A1. Secreted PLA2 has a molecular mass of 14-16 kDa (Schaloske and Dennis, 
2006; Dennis et al, 2011) and annexin A1 has a molecular mass of 37 kDa 
(Parente and Solito, 2004; Lim and Pervaiz, 2007). cvPLA2 can be found as 
dimers and other oligomers in the presence of calcium (Plückthun and Dennis, 
1985; Jabeen et al, 2005; Dennis et al, 2011). It has been proposed that   
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Figure 5.15 Effect of annexin A1 on S. aureus viability 
The effect of 1.5µl of human annexin A1 (50µg/ml final concentration) on 105 cells/ml of 
S. aureus SH1000 viability was measured. The experiments were carried out in 
triplicate (i.e. biological triplicates) and the error bars represent the standard deviation 
of the means. Student’s t-tests were carried out and no significant differences were 
found. 
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Figure 5.16 Effect of purified annexin A1 on cvPLA2 bactericidal activity on S. 
aureus 
A. 65 units (43µg/ml) and B. 32.5 units (21.5µg/ml) of cvPLA2 were added to PLA2 
Buffer in presence or absence of 1.5µl of annexin A1 (50µg/ml final concentration) prior 
to an S. aureus SH1000 killing assay using an initial inoculum of 105 cells/ml. These 
experiments were carried out in triplicate (i.e. biological triplicates) and significant 
differences are shown with asterisks (Student’s t-test, p<0.01). The error bars 
represent the standard deviation of the means. 
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annexin A1 forms a dimer causing membrane fusion between cells (Rescher 
and Gerke, 2004; Donato et al, 2013; Lizarbe et al, 2013). 50 µg/ml of annexin 
A1 and 50 µg/ml of PLA2 were mixed and incubated at 37ºC for 30 minutes 
before native separation. In order to achieve protein migration in native gels, the 
isoelectric point of each protein (4.5-5.0 for cvPLA2 and 6.5 for annexin A1) 
was taken into consideration. After electrophoresis, the gels were silver stained 
(Chapter 2.21.5) and a Western blot with anti-annexin A1 antibodies performed 
(Chapter 2.21.7). Silver staining confirmed the presence of the proteins (data 
not shown), whilst the western blot showed a single band for annexin A1 
(Figure 5.17). This band was shifted in the presence of PLA2 indicating an 
interaction between the two proteins.  
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Figure 5.17 Native gel electrophoresis of annexin A1 and cvPLA2 
Aliquots of 50 µg of cvPLA2 (lane 1), human annexin A1 (lane 2) and a mixture of both 
proteins (lane 3) were analysed by 8% (w/v) native polyacrylamide gel electrophoresis 
and Western blot with anti-annexin A1 antibodies. The arrows show the location of 
each band. 
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5.3 Discussion 
 
In the previous chapter the role of the secreted phospholipase A2 (sPLA2) in 
the bactericidal activity of NRS against S. aureus was identified. However, as 
these results were obtained within the context of complete rabbit serum, 
experiments were carried out using purified PLA2 to determine its specific 
bactericidal activity. 
 
As rabbit phospholipase A2 is not commercially available, recombinant human 
phospholipase A2 and sPLA2 purified from spitting cobra and honey bee venom 
were used. Due to differences in both the concentration and catalytic activity of 
the PLA2 present in human and rabbit serum (Aufenanger et al, 1993; Kudo et 
al, 1993; Zhang et al, 2005; Nevalainen et al, 2008), experiments were carried 
out using the three types of PLA2 at different concentrations. This showed that 
whilst human and bee PLA2 had no effect on the bacteria, 65 units (43 µg/ml) of 
spitting cobra PLA2 (cvPLA2) was able to kill S. aureus with similar kinetics to 
NRS, causing a decrease in the bacterial count lower than the detection limit of 
the experiment after 2 hours of incubation (Figure 5.3). 
 
As the specific phospholipase activities of honey bee and cvPLA2 obtained 
were similar (Figure 5.14), this suggests that the lack of bactericidal activity 
against S. aureus observed for the honey bee PLA2 (Chapter 5.2, figure 5.2B) 
is not due to the absence of catalytic activity but might be caused by differences 
in affinity of the spitting cobra and the honey bee enzymes for the bacterial cell 
wall. 
 
It seems plausible that the bactericidal activity of the rabbit serum against S. 
aureus could be attributed to the activity of phospholipase A2. Even though this 
enzyme is present in the serum of both humans and rabbits, the difference in 
the activity of the PLA2 present in NRS may be the key. This hypothesis was 
supported when the specific phospholipase activity of rabbit and human serum 
was compared, as the human serum had significantly less specific PLA2 activity 
than the rabbit serum (p<0.001; Figure 5.11B). 
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However, the addition of cvPLA2 to NRS led to bacterial growth instead of the 
expected enhanced bacterial killing, suggesting that the cobra enzyme interacts 
with some component of the rabbit serum and inactivates not only its own 
activity but also the bactericidal activity of the NRS. As the cvPLA2 used was 
purified from spitting cobra venom, it is also possible that the purification not 
only contains cvPLA2 but also contaminants or peptides that might influence 
the activity of the components of the NRS responsible for the killing of S. aureus 
(Zhao and Kinnunen, 2003; Samy et al, 2007). Further experiments showed 
that the structure of the cvPLA2 was important for the interaction with the rabbit 
serum components, not its activity. 
 
This interaction was specific for rabbit serum, as the addition of cvPLA2 to 
human serum had no effect on the serum. This supported the hypothesis that 
species-specific components of the rabbit serum are able to interact with the 
PLA2 and affect its activity, which might explain why rabbit serum is the only 
serum with bactericidal activity against S. aureus.  
 
The importance of the interaction of the PLA2 with other factors present in the 
rabbit serum was also supported by the study of phospholipase activity of 
diluted rabbit serum. The bactericidal activity of the NRS disappears when the 
serum is diluted 4-fold, whereas significant differences in the specific 
phospholipase activity are found only when undiluted serum is compared to 
100-fold diluted NRS (p<0.01; Figure 5.13). The loss of bactericidal activity by 
4-fold dilution may therefore be caused by a dilution of other components 
present in the serum that are necessary for PLA2 killing. 
 
In the previous chapter the importance of the interaction of the PLA2 with the 
bacterial cell wall for its bactericidal activity was shown extensively by the use of 
different cell wall fractions as affinity matrices. It has been widely reported that 
cell wall interaction corresponds to the first step of activity of PLA2 (Foreman-
Wykert et al, 1999; Koprivnjak et al, 2008). Experiments were carried out to 
study the ability of the purified cvPLA2 to bind to different cell wall components, 
as this could shed light on the requirements for other factor in PLA2 activity. 
This showed that whilst the unidentified components of the rabbit serum are 
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involved in PLA2 activity, they are not required for cell wall binding (Figures 5.8 
and 5.9). 
 
The work also highlighted potential differences in the affinity of cvPLA2 and 
sPLA2 in rabbit serum for the cell wall components. Whilst the pre-incubation of 
cvPLA2 with pure peptidoglycan, pure WTA and peptidoglycan with WTA from 
S. aureus SH1000 caused a similar level of inactivation of the bactericidal 
activity of this purified PLA2 (Figure 5.8), pre-incubation of NRS with pure 
peptidoglycan and pure WTA caused partial inactivation (Figure 3.17A and 
3.18). Total inactivation was caused by treatment with peptidoglycan with WTA 
(Figure 3.17B).  
 
Other factors interacting with PLA2 activity are also likely to show affinity for cell 
wall fractions. The mass spectrometry analysis of the serum proteins bound to 
the different types of cell walls provided a list of proteins as candidates for PLA2 
modulators. 
 
One of the proteins was annexin A1, a known regulator of the activity of 
phospholipase A2 (Parente and Solito, 2004; D’Acquisto et al, 2008). It has 
been reported that annexin A1 is able to inhibit the activity of cytosolic PLA2 
through either substrate depletion (Davidson et al, 1987) or direct interaction 
with this phospholipase (Kim et al, 1994; Lim and Pervaiz, 2007). However, 
even though annexin A1 plays an inhibitory role against against the cytosolic 
PLA2 and modulates the inflammatory response (Parente and Solito, 2004), the 
presence of annexin A1 in the cell wall material purified from the ΔdltA strain 
suggested a different role. As explained previously, the ΔdltA mutant is much 
more sensitive to the bactericidal activity of NRS than its parent and pre-
incubation of the serum with cell wall material purified from this mutant 
completely inactivates the serum. This led to the hypothesis that the bactericidal 
elements present in the rabbit serum have more affinity for the cell wall of this 
mutant than for the parent strain, which is supported by the literature 
(Koprivnjak et al, 2002; Hunt et al, 2006). If the annexin A1 inhibited the activity 
of sPLA2, its presence on the cell surface of the ΔdltA strain should cause an 
inhibition of the bactericidal activity, but that is not the case. 
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Whilst the inhibitory role of annexin A1 for the activity of cPLA2 has been 
studied and reported (Kim et al, 1994; Parente and Solito, 2004; Lim and 
Pervaiz, 2007; D’Acquisto et al, 2008), and the role of annexin V on different 
types of sPLa2 has been reported (Buckland and Wilton, 1998), the effect of 
annexin A1 on the secreted PLA2 has not been demonstrated. 
 
As annexin A1 had no bactericidal activity by itself, this protein was chosen as a 
serum factor to test for its modulating role on the bactericidal activity of sPLA2 
against S. aureus. To differentiate positive or negative roles for annexin A1, it 
was added to aliquots of cvPLA2. The addition of annexin A1 to 32.5 units (21.5 
µg/ml) of cvPLA2 led to bacterial death after 4 hours of incubation, whereas 
cvPLA2 alone did not kill (p<0.01; Figure 5.16B). Thus annexin A1 interacts with 
cvPLA2 and enhances its bactericidal activity against the bacteria. This 
interaction is also direct as shown by native polyacrylamide gel electrophoresis 
and Western blot with anti-annexin A1 antibodies (Figure 5.17). The picture of 
how NRS mediates its bactericidal effect on S. aureus has now become more 
complex with the identification of annexin A1 as a likely regulating factor. 
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6 Chapter 6: 
General Discussion 
 
S. aureus is an important pathogen with the ability to cause a wide range of 
diseases (Archer, 1998; Lowy, 1998; Foster, 2005; Lowy 2010; Hennekinne et 
al, 2012) and can rapidly gain resistance against antibiotics (Demerec, 1945; 
Lowy, 2003; Gordon and Lowy, 2008; Chambers and DeLeo, 2009). Against the 
backdrop of an increasing need to control S. aureus the novel bactericidal 
mechanism in rabbit serum was studied. Previously the antibacterial activity 
was characterized and the importance of wall teichoic acids (WTA) was 
identified (Bozakouk, 2011). However the mechanism involved in the bacterial 
killing remained unknown. 
 
Evidence gathered during this project led to the identification of wall teichoic 
acid as the bacterial receptor for the ‘killing factor’ present in the rabbit serum. 
WTA is also important due of the presence of D-alanine esters, molecules that 
affect the interaction of the ‘killing factor’ with the bacterial surface and its 
bactericidal activity. 
 
The secreted phospholipase A2 (sPLA2) was identified as the bactericidal 
component responsible for the antibacterial activity of the rabbit serum. It has 
been reported that sPLA2 has potent antibacterial activity against S. aureus 
(Weinrauch et al, 1996; Qu and Lehrer, 1998; Koprivnjak et al, 2002; Merchant 
et al, 2011). The role of sPLA2 as the ‘killing factor’ corroborates the importance 
of WTA and of D-alanylation on the survival of S. aureus on NRS (Koprivnjak et 
al, 2002; Hunt et al, 2006; Koprivnjak et al, 2008).  
 
The species specificity of the sPLA2 bactericidal mechanism and the 
differences between the bactericidal and the phospholipase activity of diluted 
NRS suggested that other components present in the rabbit serum could affect 
the activity of sPLA2. Annexin A1, a known regulator of the activity of PLA2 
(Parente and Solito, 2004; D’Acquisto et al, 2008), was found bound to a cell 
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wall affinity matrix along with sPLA2. Experiments carried out showed that 
annexin A1, without bactericidal activity by itself, was able to interact with the 
PLA2 and support its bactericidal activity against S. aureus.  
 
All the evidence gathered during this project leads to a model for the 
bactericidal mechanism of the NRS against S. aureus. The sPLA2 present in 
the NRS is able to recognize and bind to the WTA in the cell wall of S. aureus. 
The protein then crosses the peptidoglycan with the help of the WTA until it 
reaches the bacterial membrane, where the enzyme hydrolyses phospholipids 
and cause bacterial death (Figure 6.1A). 
 
The role of WTA in both the initial interaction between sPLA2 and the bacterial 
cell (Koprivnjak et al, 2002) and its involvement in the movement of sPLA2 
through the peptidoglycan (Koprivnjak et al, 2008) has been demonstrated. 
However, questions about these processes remain. 
 
As stated previously (Chapter 4.3), the initial interaction between sPLA2 and 
the bacteria is based upon electrostatic interactions due to the highly cationic 
nature of sPLA2 and the overall anionic charge of the bacterial surface 
(Foreman-Wykert et al, 1999; Beers et al, 2002; Koprivnjak et al, 2002). 
However, there are no reports about the identity of the component of the 
bacterial cell wall that interacts with sPLA2 and allows the entry of the protein 
into the peptidoglycan. Whilst the role of teichoic acids has been speculated 
(Foreman-Wykert et al, 1999), this has not been demonstrated. We showed that 
pre-incubation of NRS with purified peptidoglycan containing wall teichoic acids 
completely inactivates its bactericidal activity (Figure 3.17B) due to the binding 
of sPLA2 to this affinity matrix (Table 4.2). This suggests that WTA directly 
interacts with sPLA2 and that it might act as the entry point on the outer 
surface, allowing the penetration of sPLA2 through the peptidoglycan layer. 
 
Once sPLA2 is bound to the S. aureus cell surface, the protein has to cross the 
peptidoglycan in order to reach the cell membrane. Therefore, the permeability 
of the cell wall is an important factor in the bactericidal activity of sPLA2. It has 
been suggested that the level of cross-linking of the cell wall plays a role in the 
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susceptibility of different bacteria to sPLA2 (Qu and Leher, 1998; Buckland and 
Wilton, 2000). It has also been reported that the growth phase also affects the 
susceptibility of S. aureus to sPLA2 (Foreman-Wykert et al, 1999). Bacteria in 
logarithmic growth phase are more susceptible to sPLA2 as it is less difficult for 
the protein to reach the membrane through the dividing cell (Foreman-Wykert et 
al, 1999; Dennis et al, 2011).  
 
As teichoic acids form a negatively charged network that connects the bacterial 
cell wall and the membrane (Neuhaus and Baddiley, 2003), it has been 
proposed that WTA and LTA act as a polyanionic ladder through which 
positively charged molecules, such as sPLA2, are able to move from the 
outside to the bacterial membrane (Foreman-Wykert et al, 1999; Hunt et al, 
2006; Koprivnjak et al, 2008). The results obtained using the ΔtagO strain 
(Figures 3.6 and 3.19A) support this model, but only if WTA is the first step in 
this polyanionic ladder. These results confirm that the absence of WTA in the 
cell wall of S. aureus gives resistance to the activity of sPLA2 (Figure 6.1B). 
 
The electrostatic nature of the initial interaction of sPLA2 and S. aureus, along 
with the use of the negatively charged teichoic acids as a ladder in order to 
reach the bacterial membrane, also explains why the lack of D-alanylation in the 
WTA increases the affinity of these interactions, helping sPLA2 to reach its 
target (Figure 6.1C). 
 
After crossing the peptidoglycan, sPLA2 contacts the phospholipids present in 
the bacterial membrane. It has been reported that sPLA2 attaches itself to the 
bacterial membrane before loading a single phospholipid molecule into the 
active site to start the hydrolysis reaction (Jain et al, 1986; Bezzine et al, 2002), 
generating a fatty acid and a lysophospholipid (Schaloske and Dennis, 2006; 
Dennis et al, 2011). Different mechanisms have been proposed for the killing 
mechanism of sPLA2, such as the negative effect that the hydrolysis of the 
membrane phospholipids has on S. aureus cell division due to the accumulation 
of fatty acids (Ocampo et al, 2010). The important role that bacterial autolysins, 
activated by the activity of sPLA2, play in killing and lysis of S. aureus has also 
been reported, as autolysis-deficient strains were not lysed and were able to 
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repair the damage caused by sPLA2 (Foreman-Wykert et al, 1999). Further 
work needs to be carried out in order to demonstrate which of these 
mechanisms is directly responsible for the death of S. aureus.  
 
Results obtained in this project (Chapter 5.2.7) showed that annexin A1 
contributes to the interaction of the sPLA2 with the bacteria (Figure 6.1D). Even 
though there are no reports about the enhancement of sPLA2 activity by 
annexin A1, it has been suggested that not all the members of the annexin 
family are able to inhibit the activity of cPLA2 (Kim et al, 2001). 
 
It has been reported that annexin I (or A1), IV and V are capable of binding to 
the lipopolysaccharide and the lipoteichoic acid present in the surface of Gram-
negative and Gram-positive bacteria, respectively (Gotoh et al, 2005; Rand et 
al, 2012). As the binding of annexin V to a surface results in the displacement of 
sPLA2 (Buckland and Wilton, 1998), it is possible that the binding of annexin A1 
to the LTA present in S. aureus encourages sPLA2 to bind to the WTA also 
present in the cell wall, helping in the first step of the bactericidal activity of 
sPLA2. This, however, needs to be studied further. 
 
Whilst the direct interaction between annexin A1 and sPLA2 was shown in this 
project (Figure 5.18) and the interaction between cPLA2 and annexin A1 has 
been reported (Kim et al, 2001; Parente and Solito, 2004), the relevance of this 
to NRS bactericidal activity is unknown. 
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Figure 6.1 Model of the bactericidal mechanism of NRS against S. aureus 
A) The presence of WTA in the cell surface allows the binding and translocation of the 
sPLA2 through the peptidoglycan to the bacterial membrane, causing bacterial death.  
B) The absence of WTA gives the bacteria resistance to the bactericidal activity of 
sPLA2 due to the inability of sPLA2 to interact with the bacteria and to reach the 
phospholipids in the bacterial membrane. 
C) Absence of D-alanine increases the affinity of sPLA2 for the bacterial cell wall, 
causing enhanced bacterial death. 
D) Annexin A1 contributes to the interaction of the sPLA2 with the bacteria, leading to 
enhanced bacterial death. 
 
LTA: lipoteichoic acid; PG: peptidoglycan; sPLA2: secreted phospholipase A2; WTA: 
wall teichoic acid. 
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6.1 Future work 
 
This project has identified sPLA2 as the component of the NRS responsible for 
the bacterial killing. However, more information about how it interacts with the 
cell surface and crosses the peptidoglycan layer is needed. The interaction and 
translocation of the protein could be explored using labelled sPLA2 and 
fluorescence microscopy. Rabbit recombinant sPLA2 could be expressed in 
either in E. coli or Chinese hamster ovary (CHO) cells as for the human protein 
(Levine et al, 1992; Stadel et al, 1992; Weiss et al, 1994; Huang et al, 2006), 
with a fluorescent protein fused to it or using the SNAP-tag technique (Sun et 
al, 2011). Another option could be to purify the sPLA2 from rabbit serum (Gijón 
et al, 1995; Grönroos et al, 2002) and then bind a fluorescent dye to the protein 
(Kim et al, 2008; Izquierdo-Alvarez and Martínez-Ruiz, 2011). It is important to 
test that the fluorescent probe does not affect the initial binding of the sPLA2 to 
the bacteria, its translocation through the peptidoglycan, or its enzymatic activity 
in the phospholipids present in the bacterial membrane.  
 
Even though the bactericidal mechanism of the NRS against S. aureus was 
uncovered in this project, identifying WTA as the bacterial receptor for the 
bactericidal activity of the sPLA2 present in the rabbit serum, the modulating 
role of annexin A1 on this activity needs to be further explored. The presence of 
the annexin A1-sPLA2 complex could be verified by gel filtration 
chromatography, as this technique is commonly used to identify protein 
complexes. Immunoprecipitation of sPLA2 present in NRS could be used to 
examine this interaction and to identify any other serum components that able 
to bind to sPLA2, along with confirm sPLA2 as the bactericidal component of 
the rabbit serum. 
 
Current treatments against S. aureus are expensive and difficult not only 
because of multi-antibiotic resistance, but also due to high number of virulence 
factors produced by the bacteria that damage the host. Along with new 
antibiotics (Ling et al, 2015) and vaccines (Spellberg and Daum, 2012; Fowler 
and Proctor, 2014), the use of elements of the immune system (Hancock and 
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Sahl, 2006; Seo et al, 2012; Faccone et al, 2014) is also being studied in order 
to fight this bacterium.  
 
Mastitis corresponds to the inflammation of the mammary gland due to a 
bacterial infection commonly caused by S. aureus (Ostermar and Rahm, 2000; 
Jahanfar at al, 2013; Ju et al, 2015). This infection leads to significant economic 
loss of diary livestock, such as cows, sheep and goats (Da Silva et al, 2005; 
Virdis et al, 2010; Ju et al, 2015). It also affects approximately 20% of 
breastfeeding women (Cullinane et al, 2015) and treatment normally involves 
pain medication and oral antibiotics that do not interfere with the breastfeeding 
process (Amir et al, 2006; Jahanfar et al, 2013; Cullinane et al, 2015). Rabbit 
sPLA2 could be produced in the milk of transgenic animals and help inhibit the 
growth of E. coli and S. aureus responsible for mastitis, as it has been reported 
that human lysozyme production in transgenic goat’s milk inhibits bacterial 
growth (Maga et al, 2006). 
 
It has also been reported that the consumption of this milk with human 
lysozyme helps young pigs to recover faster from diarrhea caused by 
enterotoxigenic E. coli (Cooper et al, 2013), and rabbit sPLA2 in milk could also 
be used for this type of treatment. This infection kills a significant number of 
children in developing countries and current treatment includes the 
administration of fluids and rest in order to prevent dehydration and fatigue 
(Gohar et al, 2016), along with the use of antibiotics (García et al, 2011). 
 
As MRSA and other antibiotic resistant S. aureus strains have been found in 
livestock (Weese, 2010; Fitzgerald, 2012; McCarthy et al, 2012), rabbit sPLA2 
could be used to fight S. aureus infection and stop spreading from animal to 
animal and from animal to human. Enhanced versions of sPLA2 could be 
synthesized, resulting in a more potent protein that could be tested in local skin 
infections. 
 
After testing the ability of the enhanced rabbit sPLA2 in livestock, it could be 
used to treat S. aureus infections in humans, especially as a prophylactic 
treatment for implants and catheters. It has been reported that S. aureus is 
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responsible for most of the bacterial infections related to catheters and are 
currently controlled by constant use of antibiotics followed by catheter removal 
or surgery (Fysh et al, 2013; Lui et al, 2016). The urgent need for alternative 
antibiotics necessitate new approaches to control such a difficult adversary. 
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